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Abstract 
 
Otosclerosis is a common form of conductive hearing loss. It is characterised by abnormal bone 
remodelling within the otic capsule, leading to formation of sclerotic lesions of the temporal 
bone. Encroachment of these lesions on to the footplate of the stapes in the middle ear leads 
to stapes fixation and subsequent conductive hearing loss. The hereditary nature of 
otosclerosis has long been recognised due to its recurrence within families, but its genetic 
aetiology is yet to be characterised. Although many familial linkage studies and candidate gene 
association studies to investigate the genetic nature of otosclerosis have been performed in 
recent years, progress in identifying disease causing genes has been slow. This is largely due to 
the highly heterogeneous nature of this condition.  
The research presented in this thesis examines the molecular and genetic basis of otosclerosis 
using two next generation sequencing technologies; RNA-sequencing and Whole Exome 
Sequencing. RNA–sequencing has provided human stapes transcriptomes for healthy and 
diseased stapes, and in combination with pathway analysis has helped identify genes and 
molecular processes dysregulated in otosclerotic tissue. Whole Exome Sequencing has been 
employed to investigate rare variants that segregate with otosclerosis in affected families, and 
has been followed by a variant filtering strategy, which has prioritised genes found to be 
dysregulated during RNA-sequencing. This has identified multiple variants predicted to be 
involved in splicing within genes involved in the bone disorder Osteogenesis Imperfecta, 
indicating a shared genetic aetiology for this condition and otosclerosis and a possible disease 
mechanism involving alternative splicing in the stapes. 
Whilst the hereditability of otosclerosis remains elusive, the identification of new candidate 
genes will make a significant contribution to the current literature. It is hoped that long term, 
this research will help reveal disease mechanisms and thereby improve treatment options for 
otosclerosis patients. 
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1 Introduction 
 
1.1 Deafness and hearing loss 
Hearing loss is the most common human sensory impairment, affecting over 5% of the world’s 
population (www.who.org).  It can manifest at any age and is thought to affect approximately 
six in every 1000 new born infants and about one third of those aged 65 and over 
(www.who.org). In the UK, it is estimated that ten million people are living with a hearing 
impairment (www.actiononhearingloss.org.uk) and it is expected that this number will 
increase by 10-15% in population terms over the next 15 years with the growing ageing 
demographic of the population (Davis et al., 2012).  
A large proportion of those affected by hearing loss live in low and middle-income countries, 
which is partly due to the contribution of environmental factors to the development of 
deafness. Environmental contributors include noise exposure, particularly involving those 
working in manufacturing industries, bacterial and viral infection, and ototoxicity as a result of 
wide-spread use of certain antibiotics such as aminoglycosides. Whilst these environmental 
factors remain considerable problems in developing countries, the shift away from 
manufacturing industry in the UK and the development of new medications with reduced 
ototoxicity has resulted in a reduction of exposure to these agents. Despite this, incidence of 
hearing loss remains high in developed countries. This is in part a result of the genetic factors 
which contribute to hearing loss. It is estimated that two thirds of all cases of prelingual 
deafness are caused by known genetic factors, whilst unidentified genetic factors and the 
environment contribute to the remaining third (Hilgert et al., 2009). Deafness is genetically 
heterogeneous, caused by mutations in a multitude of genes which encode proteins with a 
variety of functions. To date, more than 50 deafness genes and 80 additional genetic loci have 
been identified (Dror and Avraham, 2010).  
Despite recent advances in the identification of genes involved in hereditary deafness, there 
has been a lack of progress in elucidating the genetic basis of one of the most common forms 
of hereditary hearing loss; otosclerosis. This is an acquired form of adult-onset deafness 
caused by fixation of the stapes bone in the middle ear. The focus of this thesis is to investigate 
the genetic factors involved in the development of this condition. In this introductory chapter, 
the structure and function of the ear is discussed followed by an introduction to otosclerosis 
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and its clinical characteristics along with currently available treatment options. The 
development of the middle ear will then be outlined followed by an introduction to bone 
remodelling before an overview of progress made in investigating both environmental and 
genetic factors that contribute to disease pathogenesis. Finally I will summarise the key aims 
and objectives of this thesis, where for the first time, two Next Generation Sequencing 
technologies will be used in combination with one another in the hope of identifying genetic 
factors involved in the development of otosclerosis. 
 
1.2 Structure and function of the ear  
The mammalian ear is a complex organ which is composed of three main segments; the 
external, middle and inner ear.  The role of the external ear, consisting predominantly of the 
auditory meatus and pinna, is to collect sound, amplify it, and direct it into the auditory canal.  
When the sound waves reach the tympanic membrane, which forms a barrier between the 
external and middle ear, it sets the membrane in motion resulting in the transfer of sound 
waves into mechanical movement (Lee, 1999). One of three small auditory ossicles known as 
the malleus which is located in the air-filled chamber of the middle ear, is attached firmly to 
the tympanic membrane. Motion of the membrane results in transmission of mechanical 
energy through the ossicular chain, passing from the malleus to the incus and finally to the 
stapes which is attached laterally to the incus and medially to the oval window. The stapes 
transfers its mechanical energy through the oval window and into the inner ear. In the inner 
ear, mechanical energy is transformed into electrical stimuli which are then transmitted via the 
auditory nerve to the auditory cortex of the brain (Figure ‎1.1 A).   
 
1.2.1 Structure and function of the inner ear 
The inner ear consists of the vestibular and auditory systems, which are required for balance 
and perception of sound respectively. These systems are located within a bony labyrinth 
known as the otic capsule. The auditory system comprises the cochlea, a snail-shaped fluid-
filled tube which is coiled around a central bony modiolus.  Three compartments known as the 
scala media, scala vestibuli and scala tympani make up the cochlear canal. The scala media is 
filled  with endolymph, which has a unique electrolyte composition rich in potassium and low 
sodium ions (Wangemann, 1996) and is separated from the scala tympani by the basilar 
membrane (Figure ‎1.1 B).  
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The scala media contains the sensory epithelium of the cochlea known as the organ of Corti 
which sits on top of the basilar membrane.  Sensory hair cells are located within the organ of 
Corti and are arranged in four rows; three rows of outer hair cells (OHCs) and one row of inner 
hair cells (IHCs). These are separated from one another by two rows of pillar cells and three 
rows of Deiter’s cells, which together with Hensen’s cells and the inner sulcus cells make up 
the organ of Corti’s supporting cells. These surround the hair cells in order to support and 
maintain them (For review see Lim, 1986). When vibrations from the middle ear are 
transmitted to the inner ear, movement is generated in the fluid of the cochlea, activating the 
hair cells and converting the mechanical stimulation into an electrical signal (Figure ‎1.1 C).  
Both inner and outer hair cells have projections of actin-rich filaments known as stereocilia on 
their apical surface.  These are immersed in the endolymph of the scala media and are known 
as hair bundles.  Mechanical activation of the stereocilia results in deflection of the hair 
bundles, which leads to the opening of mechano-electrical transduction channels located at 
the stereocilia tips.  The synchronised opening of these channels results in an influx of 
potassium ions which depolarise the cell resulting in release of neurotransmitter at the base of 
the hair cells (Dallos, 1996). This generates an action potential in the nerves connected to the 
hair cells, which pass along the auditory nerve pathway to the brainstem (Figure ‎1.1D). When 
hair cells become damaged, the ability of the inner ear to transmit signals to the brain is 
impaired, leading to hearing loss) (For review see Guinan et al., 2012).  
Loss and damage of hair cells occurs naturally during the process of ageing, leading to the 
progressive hearing condition presbycusis, more commonly known as age-related hearing loss. 
Presbycusis is the most common form of adult onset deafness affecting a third of people aged 
65 and over (www.who.org). Hair cell damage can also be caused by a range of environmental 
factors including exposure to loud noise or ototoxic drugs, head trauma and viral infection. 
Genetic factors are also known to contribute to hair cell damage and may cause congenital 
deafness as well as childhood and adult-onset forms of the condition. Since hair cell loss is 
irreversible in humans, the resulting hearing impairment is permanent. Hearing loss due to hair 
cell damage, as well as damage to the auditory nerve which may be caused by benign tumours 
or head trauma, is known as sensorineural hearing loss. This is the most prevalent form of 
hearing impairment, responsible for approximately 90% of all cases and is associated with 
damage to the inner ear. The remaining 10% of cases are caused by conductive hearing loss, 
which occurs when sound waves are impeded from reaching the cochlea, and is associated 
with damage to the middle ear. 
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Figure ‎1.1 Anatomy of the Mammalian Ear 
(A) The ear is composed of the external, middle, and inner ear. The cochlea, responsible for hearing, and the 
vestibule, responsible for balance, make up the inner ear. (B) A cross-section of the cochlear duct reveals the scala 
media, scala tympani and scala vestibuli that are filled with fluids over the organ of Corti. (C) An enlargement of the 
organ of Corti, the cochlear sensory epithelium, showing three rows of OHCs and one row of IHCs, flanked by 
various types of supporting cells. (D) A diagram depicting the outer hair cells and the hair bundles of stereocilia on 
their apical surface (Adapted from Dror and Avraham, 2010). 
 
1.2.2 Structure and function of the middle ear 
The role of the middle ear is to transmit and amplify sound from the external to inner ear.  All 
animals relay sound via the middle ear, an air filled cavity containing the suspended auditory 
ossicles whose role it is to pass sound from the tympanic membrane to the basilar membrane. 
Unlike non-mammalian vertebrates which have a single ossicle called the columella, 
vertebrates have three ossicles arranged in an ossicular chain, which serve the same function.  
These ossicles are called the malleus, the incus and stapes (Figure ‎1.2). The malleus is inserted 
into the tympanic membrane at the distal end of the chain and is linked to the incus by the 
incudo-malleal joint. The incus acts as a bridge to the stapes, which link together at the incudo-
stapedial joint (Amin and Tucker, 2006). The footplate of the stapes is inserted into the oval 
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window of the otic capsule and is held in place via the annular ligament, which allows the 
stapes to move. The stapes acts as piston, transducing sound waves from the air-filled cavity to 
the endolymph of the scala media, where mechanotransduction occurs.  Since the tympanic 
membrane has a much larger surface area than the oval window, pressure is exerted on the 
stapes footplate which results in amplification of the signal (for review see Chapman, 2011).  
 
Figure ‎1.2 Middle ear anatomy 
The middle ear transmits movement of the tympanic membrane to the inner ear via the three auditory ossicles; the 
malleus, incus and stapes, which are held in position by the ligaments and muscles of the inner ear. (From  
http://droualb.faculty.mjc.edu) 
 
Conductive hearing loss occurs when the middle ear is unable to transfer sound from the outer 
to the inner ear. The most common form of adult-onset conductive hearing loss is otosclerosis 
which is caused by abnormal bone remodelling within the otic capsule leading to fixation of 
the stapes (For review see Ealy and Smith, 2011). Another common cause of conductive 
hearing loss is the presence of a physical barrier which obstructs the transmission of sound 
waves, such as a build-up of fluid or ear wax in the external ear canals, or due to chronic ear 
infection such as otitis media (For review see Pichichero, 2013). In addition, a number of rare 
syndromic conditions may also cause conductive hearing loss by affecting bone remodelling 
within the ear, including deafness due to Osteogenesis Imperfecta (Verstreken et al., 1996) 
and stapedial ankylosis. Conductive hearing loss may also be caused by a congenital defect as a 
result of abnormal development of the external and middle ear in the developing foetus, and 
affects approximately one in every 3,000 to 5,000 new-borns (Chapman, 2011). 
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1.3 Otosclerosis 
Otosclerosis is a condition that was first described by Adam Politzer in 1893 and is 
characterised by abnormal bone remodelling within the otic capsule, the skeletal element that 
encloses the inner ear (Nager, 1969). It occurs when foci of spongy, irregular bone, invade the 
stapediovestibular joint, interfering with free motion of the stapes bone in the middle ear. As 
the otosclerotic foci advance, the stapes becomes fixed in place, resulting in progressive 
conductive hearing loss. The stirrup-shaped stapes is the smallest and lightest bone in the 
human body and is composed of two distinct parts; the stapes suprastructure and footplate, 
which sits in the oval window niche. The suprastructure consists of two arms (crus) which 
surround the stapedial foramen, joining at the base to form the stapedial footplate 
(Figure ‎1.3).  
 
Figure ‎1.3 Bright field microscope image of a human stapes bone 
Image depicts the stapes footplate and the suprastructure. The suprastructure consists of the anterior and posterior 
crus which join the footplate, forming the stapedial foramen through the centre of the stapes bone. (Produced for 
the purpose of this thesis in July 2013.) 
 
1.3.1 Clinical characteristics of otosclerosis 
Otosclerosis is the most common form of adult-onset conductive hearing loss, affecting 
approximately 0.3-0.4% of the Caucasian population (Pearson et al., 1974, Gapany-
Gapanavicius, 1975, Declau et al., 2007b). There is considerable variation in incidence figures 
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cited by different investigators, which may be due to the varying incidence of this condition 
between different ethnic groups. Otosclerosis most commonly affects Caucasians, whilst the 
incidence is lower in black African and Oriental populations (Declau et al., 2007a). A 
particularly high incidence has been noted in the Todas population in Southern India (Kapur 
and Patt, 1967). Another possible reason for the discrepancy in incidence figures is that over 
the last two decades, it has become apparent that the number of patients seeking treatment 
for otosclerosis has fallen dramatically (Arnold, 2007). This has led some clinicians to conclude 
that the incidence of the condition is falling. However, a conflicting clinical opinion is that after 
the introduction of stapes surgery in the late 1950s, the large ‘back-log’ of otosclerosis patients 
seeking treatment was cleared. Therefore, the current situation is probably a more clear 
reflection of the true incidence of the disease (Saeed, 2002).  
The age of onset of otosclerosis is variable, but typically the first symptoms present in the third 
decade of life. Although rare cases have been reported in early childhood, this is very 
uncommon. Development of otosclerosis after the age of 50 is unusual but not unheard of, 
and cases have been reported into the sixth decade of life (Gapany-Gapanavicius, 1975).   
For many years, clinicians observed fewer cases of otosclerosis in males than females and an 
extensive study by Davenport et al. in the 1930s concluded that otosclerosis was twice as 
common in women as in men (Davenport, 1933). However, subsequent investigations in the 
1960s found that the condition was equally common in both sexes (Larsson, 1960, Morrison, 
1967). It is now thought that the condition exhibits a sex ratio of 1:1, although females are 
more likely to be seen in clinical practice due to a higher incidence of bilateral disease and 
progression of hearing loss during pregnancy due to hormonal changes (Browning and 
Gatehouse, 1992). Other theories include that women are more likely to consult their General 
Practitioner regarding hearing loss, resulting in more referrals to the clinic, and that women 
are less likely to work in environments where they are exposed to noise induced damage and 
so are more likely to notice and report a deterioration in their hearing (Browning and 
Gatehouse, 1992, Smyth, 1997). 
Hearing loss is bilateral in approximately 70-85% of otosclerosis cases and is usually 
asymmetrical, developing initially in one ear before progressing to the other (Emmett, 1993). 
The progression of hearing loss may be interrupted by periods of stability or rapid 
deterioration. The majority of patients with otosclerosis experience solely conductive hearing 
loss as a result of stapes fixation, however, approximately 10% of clinical cases also have a 
sensorineural component to their deafness (Browning and Gatehouse, 1984), which is more 
difficult to treat. It has been suggested that sensorineural hearing loss occurs when toxic 
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proteolytic enzymes are released from the otosclerotic foci, affecting the inner ear (Schrauwen 
and Van Camp, 2010). It is thought that sensorineural hearing loss occurs in advanced stage 
disease, although this belief is somewhat contentious. About 80% of otosclerosis patients 
experience tinnitus, which has been attributed to cochlear involvement.  It is possible that 
tinnitus is a secondary symptom to otosclerosis caused by amplification of sound following 
hearing loss. Imbalance and vertigo are less common than tinnitus in individuals with 
otosclerosis, but may be caused by the proteolytic enzymes from otosclerotic foci affecting the 
vestibular system (Smyth, 1997). 
Otosclerosis patients often experience Paracusis Willisii, the ability to hear speech better in 
noisy surroundings, an indicator of conductive hearing loss. This contrasts with typical 
sensorineural deafness and probably occurs because noisy environments encourage those 
with normal hearing to speak louder, above the hearing threshold of the person with 
otosclerosis (Smyth, 1997). Otosclerosis patients often have quiet speech, as they are able to 
hear their own voice by bone conduction through the skull, rather than through air conduction 
(Emmett, 1993). 
 
1.3.2 Histologic otosclerosis 
It is crucial that a distinction is made between ‘clinical otosclerosis’ and 'histologic 
otosclerosis'.  The former is the clinically relevant form of the condition where otosclerotic 
lesions interfere with stapes motion leading to conductive hearing loss. In contrast, the latter is 
identified post-mortem, when otosclerotic lesions are found in the temporal bone of 
symptom-free  individuals (for review see Thys and Van Camp, 2009). In 1967, research by 
Altmann et al. concluded that approximately 8.3% of Caucasians possess histologic otosclerotic 
lesions at death, of which 12% are located at the stapediovestibular joint, indicative of clinical 
otosclerosis. However, if the statistics derived from this study are used to calculate the 
population frequency for clinical otosclerosis, the frequency would be estimated at 0.996%, 
substantially greater than the 0.3-0.4% indicated from clinical data (Declau et al., 2007b). One 
possible explanation for this discrepancy is that the temporal bone collections analysed during 
the Altmann et al. study were biased for diseased otologic tissue, resulting in an overestimate 
of the frequency of histologic otosclerosis. This explanation is supported by a more recent 
analysis of 236 temporal cadaveric bones, which concluded that histologic otosclerosis is 
present at a frequency of 2.5% in the population (Declau et al., 2007b). Using the statistics 
derived from this study, the frequency of clinical otosclerosis would be predicted to be 0.3%, 
which supports the clinical data. 
 
 
23 
 
1.3.3 Histology of otosclerosis 
The terms otosclerosis and otospongiosis are often used interchangeably in the published 
literature. Otospongiosis is the descriptive term coined by Siebenmann in 1912 during the 
identification of spongiform foci in temporal bone of otosclerosis patients during post-mortem 
analysis. These foci are pleomorphic in nature and vary from those consisting of spongiform 
bone accompanied by large fibrous regions to those of dense sclerotic bone (Linthicum, 1993). 
In all cases, the composition of the lesion is highly disorganised in comparison to the normal 
bone that it replaces. Lesions can be categorised into three histopathologic groups; active, 
intermediate and inactive, although it is possible that all may be present within a single lesion 
at any one time. Active lesions, also known as spongiotic lesions, are typified by abnormal 
vasculature and enlarged spaces within the bone marrow, as well as finger-like projections, 
which extend into the surrounding bone (Linthicum, 1993). In contrast, inactive lesions are 
characterised by sclerotic mineralised bone, which does not appear to have undergone any 
recent bone remodelling and which is largely acellular in composition (Linthicum, 1993). 
Intermediate stage lesions have features common to both active and inactive stages. It is 
generally considered that inactive lesions occur in later stage disease. 
In otosclerosis, these spongiform foci develop in a variety of locations around the temporal 
bone and middle ear ossicles, as well as in the oval window niche. Early studies in the 1940s 
indicated that 80-90% of otosclerotic foci occur in the oval window niche whilst the round 
window is affected in 30-40% of cases(for review see Bretlau and Jorgensen, 1968). The most 
common location for otosclerotic lesions is at the anterior portion of the oval window at a cleft 
known as the fissula ante fenestram. As the focus gradually expands, the anterior portion of 
the stapes footplate is enveloped, causing it to become fixed (Figure ‎1.4 A). Occasionally, a 
large mass of otosclerotic bone may grow so large that it fills the oval window niche and may 
obscure the footplate entirely.  This rare form of the condition is known as obliterative 
otosclerosis (Figure ‎1.4 B).  
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Figure ‎1.4 Photographs by Politzer 1894 depicting stapes fixation in otosclerosis.  
(A) Otosclerotic lesion (indicated by arrow) at the fissula ante fenestrum leads to anterior fixation of the stapes 
bone (B) Otosclerotic lesion obscuring the stapes footplate causing obliterative otosclerosis. (Politzer, 1894). 
 
Otosclerosis can be categorised into four clinical sub-types based on the location and the 
nature of the lesion in relation to the stapes footplate. A Type I footplate exhibits fixation in 
the absence of an otosclerotic focus, a Type II footplate is characterised by stapes fixation 
accompanied by a single small otosclerotic focus, a Type III footplate occurs when the lesion 
involves approximately 50% of the footplate, and a Type IV footplate is characterised by 
obliteration of the entire annular ligament and oval window niche by the invading lesion 
(Tange et al., 1998). 
 
1.3.4 Diagnosis of otosclerosis 
Otosclerosis is typically diagnosed following audiometric analysis together with physical 
examination.  Audiometric analysis is used to identify the presence of the conductive hearing 
loss characteristic of otosclerosis, whilst physical examination is crucial in order to rule out 
other forms of conductive hearing impairment such as otitis media or perforation of the 
tympanic membrane.   
The human ear is able to detect frequencies in the range of 20 Hertz (Hz) to 20 kHz, with 
individuals with normal hearing usually able to hear frequencies from 125 Hz to 8 kHz at 
intensities between 0 and 10 decibels (dB). Mild, moderate, severe and profound hearing loss 
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occur when the hearing threshold increases to 20-40 dB, 41-70 dB, 71-90 dB and >90 dB 
respectively (Figure ‎1.5 A). 
Otosclerosis patients typically display a progressive low-frequency hearing loss that can be 
detected on an audiogram (Figure ‎1.5 B). However, they are often not aware of a problem at 
the early stages of disease. This is because speech perception occurs at higher frequencies. As 
the condition progresses and the stapes becomes fixed, higher frequencies also become 
affected.  Otosclerosis patients therefore often do not become aware of their hearing loss until 
the condition has progressed. When a patient presents with symptoms characteristic of 
otosclerosis in the clinic, audiometric analysis is carried out.  During this process both air 
conduction and bone conduction are analysed. Air conduction measures the sound waves 
which pass through the external and middle ear into the cochlea, whilst bone conduction 
measures the conduction of sound to the inner ear via the bones of the skull.  Conductive 
hearing loss is characterised by a reduction in hearing thresholds of air conduction, whilst bone 
conduction remains unaffected, resulting in the development of an air-bone gap (ABG). As the 
condition progresses and the stapes becomes fixed, higher frequencies become affected 
causing the ABG to increase. Conductive hearing loss is diagnosed when the ABG exceeds 10 
dB. For otosclerosis patients who don’t have sensorineural hearing loss, the hearing level 
usually increases to 60-65 dB and frequently displays a characteristic Carhart’s notch (Carhart, 
1962) on the audiogram where the hearing threshold reduces at about 2 kHz (Figure ‎1.5 B).  
 
Figure ‎1.5 Normal hearing and otosclerosis audiograms.  
(A) Hearing loss can be classified as mild, moderate, severe, or profound. A normal hearing person typically can hear 
frequencies spanning 125 Hz to 8,000 Hz at intensities between 0 and 10 dB. (B) Typical audiogram of an individual 
with otosclerosis. A gap between air conduction (o) and bone conduction ( [ ) is seen in these individuals. A 
characteristic Carhart’s notch is evident at the 2,000 Hz frequency (Audiogram based upon image from Uppal et al., 
2009). 
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Upon physical examination, the tympanic membrane may display a characteristic pink tinge 
due to the vascular nature of the lesion below. This is often referred to as the Schwartz sign. 
Although physical examination combined with audiometric analysis is usually effective at 
diagnosing otosclerosis, the most definitive diagnosis is confirmation during stapes surgery. 
 
1.3.5 Treatment for otosclerosis 
There are several treatment options for a patient once diagnosed with otosclerosis including 
both non-surgical and surgical options.  The choice of treatment will be determined by the 
patient's personal circumstances, age and general health and will be decided upon during a 
consultation between the otosclerosis patient and an otolaryngologist. 
 
1.3.5.1 Non-surgical management of otosclerosis 
Some patients may choose not to actively treat their hearing loss, but instead to monitor its 
progression. This is most likely to be suitable for elderly patients or those in poor health.  It 
may also be suitable for patients with unilateral disease who do not find that their hearing loss 
considerably impacts their quality of life. These patients will be regularly monitored for signs of 
progression of hearing loss, and in the case of those with unilateral disease, for deterioration 
in their other ear. If progression of symptoms were to occur, these patients may choose to 
discuss alternative treatment options with their otolaryngologist. 
Other otosclerosis patients may opt for a hearing aid. This is predominantly suitable for those 
with losses of 60dB or less and with purely conductive hearing loss. Although patients with a 
sensorineural component to their deafness may experience problems with amplification when 
using hearing aids, some may benefit from their use (Johnson, 1993). Compression-type 
hearing aids may also be used by patients following successful stapes surgery. The advantage 
of using hearing aids over other treatments is the lack of associated side-effects. However 
despite this, few otosclerosis patients in the UK opt for hearing aids, favouring alternative 
treatments. 
Fluoride therapy is another option for patients who cannot or choose not to undergo surgery.  
In the 1960s, it was suggested that treatment with sodium fluoride may slow the progression 
of otosclerosis symptoms (Shambaugh and Scott, 1964) and a number of case-control studies 
in the 1980s indicated that there was less hearing deterioration in otosclerosis patients who 
had been treated with sodium fluoride (Bretlau et al., 1985, Bretlau et al., 1989). However this 
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correlation has not been supported by all studies (Vartiainen and Vartiainen, 1997a, Vartiainen 
and Vartiainen, 1997b). A recent review of the literature published since the 1960s concluded 
that there is some evidence to suggest that sodium fluoride may be of benefit to preserve 
hearing in otosclerosis patients but that the quality of evidence in some of these studies is 
weak (Cruise et al., 2010). Currently, sodium fluoride treatment is not common practice in the 
UK although it is recommended in some rare cases.  
Bisphosphonates, which are known to affect bone remodelling, have also been used in the 
treatment of otosclerosis, specifically for patients with a sensorineural component to their 
hearing loss. The benefits of first-generation bisphosphonates such as etidronate were 
investigated in the early 1990s, but were not found to have a significant impact on progression 
of otosclerosis (Kennedy et al., 1993). However, over the past several years, nitrogen-
containing bisphosphonates such as risedronate and zoledronate which offer more potent 
bone remodelling inhibition than early generation bisphosphonates have been developed. A 
recent study using these drugs indicated that progression of sensorineural hearing loss in 
otosclerosis was reduced following treatment (Quesnel et al., 2012). However, like fluoride 
therapy, bisphosphonate treatment is not common practice in the UK. 
 
1.3.5.2 Surgery for otosclerosis 
In the UK, stapes surgery is the most common treatment option for conductive otosclerosis. 
Most surgeons opt for laser-assisted stapedotomy surgery, which involves the surgical removal 
of the stapes suprastructure and insertion of a piston-like prosthesis which connects the incus 
to the inner ear.  Stapedectomy surgery is a less common alternative where the whole stapes 
bone is excised and replaced with a micro prosthesis. This technique was used predominantly 
prior to the introduction of stapedotomy and remains common practise in some countries. 
Although the choice of technique is dependent on the surgeon and patient, evidence suggests 
that stapedotomy is less likely to result in complications such as uncontrolled leakage of 
perilymph and damage to the inner ear than stapedectomy (Thamjarayakul et al., 2010). Other 
complications associated with stapes surgery include dizziness following the procedure, which 
is usually transient though occasionally may be permanent, and in rare cases total loss of 
hearing may occur in the operated ear, although this occurs in less than 1% of cases. There is 
also a minimal risk of facial palsy due to the close proximity of the facial nerve and the stapes, 
which should be discussed with patients prior to surgery. Recent studies have suggested that 
the stapedotomy procedure can be further improved by use of a CO2 laser in conjunction with 
a scanner system, which reportedly increases accuracy of the technique and reduces the risk of 
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irradiation of inner ear structures (Albers et al., 2011). Although stapes surgery is very effective 
and in most cases improves or fully restores hearing, disease recurrence may occur if 
complications are encountered. In such cases, revision surgery may be required. In otosclerosis 
patients with bilateral hearing loss, the surgeon will usually choose to operate on the most 
severely affected ear first and will wait until the outcome of the surgery is known before 
deciding whether or not to proceed with stapes surgery on the second ear. 
 
1.4 Development of the stapes 
The middle ear is a composite organ formed from all three primary germ layers; the 
endoderm, mesoderm and ectoderm of the developing embryo, as well and the neural crest, a 
pluripotent cell population which is derived from the neural plate during early embryogenesis 
(Couly et al., 1993).  During embryonic development, the neural crest cells disperse from the 
surface of the neural tube giving rise to a variety of differentiated cell types.  At the initiation 
of craniofacial development, the neural crest cells begin to populate the branchial arches 
which give rise to various skeletal structures of the head and neck including the jaw, larynx, 
trachea and the auditory ossicles. The way in which the auditory ossicles develop in the middle 
ear of the human embryo is unclear and this is particularly true of the stapes (Rodriguez-
Vazquez, 2005). Whilst it is thought that the malleus and incus develop from the first branchial 
arch, the stapes is thought to develop from the second.  
A number of theories have been proposed to explain stapedial development in the embryo. 
The one most widely accepted is that the stapes develops from a unique source of cartilage 
within the second branchial arch known as Reichart’s cartilage (Hamilton, 1975). However, it 
has also been proposed that the stapes originates from a double source, where the stapes 
suprastructure develops from Reichert’s cartilage and the footplate from the tissue of the otic 
capsule (Cauldwell, 1942).  This theory was supported by a recent study which used transgenic 
reporter mice to demonstrate the dual origin of the stapes. This study found that the stapes 
suprastructure and base of the stapes develops from tissues of the neural crest, whilst the 
outer rim of the stapes footplate develops from the mesoderm (Thompson et al., 2012). This 
supports the concept of a dual origin for the stapes, indicating that development of the stapes 
footplate is intricately linked with development of the otic capsule.  
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1.4.1 Development of the otic capsule 
The otic capsule is the cartilaginous structure which surrounds and protects the mechanism of 
the inner ear. It initially develops through the process of chondrogenesis in response to growth 
factors secreted from the developing embryonic otocyst, such as transforming growth factor 
beta 1 (TGFβ1) and other members of the transforming growth factor beta superfamily 
including bone morphogenetic proteins 2 and 4 (BMP2 and BMP4) (Thompson et al., 2012). 
Chondrogenesis of the otic capsule is followed by endochondral ossification, where bone 
develops via the calcification of cartilage.  Ossification begins to appear around the round 
window at gestational week 16.5 and by 22 weeks of gestation covers the cochlea and 
vestibule (Declau et al., 1989). Remnants of embryonic cartilage known as globuli interossei 
remain in the otic capsule into adulthood (Schuknecht and Gacek, 1993). These Globuli 
interossei express collagen type II genes (Niedermeyer et al., 2007) and have been proposed to 
predispose the otic capsule to development of otosclerotic lesions (Wang et al., 1999). 
 
1.5 Bone remodelling in the otic capsule 
Bone remodelling is the dynamic process responsible for turnover and renewal of the skeleton 
which is coordinated by osteoblast and osteoclast cells, which form and resorb bone 
respectively. The remodelling cycle involves removal of mineralised bone which is carried out 
by osteoclasts, followed by production of new bone matrix by osteoblasts which subsequently 
become mineralised resulting in the production of osteocytes, the most commonly found cell 
in mature bone.  The cycle consists of a series of overlapping phases including osteoclast 
recruitment, bone resorption, and bone formation. The adult human skeleton experiences 
bone turnover at a rate of approximately 10% per year which is crucial for maintenance and to 
repair damage to the bone matrix. However, unlike the other bones in the human skeleton, 
the otic capsule normally undergoes limited remodelling after development, with turnover 
rate of just 0.13% per year (Frisch et al., 2000).   
During bone remodelling, mesenchymal stem cells are recruited to the site of damage and 
produce macrophage colony stimulating hormone which stimulates the differentiation of cells 
from the haematopoetic stem cell lineage into mononuclear cells or pre-osteoclasts 
(Figure ‎1.6). These express the receptor activator of NFκB known as RANK on their surface. 
Differentiation factors such as runt-related transcription factor 2 (RUNX2), cause the 
Mesenchymal Stem Cells to differentiate into pre-osteoblasts (Figure ‎1.7). These express the 
RANK ligand (RANKL) on their surface which interacts with the RANK membrane receptors on 
the surface of pre-osteoclast cells, stimulating differentiation into mature osteoclasts. This 
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process of osteoclastogenesis is triggered indirectly by the production of parathyroid hormone 
in response to damage.  Parathyroid hormone stimulates the up-regulation of RANKL on the 
surface of pre-osteoblasts, which results in increased binding with RANK on the surface of pre-
osteoclasts, activating the signalling pathways that lead to osteoclast differentiation. Mature 
osteoclasts are large multinucleated cells that release the lysosomal enzymes that trigger bone 
resorption. The mature osteoclasts resorb bone on the matrix surface before undergoing 
programmed cell death via apoptosis. As the bone matrix is resorbed, it is replaced by the 
action of osteoblasts. Osteoblasts develop from pre-osteoblasts when stimulated by 
osteoblastogenesis inducing factors such as bone morphogenetic proteins and Wnt ligands.  
These inducing factors suppress the transactivation of peroxisome proliferator-activated 
receptor γ (PPARγ), a transcription factor that supresses osteoblastogenesis (Takada et al., 
2009) (Figure ‎1.7). Mature osteoblasts secrete osteoprotegerin (OPG), a member of the TNF 
receptor superfamily which can also bind to the RANK ligand, out-competing RANK and thus 
inhibiting osteoclast activation. The rate of bone turnover can therefore be controlled by the 
OPG/RANKL ratio. Mature osteoblasts express type 1 collagens and bone sialoprotein, which 
are key components of the bone matrix.  As they lay down the matrix, some osteoblasts 
become embedded as it calcifies. These osteoblasts become osteocytes, the most common cell 
within bone (For review see Hadjidakis and Androulakis, 2006) (Figure ‎1.6).   
 
 
Figure ‎1.6 The bone remodelling cycle 
Remodelling begins when osteoclasts resorb bone mineral and matrix. Mononuclear cells prepare the resorbed 
surface for osteoblasts, which generate newly synthesised matrix as they differentiate. Matrix mineralisation and 
the differentiation of some osteoblasts into osteocytes completes the remodeling cycle (From Kapinas and Delany, 
2011). 
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Figure ‎1.7 Molecular interactions involved in bone remodelling 
The first step in bone remodeling involves commitment by Mesenchymal Stem Cells (MSCs) to the osteoblastic 
lineage.  RUNX2 is required for MSC differentiation into preosteoblasts. PPARγ inhibits osteoblastogenesis, reducing 
the number of osteoblasts in the bone marrow. PPARγ also stimulates osteoclastogenesis from Haematopoetic 
Stem cell (HSCs). The OPG/RANKL ratio regulates the balance between osteoblastogenesis and osteoclastogenesis 
(Adapted from Kawai et al., 2009). 
 
It has been suggested that the reduced rate of bone turnover in the otic capsule relative to 
other skeletal structures is due to the production of the osteoclastogenesis inhibitory factor 
OPG by the cochlea. It is thought that when OPG is secreted into the cochlear perilymph, it can 
diffuse into the otic capsule inhibiting remodelling (Zehnder et al., 2005). In the absence of 
OPG, mice experience activation of bone remodelling in the otic capsule and subsequent 
progressive hearing loss (Zehnder et al., 2006). This suggests that OPG is a crucial factor for 
regulation of bone turnover within the otic capsule. 
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1.6 Animal models for otosclerosis 
Otosclerosis is a condition unique to humans affecting exclusively the human temporal bone 
for which no representative animal model has been proposed. The aforementioned 
(section ‎1.5) OPG knock-out mouse is possibly the best candidate animal model for 
otosclerosis suggested to date. These mice experience activation of bone remodelling in the 
otic capsule and display well- defined regions of bone resorption and deposition within the otic 
capsule, similar to those seen in otosclerosis. However, these mice also experience active bone 
remodelling throughout the skeleton including the other auditory ossicles, which is not seen in 
otosclerosis. Furthermore, stapes fixation is not observed in these mice (Zehnder et al., 2006). 
Despite the differences between the OPG knock-out mouse and otosclerosis, it is possibly the 
best model available for studying abnormal bone remodelling within the otic capsule, which 
resembles otosclerosis. 
In addition to the OPG knock-out mouse, two additional animal models which display 
abnormal bone remodelling within the otic capsule were proposed in the past. In the 1980s, 
the LP/J mouse which spontaneously develops abnormal bony lesions in the auditory ossicles 
and otic capsule that are histologically similar to those found in otosclerosis, was suggested as 
an appropriate animal model for otosclerosis. Like in many humans with otosclerosis, these 
mice have both conductive and sensorineural hearing loss, but in addition, they possess an 
accompanying inflammatory reaction that is not seen in otosclerosis. In addition, they display 
an autosomal recessive inheritance pattern which contrasts with the autosomal dominant 
inheritance pattern with incomplete penetrance that is seen in otosclerosis (Henry and Chole, 
1987).  
In 1990, the incisor-absent rat was also proposed as suitable model for otosclerosis. This rat 
displays progressive conductive hearing loss which manifests at puberty accompanied by bony 
abnormalities of the ossicles and oval window. These bony lesions are located at the 
incudostapedial joint and stapes footplate, and appear histologically similar to those seen in 
otosclerosis. However, although there are some similarities in abnormal otic capsule 
remodelling between the incisor-absent rat and otosclerosis, remodelling is not localised to 
the temporal bone (Kaniff et al. 1990).  
Despite a certain degree of resemblance between the phenotype of otosclerosis and each of 
the OPG knock-out mouse, LP/J mouse and the incisor-absent rat, none represent an ideal 
animal model for studying this condition. A lack of an appropriate animal model to study is just 
one of the numerous reasons why the pathophysiology of otosclerosis is yet to be elucidated. 
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1.7 The disease aetiology of otosclerosis 
Although otosclerosis is one of the most common forms of adult-onset hearing loss, little is 
understood about its pathophysiology. Since the 19th century, when familial otosclerosis was 
first described, otosclerosis has been known to have a genetic component (for review see Ealy 
and Smith, 2011). Approximately 50% of all otosclerosis cases reportedly occur in individuals 
with a family history of the condition, whilst sporadic incidents in individuals who lack a 
positive family history comprise the remainder of cases (Cawthorne, 1955). Although this 
figure of 50% is broadly accepted amongst clinicians as the proportion of otosclerosis cases 
that are familial, there is no recent evidence in the current literature to substantiate this, so it 
should be considered as an indication of familial incidence rather than as fact. The most 
plausible explanation for the occurrence of otosclerosis in both individuals with a family 
history of the condition and those without, is that single gene defects are predominantly 
responsible for the development of otosclerosis within families, whilst complex inheritance, 
where a combination of genetic and environmental factors interact leading to the disease 
phenotype, is responsible for non-familial cases (Gordon, 1989). Despite this, there is likely to 
be considerable overlap between the genetic and environmental factors involved in familial 
and non-familial disease. For example, although familial otosclerosis tends to exhibit 
monogenic autosomal dominant inheritance (Albrecht, 1922), other modes of inheritance have 
also been suggested including digenic recessive inheritance and digenic inheritance of one X-
linked dominant gene and one autosomal recessive gene (Moumoulidis et al., 2007), indicating 
that multiple genes may be involved in development of the condition in some families. In 
addition, reduced penetrance of otosclerosis is common in affected families with a reported 
frequency of approximately 40% in some studies (Larsson, 1960, Morrison, 1967), suggesting 
that environmental factors or additional modifier genes may be involved in the disease 
process.  
Monogenic inheritance and complex inheritance should therefore not be considered two 
distinct categories but rather a continuous spectrum. In general, genetic variants responsible 
for monogenic inheritance of a disease are very rare but have a large effect size which results 
in the disease phenotype. In contrast, variants that contribute to complex diseases are likely to 
be more common but tend to have smaller effect sizes, so numerous small effect variants are 
required for the disease phenotype to result (Figure ‎1.8). In otosclerosis, there is some 
evidence to suggest that both common and rare variants, as well as environmental factors are 
involved in the disease process, but the extent to which these contribute to disease 
pathogenesis has not been defined. A number of large families with monogenic inheritance of 
otosclerosis have been identified in linkage analysis studies, indicating that rare variants with 
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large effect sizes contribute to the disease process, although no definitive genes have been 
identified. In addition, common variants within otosclerosis candidate genes have been 
proposed through genetic association studies, although their effect sizes remain unknown.  
 
 
Figure ‎1.8 A spectrum of genetic variation  
At the severe (red) end of the spectrum are extremely rare (<1% minor allele frequency) mutations that have strong 
effects and typically result in monogenic disorders. In the middle of the spectrum (yellow) are rare variants with 
moderate effects that often require a second hit (eg. genetic modifier). Lastly, at the benign (green) end of the 
spectrum are common (>5% minor allele frequency) variants that have weak effects and only contribute to the 
disease in rare circumstances when multiple hits (genetic and environmental) are present (Adapted from Giudicessi 
and Ackerman, 2013). 
 
It is possible that both familial and non-familial otosclerosis are caused by genetic and 
environmental factors that affect the same gene regulatory network, but that in familial 
otosclerosis, a single gene mutation is responsible for disrupting this network, whilst in non-
familial cases, a number of genetic and environmental factors make modifications to the 
regulation of the network, which when combined result in its disruption. Here the evidence for 
both environmental and genetic factors that have been implicated in otosclerosis pathogenesis 
is evaluated, along with an overview of possible disease mechanisms. 
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1.7.1 Environmental contributors to otosclerosis 
A number of environmental factors have been implicated in the pathogenesis of otosclerosis, 
however limited progress has been made in determining the contribution of these to disease 
aetiology. Viral and endocrine influences, as well as exposure to environmental agents such as 
sodium fluoride have all been suggested to play a causative role in the development of 
otosclerosis, but despite a considerable body of research investigating these factors, the role 
that they play in disease pathogenesis is yet to be established. The lack of progress in 
elucidating the role of environmental contributors in the development of otosclerosis is 
probably largely due to the heterogeneous nature of this disorder, in which a combination of 
genetic and environmental factors are involved in disease aetiology. This makes it difficult to 
identify the precise role of each environmental contributor to the pathophysiology of 
otosclerosis. 
 
1.7.1.1 Viral infection as an otosclerosis susceptibility factor 
Since the late 1980s, there has been considerable interest in the role of persistent viral 
infection in the development of otosclerosis. A study published in 1987 detected antigens from 
the measles, mumps and rubella viruses in otosclerotic lesions through a series of 
immunohistochemistry experiments using monoclonal and polyclonal antibodies (Arnold and 
Friedmann, 1987), and early gene expression studies that detected measles virus protein 
within otosclerotic tissue supported the theory that the measles virus was implicated in 
otosclerosis development (McKenna et al., 1989). In addition, a number of reports in the 1990s 
suggested that RNA or protein from the measles virus was present in some but not all 
histologically positive otosclerotic lesions from formalin-fixed temporal bone specimens 
(Niedermeyer et al., 1994, McKenna et al., 1996), further supporting a role for viral infection in 
the disease process in some otosclerosis cases. However, when RNA was extracted from 28 
non-formalin fixed otosclerotic tissue samples which had been frozen, measles virus RNA was 
not detected (Grayeli et al., 2000). This study was therefore unable to confirm the hypothesis 
that persistent measles viral infection was involved in otosclerosis. However, it has since been 
suggested that expression of anti -measles IgG is decreased in otosclerotic patients compared 
to controls (Lolov et al., 2001, Karosi et al., 2006), and measles virus receptor CD46 has been 
found to be highly expressed on the surface of cells within the otic capsule (Karosi et al., 2007), 
providing further evidence to support a role for measles viral infection in otosclerosis. 
Recently, a study of CD46 isoforms in 21 otosclerotic and 30 control stapes footplates 
identified different expression patterns in otosclerotic compared to control stapes using 
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restriction analysis and molecular weight distribution methods (Csomor et al., 2010). This was 
supported by a follow up study where histopathological examinations of control and affected 
stapes along with CD46-specific Western blot analyses were performed, identifying four novel 
CD46 isoforms in otosclerotic specimens (Karosi et al., 2008, Csomor et al., 2010). The research 
group claimed that their studies indicate the expression of a specific CD46 isoform expression 
pattern associated with otosclerosis. However quantitative data to indicate relative expression 
levels of specific CD46 isoforms in otosclerotic compared to control stapes, would be required 
to substantiate this claim. When all the evidence regarding viral infection is considered as a 
whole, there does appear to be some basis to support a role for measles viral infection as a 
trigger for the onset of otosclerosis; however this remains to be proven. 
The argument that measles infection may be an otosclerosis susceptibility factor was further 
supported by a recent study that showed a reduction in incidence of otosclerosis in Germany 
since the introduction of the measles immunisation vaccine (Arnold et al., 2007). This research 
group proposed that their observations could explain the correlation between increasing 
measles vaccination uptake rates since the 1970s and the reported decline in incidence of 
otosclerosis during recent years. However, since vaccination programmes were only 
introduced into Germany in 1974, individuals who received vaccination in childhood are only 
now reaching the typical age of onset for otosclerosis. This is therefore unlikely to be a valid 
explanation for the decreasing incidence figures. Moreover, since otosclerosis is more 
common in developed countries where measles vaccination is common, than in less developed 
countries where vaccination is rare, it is unlikely that this theory can be substantiated. 
Although this theory cannot be ruled out, more evidence is required to determine whether 
immunisation against measles protects against the development of otosclerosis. 
 
1.7.1.2 Involvement of endocrine factors in otosclerosis 
Endocrine factors such as progesterone and oestrogen have also been suggested to be 
involved in otosclerosis. This is due in part due to the discrepancy in prevalence of the disease 
between males and females and also due to the long-held belief that otosclerosis often 
manifests after or during pregnancy. Oestrogen is known to stimulate osteocyte activity 
(Arnold et al., 1996) which may account for the increase in disease development rate during 
pregnancy when there is a steady increase in oestrogen levels from the tenth week of 
gestation. In the 1980s, a large, retrospective study of 479 females with otosclerosis 
documented a subjective impression of deterioration of hearing during pregnancy, concluding 
that pregnancy does trigger deterioration of hearing in otosclerosis patients, particularly 
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during subsequent pregnancies (Gristwood and Venables, 1983). However, the evidence 
attributing otosclerosis development to hormonal changes during pregnancy has been 
somewhat contradictory in more recent studies (Vessey and Painter, 2001, Lippy et al., 2005), 
with a 2005 study showing no difference in hearing ability between 47 women with children 
and 47 without, all of whom had undergone stapes surgery (Vessey and Painter, 2001, Lippy et 
al., 2005). The lack of support for a role of hormonal changes in otosclerosis from recent 
studies suggests that the link between otosclerosis and pregnancy may be spurious. It is 
possible that this is due to the fact that the typical age of onset of otosclerosis coincides with 
average child-bearing age, indicating that the link be may coincidental rather than causal.  In 
addition, it appears that the origin for the argument that pregnancy accelerates hearing loss in 
otosclerosis originally stemmed from a 1939 paper by the Agency of Expert Opinion of the 
German Reich, indicating abortion and sterilisation as treatment for otosclerosis. It is therefore 
possible that the initial link between otosclerosis and pregnancy was falsified by the Nazis in an 
attempt to prevent reproduction for eugenic purposes (for review see Lippy et al. , 2005). 
Prolonged use of oral contraceptives and hormone replacement therapy have also been 
suggested as susceptibility factors in otosclerosis (Podoshin et al., 1978), however no evidence 
was found to support this during a study which investigated adverse effects of oral 
contraceptives on otosclerosis and vestibular disorders in a large population (Vessey and 
Painter, 2001). Overall, with the exception of one large study conducted in the 1980s, there is 
little evidence to support a role for hormonal factors in otosclerosis pathogenesis. However, it 
should not yet be ruled out as a possible susceptibility factor. An improved understanding of 
the molecular mechanism involved in otosclerosis could help to elucidate what role, if any, 
hormonal factors play in otosclerosis pathology. 
 
1.7.1.3 The contribution of fluoride to otosclerosis development 
Another environmental factor implicated in otosclerosis is fluoride. Sodium fluoride is found 
naturally in ground water, but is also added to the water supply in some countries due to 
known dental benefits in children. An epidemiological study in the 1960s showed that 
otosclerosis is more common in areas with low fluoride content in the drinking water (Daniel, 
1969). However a residential history questionnaire supplied to individuals born between 1948 
and 1962 in two regions in Finland, one with fluoridated water and the other without, was not 
able to find any difference in cases of otosclerosis between the regions (Vartiainen and 
Vartiainen, 1997a). The same research group were also unable to find evidence that sodium 
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fluoride exposure affected hearing in 294 otosclerosis individuals in the years following their 
stapedectomy surgery (Vartiainen and Vartiainen, 1997a).  
There have been several explanations as to the role of fluoride in otosclerosis development. It 
has been proposed that sodium fluoride could inhibit proteolytic enzymes, which could 
decrease the rate of disease progression (Causse et al., 1980). Alternatively, it has been 
hypothesised that sodium fluoride may inhibit the activity of DTDST, a diastrophic dysplasia 
sulphate transporter which is involved in bone matrix synthesis (Grayeli et al., 2003). This 
could account for the association between otosclerosis and fluoride; however, it is difficult to 
quantify the role of fluoride in the disease process due to difficulties in measuring a person’s 
lifetime exposure to this ion. 
 
Overall, the evidence for a role of environmental factors in otosclerosis is inconclusive, largely 
due to limitations associated with quantifying exposure to environmental agents. Having said 
this, whilst there is minimal evidence to support a role for endocrine factors and fluoride in 
otosclerosis, the role for viral infection is better substantiated by the data. Further studies are 
essential to establish whether or not these factors are involved in disease pathogenesis. 
 
1.7.2 Genetics of otosclerosis 
Over the past several decades, the methods for gene identification in families exhibiting 
monogenic inheritance of otosclerosis have centred on traditional linkage analysis followed by 
the selection of candidate genes for genetic testing, a technique which has proven successful 
at identifying the chromosomal region in which disease causing mutations are located in many 
Mendelian traits. Association studies have also been used to investigate genetic variants 
involved in otosclerosis. Whilst family studies tend to focus on the identification of rare 
variants with large effect sizes, association studies attempt to identify more common variants 
with smaller effect sizes that work in combination with other genetic and environmental 
factors to result in the disease phenotype. In addition, analysis of gene expression profiles in 
diseased stapes tissue has also been used to investigate genetic contributors to this disease. 
Whilst gene expression analysis is unlikely to pinpoint a specific disease causing gene, it can be 
used to identify dysregulated gene pathways in the tissue of interest, which can help improve 
understanding of molecular processes involved in disease development. Here, the various 
approaches taken in attempts to identify otosclerosis causing genes will be discussed and the 
outcomes of these strategies evaluated. 
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1.7.2.1 Linkage analysis in otosclerosis families 
Linkage analysis is a technique that involves pinpointing a location in the genome at which a 
disease causing mutation is located. Thousands of genetic markers are used to identify a locus 
that segregates with the disease in affected family members, in the hope of identifying the 
disease causing mutation within the segregating region. Although this technique has been 
extremely successful in the identification of genetic mutations in numerous Mendelian 
disorders, the success of linkage analysis in otosclerosis families has been limited. This is 
largely due to the fact that otosclerosis exhibits reduced penetrance, and as a result, 
unaffected individuals in the family may possess the disease genotype but not display 
symptoms, which has hampered the identification of true familial controls. This has hindered 
investigators from effectively honing in on the disease causing region, resulting in the 
identification of large linked regions in which the disease causing mutation is presumed to be 
located. In most cases, these regions contain large number of genes and given that the disease 
process involved in otosclerosis is unknown, identifying appropriate candidate genes within 
these large regions has proven problematic. Success of linkage analysis has also been limited 
by difficulty in identifying appropriate families. Since otosclerosis is an adult onset disorder, 
there are few large families with living affected individuals across multiple generations, which 
are required for the success of this technique. In addition, since otosclerosis is a 
heterogeneous disorder in which variants within different genes are responsible for onset of 
the condition in different families, a pooling strategy using multiple families is not appropriate 
for the identification of disease causing genes. 
Despite these limitations, at least eight loci have been identified through linkage analysis, 
which have been designated OTSC1 to 10 (loci OTSC6 and OTSC9 remain unpublished) 
(Table ‎1.1). These loci vary in size from just 12 protein coding genes identified in the 
overlapping segregating regions between two families in OTSC7 (Thys et al., 2007b), to as 
many as 423 protein-coding genes in OTSC3 (Chen et al., 2002, Ali et al., 2007). However, 
despite further investigation, no disease causing mutations have been identified within any of 
these regions. This is likely due to the variable penetrance issue which results in the 
identification of large linked regions containing numerous genes from which it is difficult to 
select appropriate candidates for sequencing. Alternatively the presence of phenocopies 
within these families, where an individual displays a phenotype difficult to distinguish from 
otosclerosis on clinical grounds, may also have hindered the identification of disease-causing 
genes. Despite this, a number of good candidate genes have been identified within each of 
these regions, as is discussed below. 
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Locus Position 
County of 
origin of 
family 
Publication reference 
Maximum 
multipoint 
LOD score 
No. protein 
coding genes in 
linked region 
OTSC1 15q25-26 India (Tomek et al., 1998) 3.4 89 
OTSC2 7q34-36 Belgium (Van Den Bogaert et al., 2001) 3.54 93 
OTSC3 6p21-22 
Cyprus (Chen et al., 2002) 3.83 
423 
Tunisia (Ali et al., 2007) 2.04 
OTSC4 16q21-23 Israel (Brownstein et al., 2006) 3.97 115 
OTSC5 3q22-24 Netherlands (Van Den Bogaert et al., 2004) 3.46 79 
OTSC7 6q13-16 
Greece 
(Thys et al., 2007b) 
7.5 72 
Netherlands 1.96 22 
OTSC8 9p13-9q21 Tunisia (Bel Hadj Ali et al., 2008) 4.13 49 
OTSC10 1q41-44 Netherlands (Schrauwen et al., 2011) 3.3 148 
 
Table ‎1.1 Table of otosclerotic loci identified by linkage analysis  
Otosclerotic loci identified during linkage analysis in families exhibiting autosomal dominant inheritance of 
otosclerosis. Number of protein coding genes located within the linked regions based on Ensembl release 69 
Assembly Grch37 
 
The first linkage analysis study for otosclerosis was performed on a large multigenerational 
Indian family exhibiting autosomal dominant inheritance of otosclerosis, in which no 
consanguinity was recorded. Five members of this family had surgically confirmed otosclerosis 
and an additional nine had conductive hearing loss suggestive of otosclerosis but had not 
undergone stapes surgery. In this family, severity of hearing loss based on audiometric analysis 
increased with advancing age. Genetic linkage analysis was performed using short tandem 
repeat polymorphisms (STRPs) throughout the genome which indicated a 14.5cM region 
flanked by centromeric marker FES and telomeric marker D15S657 on chromosome 15q25-26 
that segregated with the disease in the family (maximum lod score=3.4) (Tomek et al., 1998).  
Since the identification of this first linked region, seven additional otosclerotic loci have been 
published that reportedly segregate with otosclerosis in large affected families. All families 
investigated are reported to exhibit autosomal dominant inheritance of otosclerosis. However, 
two of these families, the Greek family segregating with OTSC7 and the Tunisian family 
segregating with OTSC8, reported a history of consanguinity which could be suggestive of 
autosomal recessive inheritance. However analysis of these family pedigrees, suggests that this 
is unlikely. The age of onset of hearing loss was variable across affected family members in all 
of the families, with the exception of the Greek family in which the OTSC7 locus was identified, 
where disease onset commonly occurs during childhood at an average of age 10.  
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In total, six of the eight published otosclerotic loci have been mapped in just one otosclerosis 
family, whilst two loci, OTSC3 and OTSC7, have been mapped in multiple families. The OTSC3 
locus was identified in two families, one of Cypriot origin and one of Northern Tunisian origin, 
and the OTSC7 locus was identified in two families, one of Greek and one of Dutch origin. The 
subsequent identification of the Dutch family mapping to OTSC7 enabled fine mapping of the 
region, narrowing down the candidate interval to just twelve protein coding genes (Ensembl 
release 69 Assembly Grch37). At the Congres Francais d’Oto-Rhino-Laryngologie et de 
Chirurgie de la Face et du Cou in Paris in 1999, it was reported that a Tunisian family may also 
map to the OTSC1 locus (Drira, 1999), however the data from this study is not accessible for 
the identification of overlapping linked regions. There are also reports that two additional 
Belgian families may have been mapped to OTSC2 (Ealy, 2011). However, a recent study of 
seven British Caucasian otosclerosis families found no linkage to the OTSC2 locus (Alzoubi et 
al., 2007), though this was explained by a lack of power associated with the small number of 
families recruited for analysis. This explanation is likely to be accurate as due to the highly 
heterogeneous nature of the disease, confirmed by the numerous otosclerotic loci identified 
through linkage analysis, it appears that a different genetic factor or factors are responsible for 
the disease in most otosclerosis families identified. 
In all eight otosclerotic loci identified, a significant LOD score greater than 3.3 was identified in 
each of the first families mapped to the locus. This threshold of 3.3 is necessary when genome-
wide linkage analysis is performed as multiple testing must be taken into consideration. 
However, when linkage analysis is performed to investigate segregation with a known linked 
region, a LOD score greater than 1.9 is sufficient to suggest linkage to the region (Lander and 
Kruglyak, 1995). Therefore LOD scores of 2.04 and 1.96 for the second families mapped to 
OTSC3 and OTSC7 respectively are sufficient to suggest linkage to these loci, as in these cases, 
the locus had previously been mapped. The highest multipoint LOD score of 7.5 was identified 
in the Greek family, in which the OTSC7 locus was mapped, providing the strongest evidence 
for linkage of all of the families. A possible explanation for the high LOD score in this family is 
the severe phenotype, characterised by childhood onset hearing loss. This phenotype makes it 
easier to distinguish between affected and control individuals than in other families with adult 
onset symptoms. As a result, it is likely that variable penetrance was less of an issue when 
performing linkage analysis in this Greek family than in the other families. 
The regions mapped during linkage analysis range in size from the overlapping region 
identified for OTSC7, which contains just 12 protein coding genes, to OTSC3, which contains 
423 protein coding genes (Ensembl release 69 Assembly Grch37). In each family, possible 
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otosclerosis candidate genes were proposed within the linked regions and in some cases were 
sequenced, in the hope of identifying a disease causing mutation. In OTSC1, aggrecan was 
pinpointed as a possible otosclerosis candidate within the 14.5cM region mapped. This is a 
component of the extracellular matrix which is expressed in the bony labyrinth of the ear.  
However, no disease causing variants were identified through the sequencing of aggrecan, 
suggesting that it is not the causative gene in this family. In OTSC2 Procollagen-Lysine, 2-
Oxoglutarate 5-Dioxygenase 3 (PLOD3), tripartite motif containing 24 (TRIM24) and T-cell 
recptor beta (TCRβ) were suggested as potential otosclerosis candidates.  PLOD3 is involved in 
the synthesis of collagen, a key component of bone and has been implicated in Ehlers-Danlos 
syndrome type VIB, a connective tissue disorder that has been reported to occasionally occur 
concomitantly with otosclerosis (Miyajima et al., 2007). TRIM24 is a transcriptional co-
activator that plays a role in bone remodelling and is therefore a good otosclerosis candidate. 
TCRβ encodes a protein involved in antigen recognition in the immune system. Although 
sequencing of TCRβ found no causal genetic mutations within the family that mapped to this 
locus, affected members of this family have been found to have decreased expression of TCRβ 
mRNA and fewer circulating TCRαβ+ T cells relative to controls (Schrauwen et al., 2010b). 
OTSC3 maps to a region containing the MHC locus, which has been proposed as the most likely 
location of the disease-causing mutation within the family that mapped to this linked region. 
Within OTSC4, a number of zinc finger proteins were suggested by the authors who identified 
the linked region as the most likely candidates (Brownstein et al., 2006) and in OTSC5, 
procollagenase endopeptidase enchancer 2 (PCOLCE2) and carbohydrate sulphotransferase  2 
(CHST2), were suggested as candidates, though, neither was found to contain disease causing 
mutations. In OTSC7, although fine mapping of the overlapping segregating regions between 
the Greek and Belgian families enabled the identification of just twelve overlapping protein 
coding genes, none of these were found to contain a disease-causing mutation in either of the 
families during sequencing.  It is therefore possible that the mutation resides within a 
regulatory element in this region. Alternatively it is possible that different mutations are 
responsible for the disease in each of these families.  In OTSC8, genes encoding a tight junction 
protein, a protein involved in calcium signalling and osteoclast function, and a protein involved 
in craniofacial development were ruled out as good candidates by sequence analysis. In 
OTSC10, transforming growth factor beta 2 (TGFβ2) and angiotensinogen (AGT) were proposed 
as the most likely candidates but sequencing revealed no pathogenic variants (Schrauwen et 
al., 2011). 
Although eight otosclerotic loci have been successfully identified in otosclerosis families using 
linkage analysis, no disease causing mutations have been found using this technique. This may 
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be partly because even though good candidates within the mapped regions have been 
identified, and in some cases screened, in total, only a small proportion of known genes within 
these eight regions have been sequenced. Since little is known about otosclerosis 
pathogenesis, it is not surprising that the selection of arbitrary candidates based on 
assumptions about the disease process, has not yielded promising results. A better 
understanding of the disease process would enable the selection of better candidates within 
the regions, which may increase the likelihood of identifying otosclerosis causing variants 
within these families. Another limitation of these studies is that in most cases, only the coding 
regions of these good candidates have been sequenced. Whilst this is a good starting point as 
the majority of disease causing mutations are located in coding regions of genes, deep 
resequencing of promoter and enhancer elements, as well as the 5' and 3' untranslated 
regions would also be useful, as it is possible that disease causing variants could reside within 
these regulatory regions. The limited success of linkage analysis as well as the identification of 
multiple loci in different families, confirms the highly heterogeneous nature of otosclerosis.  
 
1.7.2.2 Candidate gene case control association studies for otosclerosis 
Association studies can be used to identify genetic variation that is associated with a disease or 
trait. These studies use single nucleotide polymorphisms (SNPs) as genetic markers to identify 
genetic associations. A population-based candidate gene case control association study tests 
the relationship between polymorphisms within a candidate gene and the disease or trait of 
interest. In a population-based study, an association indicates that a specific allele, genotype 
or haplotype is significantly more or less common in a cohort of affected individuals than in a 
cohort of controls.  This indicates that the associated variant increases or decreases a person’s 
susceptibility to developing the disease phenotype. In addition to population-based studies, 
association studies can also be used to investigate common variants within family trios.  
There are several limitations associated with association studies. These include that 
identification of an association with a specific variant does not always mean that it is involved 
in the development of the disease (Daly and Day, 2001). When association studies are 
performed, it is not feasible to investigate association of every single known variant within a 
region of interest. Therefore tagSNPs are used which are single SNPs located within a block of 
linkage disequilibrium (LD) which contains a number of SNPs that segregate with one another. 
Therefore finding an association with a SNP during an association study represents an 
association of an allele within the block of LD in which the tagSNP is located. The use of 
tagSNPs therefore helps to hone in on a region of the gene or genome on which further studies 
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can then be performed. Another considerable limitation of association studies is the 
identification of false positives in the data, where a polymorphism is incorrectly attributed an 
association with the disease or trait. It is important that cases and controls are age, gender and 
ethnicity matched as much as possible to avoid false positives as a result of population 
stratification (Koller et al., 2004). Due to the issue of false positives, replication of findings is 
required to confirm an association and in most cases is essential prior to publication of results. 
In addition, a cohort size with sufficient statistical power is crucial for success of association 
studies. The size of the cohort required to achieve significance is dependent upon prevalence 
of the disease or trait, the minor allele frequency of the polymorphism in question and the 
ratio of cases to control being tested. The greater the number of polymorphisms interrogated 
simultaneously, the larger the cohort required in order to account for corrections for multiple 
testing (Hong and Park, 2012). To date, members of three gene families have been 
investigated for associations with otosclerosis using this technique; the collagen gene family, 
the transforming growth factor beta gene family and genes encoding proteins involved in the 
renin-angiotensin-aldosterone pathway, which are discussed below. 
 
 Association studies to investigate members of the collagen gene family 1.7.2.2.1
Collagen is the most abundant protein in mammals and is the major component of connective 
tissues which exists in various forms as elongated fibrils (Bornstein, 1979). It is found within 
fibrous tissues and is abundant in bone, cartilage, skin, the gut, the cornea and a number of 
other tissues. It is known to be involved in the development of a number of connective tissue 
disorders affecting the bone including Osteogenesis Imperfecta (OI), a systemic disease caused 
by defective connective tissue which results in brittle bones and where patients often 
experience conductive hearing loss similar to that seen in otosclerosis. Collagen genes have 
long been postulated to be involved in the development of otosclerosis due to the crucial role 
of collagen proteins in the structure of bone and their role in OI. It is therefore not surprising 
that the earliest candidate gene case control association studies focused on members of the 
collagen gene family. 
The first otosclerosis association study was conducted in the 1990s and investigated an 
association between variants in collagen type 1A1 (COL1A1) and otosclerosis in a small 
American population. An  association was found between the condition and three polymorphic 
markers within the gene (McKenna et al., 1998). Subsequently, a larger case-control study was 
carried out in a population of 100 American cases and 108 controls by the same research 
group (McKenna et al., 2004). Analysis of the COL1A1 region showed that of the three 
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polymorphic markers previously identified, one was located within an Sp1-binding site in the 
first intron of COL1A1, which showed a strong association with otosclerosis (p <0.0001). This 
polymorphism is known to be associated with osteoporosis (Grant et al., 1996), a disease that 
causes a reduction in bone density, increasing the risk of fracture. Although the association 
found in this study was significant, the control group was not age and gender matched to the 
test population and the cohort size was small. It was therefore crucial that these findings were 
replicated before an association could be confirmed. In 2007, a larger study of American and 
German otosclerosis patients consisting of 206 cases and 385 controls identified a haplotype 
block containing the Sp1-binding site polymorphism which was present at a significantly 
greater  frequency in affecteds than controls (Chen et al., 2007b), and a recent study in a small 
population of 28 Turkish patients and 50 age and gender matched controls found a significant 
association with this polymorphism and otosclerosis (p<0.01) (Ertugay et al., 2013). However, a 
replication study in a Spanish cohort of 100 cases and controls failed to confirm these findings 
(Rodriguez et al., 2004). The difference in outcomes between these studies may have been due 
to the differing sizes of the cohorts investigated as the results obtained from analysis of 
smaller cohorts are less likely to be reliable than those from larger cohorts. It is also possible 
that the discrepancy in findings could be due to the different ethnic origins of the cohorts 
investigated, as some polymorphisms are more common in certain populations. In 2012, a 
meta-analysis was performed to analyse the genetic association between COL1A1 and 
otosclerosis by gathering data collected from all populations studied to date (Schrauwen et al., 
2012). This study supported the evidence from previous studies for an association between 
COL1A1 and otosclerosis, however it was expected that the effect sizes of the variants 
reported in earlier studies were likely to have been overestimated. 
A role for COL1A1 in disease pathogenesis can be further supported by a gene expression 
study, where COL1A1 showed evidence for reduced expression in two out of nine otosclerotic 
stapes analysed, indicating that COL1A1 mutations may be involved in a small percentage of 
cases of otosclerosis (McKenna et al., 2002). The lack of altered expression in the remaining 
seven stapes indicates that in the majority of cases, COL1A1 is not dysregulated, suggesting 
that other genes are likely to be involved in disease aetiology and confirming the 
heterogeneous nature of this condition. A more recent gene expression study conducted by a 
Hungarian group in a larger population of 55 otosclerotic stapes, failed to identify 
dysregulation of COL1A1 or Collagen type 1A2 (COL1A2), another type 1 collagen gene, in 
otosclerotic stapes tissue (Csomor et al., 2012). It has been hypothesised that otosclerosis may 
be caused by an increase in COL1A1 expression which would lead to an increase in COL1A1 
homotrimers, by affecting the ratio of COL1A1 to COL1A2, resulting in deposition of bone 
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within the otic capsule (Chen et al., 2007b).  This theory is consistent with findings that mice 
with a targeted COL1A2 deletion experience thickening of the stapes footplate and mild 
hearing loss.  Despite, this no association of otosclerosis with COL1A2 has been found 
(McKenna et al., 1998). 
 
 Association studies investigating the transforming growth factor beta superfamily 1.7.2.2.2
of genes 
The transforming growth factor beta super-family is a large family of related proteins involved 
in growth, development, homeostasis and regulation of the immune system. The name of this 
family is derived from the first member to be described, transforming growth factor beta 1 
(TGFβ1), a secreted polypeptide that stimulates osteoblastogenesis and inhibits 
osteoclastogensis. The TGFβ super-family also includes the bone morphogenetic proteins, a 
group of growth factors with the ability to induce bone and cartilage formation. For these 
reasons, members of the TGFβ super-family have been repeatedly proposed as good 
otosclerosis candidate genes and have been investigated for associations with otosclerosis 
through association studies.  
A case-control study of 632 Belgian-Dutch cases and controls conducted in 2007 found that a 
SNP in TGFβ1 encoding an amino acid change from threonine to isoleucine at residue 263  was 
significantly associated with otosclerosis (p=0.0044) (Thys et al., 2007a). This finding was 
supported by a French replication set of 457 cases and 497 controls (p=0.00019). Following 
corrections for multiple testing, this association remained significant in both populations. 
Functional analysis of this SNP with a luciferase reporter assay concluded that the 
Isoluecine263 allele is more active than the Threonine263 allele. It was therefore suggested by 
the research group that Isoleucine263 may protect against otosclerosis by preventing bone 
resorption during early disease development. Three additional rare nonsynonymous mutations 
were also identified in TGFβ1 during sequence analysis using 388 Belgian-Dutch cases and 380 
controls and a French replication set of 367 cases and 497 controls (Thys et al., 2009). In 
addition, a recent study identified a de novo heterozygous mutation in the promoter region of 
TGFβ1 in an individual with otosclerosis and also identified an increase in TGFβ1 mRNA in 
diseased stapes compared to controls (Priyadarshi et al., 2013).  
Bone morphogenetic proteins 2 and 4 (BMP2 and BMP4), also members of this family, have 
been associated with otosclerosis in the same large Belgian-Dutch and French populations 
investigated for association with TGFβ1 (Schrauwen et al., 2008).  Two SNPs were identified 
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that showed the same significant effect in both populations; SNP rs3178250 located in the 3' 
untranslated region of BMP2 (p=2.2x10-4) and SNP rs17563 in BMP4 (p=0.002). Both genes are 
known to play a role in otic capsule development in the developing chick (Chang et al., 2002) 
and have therefore been proposed as potential otosclerosis candidate genes.  
These studies investigating an association between otosclerosis and multiple members of the 
TGFβ super-family are fairly large and thus provide reliable evidence indicating that common 
variants within these genes may predispose an individual to otosclerosis. However, the effect 
size of the variants within these genes on the disease process remains unknown. Further 
functional studies are required to confirm involvement of these genes in disease aetiology and 
to quantify their contribution to pathogenesis. 
 
 Association studies to investigate the renin-angiotensin-aldosterone pathway 1.7.2.2.3
There is considerable interest in the role that hormonal factors involved in pregnancy play in 
the development of otosclerosis. This stems from the observation of a possible increased 
frequency of otosclerosis in females, and the fact that the average age of onset coincides with 
child-bearing age. For this reason, angiotensin-converting enzyme (ACE), along with 
angiotensinogen (AGT), genes that are known to be up-regulated during pregnancy (Schrier 
and Durr, 1987), were investigated for an association with otosclerosis. This study in a French 
population of 186 cases and 526 controls, identified a polymorphism in ACE that is associated 
with otosclerosis (p<0.05) (Imauchi et al., 2008). This polymorphism is characterised by the 
insertion or deletion of a 287 base pair sequence in intron 16 of this gene, which is expected to 
increase the enzymatic activity of the encoded protein. A variant in AGT which causes a 
methionine to threonine amino acid change at residue 235 shown to be related to higher AGT 
plasma concentrations, was also found to be associated with otosclerosis (p<0.01) in this study 
(Imauchi et al., 2008). However, a replication study of 692 Belgian-Dutch cases and controls 
failed to confirm these results, suggesting that the initial results may have been false positives 
as a result of the small population investigated (Schrauwen et al., 2009b). In addition, a recent 
study found no evidence for the expression of ACE in 20 human otosclerotic stapes footplates 
(Liktor et al., 2013). This suggests that the polymorphism identified in ACE which increases its 
enzymatic activity is unlikely to be involved in otosclerosis as it would be expected that this 
gene would be expressed in human stapes bone if it were involved in the disease. Further 
investigation of these polymorphisms would be required before an association could be 
confirmed. 
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Despite some success in identifying associated variants using case control association studies, 
particularly within members of the TGFβ super-family, their contribution to disease 
pathogenesis remains unproven. This is partly due to a failure to replicate findings and due to 
the small cohort sizes of many of these studies. In addition, these studies are reliant upon a 
certain degree of knowledge of disease pathogenesis in order to identify appropriate 
candidate genes for analysis. Since the disease process involved in otosclerosis is yet to be 
elucidated, this technique therefore has limited applications for research into this condition. A 
recent genome wide approach to this form of analysis was performed in 2009 in the first 
otosclerosis Genome Wide Association Study (GWAS). Unlike candidate gene association 
studies, this technique requires no prior knowledge of disease pathogenesis as it interrogates 
many thousands of polymorphisms across the genome. 
 
1.7.2.3 Genome wide association studies in otosclerosis 
Genome Wide Association Studies (GWAS) examine large numbers of common variants 
simultaneously in large cohorts of cases and controls to identify associations. GWAS have been 
successful in the identification of genetic variants involved in many complex human diseases 
and common traits. Genome wide studies have the benefit over traditional association studies 
of requiring no prior knowledge of disease pathogenesis, however they also have their own 
inherent limitations and associated challenges, most of which can be overcome or minimised 
by effective quality control and study design. Selecting appropriate age, gender and ethnicity 
matched controls is even more vital than in a candidate gene study as the likelihood of false 
positives is greatly increased during multiple testing. For the same reason, it is crucial that 
even larger cohorts of cases and controls are recruited than for candidate gene studies in 
order to achieve sufficient statistical power. Since no prior knowledge of disease pathogenesis 
is required for use of this technique, greater confidence could be had in associations found 
using this genome-wide strategy than when using a candidate-gene based approach. 
In 2009, a Genome Wide Association Study was conducted to identify variants associated with 
otosclerosis (Schrauwen et al., 2009a).  In this study 550,000 tagSNPs were interrogated in 
pooled DNA samples from a discovery group of 302 Belgian-Dutch cases and controls. From 
the genome-wide data obtained, 250 SNPs of interest were selected for validation by 
individual genotyping. These SNPs included the 200 highest ranking SNPs from the pooled DNA 
samples, 28 SNPs located within either the linked otosclerotic loci identified during linkage 
analysis or in close proximity to otosclerosis candidate genes, and 22 SNPs that were located in 
close proximity to another high ranking SNP. Of these 250 SNPs, none were located in 
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otosclerosis candidate genes investigated during previous studies, however, three were 
involved in TGFβ signalling; rs12082710 in the intronic region of TGFβR3 (p=0.002), rs3738676 
in the 3’ untranslated region of BMP8A (p=0.078) and rs2799090 in intronic TGFβ2 (0.005). In 
addition, one SNP rs1879046 was located in an intronic region of collagen gene COL22A1 
(p=0.006). The 250 selected SNPs were subsequently individually genotyped in the same 
discovery group of 302 Belgian-Dutch cases and controls, of which 196 were found to be 
associated with the disease (p>0.05). Individual genotyping was then performed in a stepwise 
manner to identify significantly associated SNPs that were replicated in two additional 
independent populations consisting of a further 392 Belgian-Dutch cases and controls followed 
by a French replication cohort of 455 cases and 480 controls. It was found that two SNPs 
rs3914132 located within the reelin gene (RELN) on chromosome 7q22.1 (p=0.0003) and 
rs670358 located in an intergenic region on chromosome 11q13.1 between two regions of high 
linkage disequilibrium (p=0.005) were associated in all replication groups, so fine mapping was 
performed in the genomic region surrounding these SNPs. The most significant association 
signal (pcombined =6.23x10
-10) was found in the reelin gene spanning 180kb from intron 1 to 4. 
This association reaches genome-wide significance as it survives correction for multiple testing 
using a Bonferonni correction; however the association on chromosome 11q13.1 does not. 
Despite this, the association with chromosome 11 was replicated in two independent 
populations, which can be considered stronger evidence of an association than a low p value 
(Neale and Sham, 2004). Resequencing of this region would be required to determine the 
causal variant.  
The association with RELN was unexpected as there is no obvious role for the reelin protein, a 
large extracellular matrix protein involved in neuronal positioning during brain development 
(Quattrocchi et al., 2002), in the pathogenesis of otosclerosis. Despite this, the association 
between RELN and otosclerosis was further supported by a recent candidate gene association 
study in an additional European population (Schrauwen et al., 2010a), although it was not 
supported by a study within an Indian population (Priyadarshi et al., 2010). Further 
investigation is required to determine the role of reelin in the pathogenesis of otosclerosis. 
 
1.7.2.4 Gene expression studies in otosclerotic stapes 
Gene expression studies have also been employed in the investigation of genetic factors 
involved in otosclerosis. Although these studies tend not to be used for the identification of 
specific disease-causing genes, gene expression analysis of multiple genes in combination with 
pathway analysis can be extremely useful in identifying pathways dysregulated in diseased 
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tissue. Single gene expression studies can also be useful in validating the results of other 
genetic studies, by demonstrating altered expression of a gene of interest.   
In otosclerosis, most gene expression studies conducted to date have been limited largely by 
difficulty in gaining access to human stapes tissue. Otosclerotic stapes bone is removed 
routinely during stapes surgery; however, since the preferred surgical technique is the 
stapedotomy which leaves the stapes footplate in place, it is difficult to accrue large numbers 
of stapes footplates for analysis. Whilst acquisition of stapes suprastructures poses less 
difficulty, these are less useful in investigating gene expression in otosclerosis since the 
otosclerotic foci, the sites most likely to display aberrant gene expression, tend to be localised 
to the stapes footplate. In addition, control stapes for comparison of gene expression between 
otosclerotic and unaffected stapes are also difficult to obtain and tend to be removed during 
only a small number of surgical procedures. For these reasons, few gene expression studies on 
otosclerotic tissue have been conducted to date. The majority of those that have been 
performed analyse only small numbers of stapes and employ a candidate gene based approach 
using either semi quantitative reverse transcription polymerase chain reaction (RT-PCR) to 
detect the presence of messenger RNA (mRNA) from genes of interest, or quantitative real 
time PCR (qRT-PCR) to analyse relative expression levels of genes in control and affected 
stapes. qRT-PCR assays have been used to analyse relative expression of single genes in 
otosclerotic stapes and also multiple genes simultaneously using an array based approach. 
The most comprehensive gene expression study conducted on otosclerotic stapes to date was 
carried out in 2008 by a research group at the University of Iowa. A microarray-based study 
was performed using qRT-PCR to compare messenger RNA transcripts from the stapes tissue of 
nine otosclerotic patients against seven control stapes from patients undergoing surgery for 
vestibular schwannoma.  Microarray analysis was performed using The Human Genome Survey 
microarray v2.0 from Applied Biosystems which annotates 29,098 genes. It was found that 110 
of these genes were differentially expressed in otosclerotic stapes compared to controls, 92 
up- and 18 down-regulated (Ealy et al., 2008).  Of these genes, four were found to be located 
within the otosclerotic loci identified during previous linkage analysis, with three of these 
being located in OTSC3, the largest of the eight otosclerotic loci containing 423 protein coding 
genes, whilst the remaining gene was located in OTSC5. The three dysregulated genes 
identified within OTSC3 were sequenced in the original family in which this locus was 
identified, but no mutations were found within the coding regions, untranslated regions or 
splice sites of these genes. The gene identified with the highest up-regulation in otosclerotic 
stapes compared to controls was platelet factor 4 (PF4), which was up-regulated 12.6 fold in 
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otosclerotic stapes. PF4 is thought to inhibit TGFβ1 signalling by inhibiting the binding of 
TGFβ1 to its receptor (Whitson et al., 1991).  The most down-regulated gene was bone 
sialoprotein (IBSP), which was down-regulated 6.22 fold in otosclerotic stapes. This is a major 
structural protein of the bone matrix required for bone formation and resorption (Wade-
Gueye et al., 2012). Single gene qRT-PCR assays were used to validate the microarray results 
for seven genes of interest including cyclin dependent kinase inhibitor 1A (CDKN1A) and 
lymphotoxin beta (LTB) located in the OTSC3 locus, the ATP-ase beta 3 sub-unit (ATP1B3) in 
the OTSC5 locus as well as PF4, IBSP and two other genes that were found to be significantly 
up-regulated, low density lipprotein receptor (LDLR) and chemokine ligand 2 (CCL2). 
Dysregulation of both PF4 and IBSP in otosclerotic stapes was confirmed by the qRT-PCR 
assays; however this was not the case for the other five genes. To investigate the molecular 
pathways involved in otosclerosis, all 110 differentially expressed genes were analysed using 
the PANTHER classification system. Pathway analysis indicated dysregulation of molecular 
processes involved in interleukin signalling and inflammation in the otosclerotic stapes, which 
indicates an inflammatory response in otosclerosis patients. Whilst the dysregulated genes 
identified indicate involvement of a number of interesting biological pathways in otosclerosis, 
further studies would be required to confirm expression of the genes in a larger number of 
otosclerotic stapes. 
 
1.7.3 Disease mechanisms for otosclerosis 
It is crucial to gain a thorough understanding of the molecular basis of disease in order to 
establish the mechanisms involved in the disease process. This is vital for the development of 
new effective therapies and treatments. Although a number of environmental and genetic 
factors have been suggested to play a role in disease aetiology of otosclerosis, no disease 
mechanism is widely accepted. However, by considering the results obtained across a number 
of studies conducted to date, various common themes have emerged indicating possible 
disease mechanisms. Here, three common themes that have emerged whilst analysing the 
published literature are discussed; otosclerosis as an autoimmune condition, the role of TGFβ 
in otosclerosis pathophysiology and otosclerosis as a localised manifestation of a systemic 
connective tissue disorder.  
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1.7.3.1 Otosclerosis as an autoimmune condition 
It has previously been proposed that an autoimmune mechanism may be involved in 
otosclerosis pathophysiology. Early research into otosclerosis hypothesised that the condition 
may occur as a result of an autoimmune reaction to type II collagen present in the residual 
embryonic cartilage of the globuli interossei within the otic capsule (Yoo et al., 1982), a theory 
which was supported by a study in which otosclerotic-like lesions were induced in rats 
immunised with type II collagens (Yoo et al., 1983). Furthermore, various cells of the immune 
system have been reported both within and in close proximity to otosclerotic lesions, 
indicating stimulation of the immune system in otosclerosis patients and a subsequent 
inflammatory tissue reaction (Altermatt et al., 1992). An autoimmune pathology for 
otosclerosis is also supported by a recent study that identified HLA class I polymorphisms in an 
otosclerosis cohort of Tunisian origin (Bel Hadj Ali et al., 2012), since HLA genes are known to 
be involved in various autoimmune conditions (Caillat-Zucman, 2009). A further study which 
demonstrated an increase in HLA antigens in otosclerosis patients (Gregoriadis et al., 1982) 
combined with the fact that the OTSC3 region identified during linkage analysis (Chen et al., 
2002) maps to a genomic region containing the MHC locus encoding the HLA genes, also 
support a role for an autoimmune mechanism. Furthermore, the results of the pathway 
analysis following the most comprehensive gene expression study on otosclerotic tissue 
conducted to date(Ealy et al., 2008) indicated dysregulation of multiple genes involved in the 
inflammatory response. Since autoimmune conditions are characterised by prolonged 
inflammation, this provides further evidence to suggest an autoimmune pathophysiology for 
otosclerosis. 
 
1.7.3.2 The role of TGFβ in otosclerosis pathophysiology 
The transforming growth factor beta super-family is a group of genes involved in growth, 
development, homeostasis and regulation of the immune system. One member of this family, 
transforming growth factor beta 1 (TGFβ1), is a cytokine that has been repeatedly proposed as 
an otosclerosis candidate gene due to its vital role in bone remodelling. During remodelling, 
TGFβ is involved in numerous processes that regulate the recruitment, differentiation and 
function of both osteoblasts and osteoclasts (Figure ‎1.9). 
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Figure ‎1.9 Transforming growth factor-β (TGFβ) involvement in bone remodelling 
TGFβ  regulates the bone remodeling cycle through the recruitment, proliferation and differentiation of osteoblasts  
(Tang, 2013).  
 
For this reason, TGFβ1, along with genes encoding other TGFβ super-family members including 
bone morphogenetic proteins, have been investigated for associations with otosclerosis (Thys 
et al., 2007a, Schrauwen et al., 2008, Thys et al., 2009). Although there are some concerns 
regarding the reliability of the results obtained during otosclerosis candidate gene association 
studies, those associating variants within members of the TGFβ super-family and otosclerosis 
are amongst the most convincing. Furthermore, a study identifying dysregulation of TGFβ1 in 
otosclerotic stapes provides further evidence that this gene may be involved in abnormal bone 
remodelling in the stapes of otosclerosis patients (Priyadarshi et al., 2013). In addition, since 
the most up-regulated gene identified in the Ealy et al. gene expression study (PF4) is known to 
be an inhibitor of TGFβ1 (Ealy et al. , 2008), it is suggestive that genes governing expression of 
this crucial regulator of bone remodelling may also be involved in the disease process. Given 
that multiple avenues of research into the genetics of otoscleorsis point to TGFβ1, it is a strong 
possibility that this gene may be involved in disease pathophysiology and is a good candidate 
to prioritise for future research. 
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1.7.3.3 Otosclerosis as a localised manifestation of a systemic connective tissue 
disorder 
Otosclerosis has been reported to occur concomitantly in individuals with other systemic 
connective tissue disorders (Miyajima et al., 2007) indicating that there may be a shared 
genetic aetiology between these conditions and otosclerosis. Connective tissue disorders are 
conditions in which connective tissues are the target for disease pathology. Connective tissues 
are those with extensive extracellular matrices consisting of the two large structural proteins 
collagen and elastin. Patients with connective tissue disorders tend to have weaknesses or 
inflammation in their connective tissues, often accompanied by autoimmunity, another 
possible otosclerosis disease mechanism discussed above.  
Most connective tissue disorders are caused by genetic mutations and are inherited within 
families. Ehlers-Danlos syndrome (EDS) is a connective tissue disorder caused by defects in 
collagen synthesis and has been reported to coincide with otosclerosis on rare occasions 
(Miyajima et al., 2007).  There are many different forms of EDS which are caused by mutations 
in the collagen genes COL3A1, COL5A1 and COL5A2, as well as in procollagen-lysines PLOD1 
and PLOD3.  Symptoms include double-jointedness, easily damaged, bruised and stretchy skin, 
scarring and poor wound healing, flat feet, increased joint mobility, arthritis, joint pain and 
dislocation, premature rupture of membranes during pregnancy and gastrointestinal 
problems. Due to the role that mutations within collagen genes play in development of EDS 
and the proposed role of collagen variants in otosclerosis, it is possible that there is a shared 
genetic basis for otosclerosis and EDS. 
Buschke-Ollendorff syndrome is a rare genetic disorder of connective tissue that has also been 
reported in individuals who have otosclerosis (Strosberg and Adler, 1981, Piette-Brion et al., 
1984, Schnur et al., 1994,). It is caused by mutations in the LEMD3 gene (LEM Domain-
Containing Protein 3), a gene which can antagonise TGFβ signalling in human cells (Hellemans 
et al., 2004).  The condition is characterised by multiple collagen-rich subcutaneous benign 
nevi or nodules on the skin and osteopoikilosis, benign sclerotic bone lesions which lead to 
joint pain. Since dysregulation of TGFβ signalling is known to be involved in the development 
of Buschke-Ollendorff syndrome and the proposed role of TGFβ in the development of 
otosclerosis discussed above, it is possible that dysregulation of the same pathway is involved 
in both conditions. 
Osteogenesis Imperfecta (OI) is a systemic disease caused by defective connective tissue which 
results in brittle bones and where patients often experience conductive hearing loss similar to 
that of otosclerosis.  It had been theorised that otosclerosis and OI have a shared genetic 
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aetiology and that otosclerosis is a localised manifestation of OI (Weber, 1930). However, 
others suggest that hearing loss in OI is caused by a series of micro-fractures combined with 
reparative vascular and fibrous tissue forming around the cochlea (Mezzedimi, 2013).There are 
eight known forms of OI, all of which are characterised by weak or brittle bones and the 
majority of which cause blue sclera, where the whites of the eyes exhibit a characteristic blue 
tinge.  In the 1920s it was proposed that otosclerosis is associated with forms of OI with blue 
sclera (Cleminson, 1927). OI types I to IV are caused by mutations in the collagen type one 
genes; COL1A1 or COL1A2, and vary in severity of symptoms with type II being the most severe 
and usually lethal within the perinatal period.  They are inherited in an autosomal dominant 
pattern although the majority of cases are caused by de novo mutations, especially in the more 
severe forms of the condition where affected individuals rarely survive to child-bearing age 
(Cole and Dalgleish, 1995). OI type V is caused by mutations in IFITM5 gene (interferon induced 
transmembrane protein 5) and exhibits autosomal dominant inheritance, while types VI, VII 
and VIII are caused by mutations in SERPINF1 (serpin peptidase inhibitor, clade F member 1), 
CRTAP (cartilage associated protein) and LEPRE1 (leucine proline-enriched proteoglycan 
(leprecan) 1) respectively, all of which exhibit autosomal recessive inheritance (Cundy, 2012). 
The co-occurrence of OI and otosclerosis has not been well documented, but it is thought that 
otosclerosis occurs most commonly in individuals with mild forms of OI, particularly with 
mutations in the COL1A1 gene (McKenna et al., 1998). The mutations that cause OI are 
commonly nonsense or frameshift mutations that lead to nonsense mediated decay of the 
gene product or dominant-negative mutations that affect the structure and function of the 
resulting protein. This results in a lack of gene product or an abnormal gene product, impacting 
all bones and other tissues in which this gene is expressed throughout the body, including the 
temporal bone. It is possible that mutations in individuals with otosclerosis affect the same 
genes but have a less damaging effect on the resulting protein leading to a localised form of 
the condition which affects exclusively the temporal bone. This theory could also explain the 
high incidence of otosclerosis in the general population, as it is possible that the less damaging 
otosclerosis-causing alleles have been preferentially selected over numerous generations over 
alleles that lead to the development of OI. 
Since otosclerosis affects approximately 0.3-0.4% of the population (Pearson et al., 1974) 
(Gapany-Gapanavicius, 1975, Declau et al., 2007b), there is a possibility that the co-occurrence 
of otosclerosis and other connective tissue disorders will occur in some individuals by chance. 
However, the phenotypic similarities, along with some genetic overlap, indicates that there 
may be some shared aetiology for otosclerosis and systemic connective tissue disorders. 
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1.7.4 Future promise for genetic research into otosclerosis 
Despite advances in genetic research throughout the last decade which has begun to help 
unravel the genetic basis of many previously uncharacterised genetic disorders, the disease 
pathology in otosclerosis remains to be elucidated. This is despite the fact that a number of 
research groups have conducted investigations into the genetics of the condition, including 
studies that have used sufficiently large cohort sizes to generate statistically significant results 
and have employed study designs that would be expected to generate reliable findings. In 
addition, since otosclerosis is common, meaning that recruitment of affected individuals is less 
problematic than for rarer forms of deafness, it is surprising that progress in this field has been 
slow in comparison to genetic research into other forms of deafness.  
The main reasons for the lack of progress are due to difficulties in gaining access to sufficient 
quantities of diseased tissue from the ear for analysis of gene dysregulation, and also due to 
issues associated with incomplete penetrance during linkage analysis studies in otosclerosis 
families. It is crucial that these obstacles are overcome in order to improve the understanding 
of genetic factors that contribute to otosclerosis in order to clarify the underlying disease 
mechanism. This could improve treatment options for those affected by aiding development of 
new therapies.  This in turn could ease the impact of this disorder on those affected as well as 
helping to reduce the social and economic burden of this common form of hearing loss.  
Recent developments in the field of genetic research provide new opportunities to help 
overcome these obstacles and unravel the genetic basis of otosclerosis. Next generation 
sequencing has become increasingly accessible and affordable for researchers investigating 
genetic conditions in recent years and has the major advantage over many traditional genetic 
analysis techniques of requiring no prior knowledge of disease pathogenesis. Such techniques 
are therefore very appealing for investigation into the genetic causes of otosclerosis where the 
disease process is unknown. In this research study, two next generation sequencing 
techniques; Whole Exome Sequencing and RNA-sequencing, neither of which have been 
previously used to investigate the genetics of otosclerosis, will be employed in combination 
with one another to investigate the genetic basis of this disorder. These unexplored 
techniques have great potential to yield promising results.  
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1.7.4.1 Whole Exome Sequencing to identify genetic variation in otosclerosis families 
Whole Exome Sequencing is a next generation sequencing technique which when combined 
with a variant prioritisation strategy, can be used to identify disease-causing variants in 
families exhibiting monogenic inheritance of genetic disorders. This technology sequences only 
the exome, the coding region of the genome as a cost–effective alternative to whole genome 
sequencing. Since only approximately 1% of the genome is protein coding but around 85% of 
disease causing mutations are located within protein coding genes (Cooper, 1998), there is a 
good chance of identifying a pathogenic variant by focusing solely on the exome.  This 
technique works on the principle of identifying a list of variants in affected individuals, and 
narrowing them down to the causative variants by selecting only variants that are common to 
affected but not unaffected individuals in the family. By applying a series of filters including 
comparing variants with databases of known non- pathogenic variants and by identifying 
whether any variants are present within candidate genes for the condition, it may be possible 
to identify the disease-causing mutation. In recent years, there have been numerous reports of 
novel genetic mutations identified using this technique, including the identification of genes 
involved in monogenic disorders that have so far eluded researchers (Bamshad et al., 2011). 
This technique therefore has potential to identify genetic mutations within otosclerosis 
families. A more detailed overview of Whole Exome Sequencing and its advantages and 
limitations are discussed at the start of Chapter 4. 
 
1.7.4.2 RNA-sequencing to investigate gene expression in otosclerotic stapes 
RNA-sequencing is a next generation approach to gene expression analysis, which analyses all 
RNA molecules expressed within a specific tissue or cell type. During application of this 
technique, a series of sequence reads are generated through high throughput sequencing, 
which are aligned to a reference transcriptome, generating a measure of expression for every 
transcript. It can therefore be used to both identify and quantify RNA transcripts and to 
provide information including localisation of transcription and alternative splicing.  Statistical 
analysis is then used identify significantly dysregulated genes along with pathway analysis to 
identify trends in the data (McGettigan, 2013). A detailed discussion of RNA-sequencing and its 
uses and associated disadvantages can be found at the beginning of Chapter 5. 
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1.8 Aims and objectives of this thesis 
Until the last decade, very little was known about the causes of otosclerosis, however recent 
research has implicated a number of genetic and environmental contributors. But despite 
these advances, the disease mechanism remains poorly understood. The aim of this project is 
to identify genetic contributors to the pathogenesis of otosclerosis. To achieve this aim, three 
key objectives were devised.  These are summarised below: 
1) To establish a recruitment process to identify individuals affected by otosclerosis and recruit 
them to the study.  The recruitment process will involve:             
 Collection of otosclerotic stapes tissue from participants undergoing stapes surgery, as 
well as collection of control stapes tissue 
 Collection of a blood or saliva sample from each study participant          
 The identification of probands with families that appear to exhibit a Mendelian 
inheritance pattern of otosclerosis                                      
 Recruitment of both affected and unaffected relatives of these probands 
2) To compare changes in gene expression between control and affected stapes bones.  
Techniques will include:  
 Single gene semi-quantitative PCR assays to demonstrate the presence or absence of 
genetic transcripts from genes of interest in stapes tissue 
 RNA-sequencing to identify previously unknown genetic contributors by analysing the 
entire transcriptome of affected and control stapes tissue 
 Quantitative PCR assays to assess the level of expression of genes of interest in stapes 
tissue 
3) To conduct genetic analysis to identify variation in the genomic DNA of individuals affected 
by otosclerosis compared with controls. Techniques will include:  
 Whole exome sequencing to identify single gene variants within families with a strong 
history of otosclerosis 
 Genotyping assays to follow up findings from Whole Exome Sequencing by testing the 
remainder of the cohort for presence or absence of the variants 
 
Identification of genetic factors will improve understanding of the disease process which will 
lead to improvements in treatment for affected individuals.   
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2 Materials and Methods 
 
Materials 
2.1 Chemicals and Equipment 
Unless otherwise stated, all chemicals were supplied by Amersham Biosciences, BDH, 
Invitrogen, Promega and Sigma-Aldrich. 
Restriction endonucleases were purchased from Promega, New England BioLabs or Thermo 
Scientific. 
Unless otherwise stated, experiments were performed using autoclaved double distilled 
deionised MilliQ water (ddH20). 
 
2.2 Abbreviations 
dNTPs Dideoxynucleotide triphosphates 
EDTA Ethylenediamine tetra-acetic acid 
TAE Tris-acetate-EDTA electrophoresis buffer 
 
2.3 Stock Solutions 
Unless otherwise stated, stock solutions were made up using autoclaved double distilled 
deionised MilliQ water (ddH20). 
6x DNA loading buffer 15% Ficoll 
0.25% bromophenol blue 
0.25% xylene cyanol 
 
50x TAE 2.0M Tris 
1M Glacial Acetic Acid 
50mM EDTA (pH 8.0) 
 
TE buffer 10mM Tris-Cl (pH8.0) 
1mM EDTA 
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Methods 
This study was approved by the London Bloomsbury Research Ethics committee (reference: 
11/LO/0489). Individuals with a diagnosis of otosclerosis were recruited via informed consent 
by Ear Nose and Throat surgeons at the Royal Free, Royal National Throat Nose and Ear 
Hospital, London, U.K. Exclusion criteria included children under 16 years of age, or those with 
a learning disability which would be likely to cause problems involving the consent procedure. 
 
2.4 Tissue collection 
2.4.1 Collection of otosclerotic and control stapes samples 
Stapes suprastructure tissue samples for gene expression analysis were obtained from 109 
unrelated individuals undergoing laser-assisted stapedotomy surgery at the Royal Free, Royal 
National Throat Nose and Ear Hospital, London, U.K. One whole stapes bone was collected 
from an individual undergoing stapedectomy surgery.  A visual diagnosis of otosclerosis was 
confirmed during surgery in all cases.   
Patients were identified in advance of surgery and sent a letter of invitation, patient 
information sheet, consent form and questionnaire (see Appendix), inviting them to 
participate in the study.  Those patients who completed and returned the consent form and 
questionnaire prior to surgery were enrolled in the study.  During surgery, the stapes 
suprastructure, which is routinely removed during surgery, was placed in AllProtect medium 
(Qiagen) to prevent RNA degradation.  
For the control group, stapes suprastructures were obtained from 9 unrelated individuals who 
did not have a diagnosis of otosclerosis, but who were undergoing a surgical procedure during 
which the stapes was removed. In addition, two whole stapes were obtained from both ears of 
one individual. The control stapes tissue was obtained during a variety of surgical procedures 
including surgery due to head trauma, glomus tumour and total petrosectomy.  The stapes 
tissue was placed in AllProtect medium (Qiagen). 
All stapes samples were stored overnight at 4°C to enable the medium to penetrate the tissue, 
before being stored long-term at -80°C.  
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2.4.2 Collection of blood and saliva samples from study participants 
Blood samples for genetic analysis were obtained from 110 unrelated individuals undergoing 
stapes surgery at the Royal Free, Royal National Throat Nose and Ear Hospital, London, U.K. 
Two 5ml EDTA blood tubes were filled from a cannula sited in a peripheral vein, during 
surgery. 
An additional 24 blood and 127 saliva samples were obtained from non-surgical participants.  
These included patients at the Royal Free, Royal National Throat Nose and Ear Hospital, 
London, U.K who had received a visual diagnosis of otosclerosis during a stapes surgery 
conducted prior to initiation of recruitment for this study.  It also included individuals who had 
received a diagnosis of otosclerosis from audiometric studies but who had opted for 
conservative management to treat their hearing loss.  In addition, samples were also obtained 
from a self-selecting population of individuals with a diagnosis of otosclerosis who were 
recruited via advertisements on social networking sites or in charity newsletters. 
Non-surgical patients were contacted by mail and were sent a letter of invitation, patient 
information sheet, consent form and questionnaire (see Appendix), inviting them to 
participate in the study.  Those patients who completed and returned the consent form and 
questionnaire were enrolled in the study and were asked to visit the phlebotomist during their 
next visit to the Royal Free, Royal National Throat Nose and Ear Hospital in London to provide 
a venous blood sample which was collected in two 5ml EDTA tubes.  If no appointment was 
scheduled and it was not possible to attend the clinic, participants were sent Oragene® DNA 
genotek saliva collection kits by mail. 
All blood samples were refrigerated at 4°C before being transferred to 2ml eppendorf tubes 
and stored at -80°C.  Returned saliva collection kits were stored at -20°C. 
 
2.4.3 Collection of saliva samples from relatives 
From the completed questionnaires received from both surgical and non-surgical participants, 
individuals with a strong family history of otosclerosis were identified. The consent forms 
returned by these participants were consulted to ensure that these individuals had stated that 
they were willing to be contacted with regards to recruitment of family members. Consenting 
participants were contacted by telephone and family pedigrees were produced. The contact 
details of both affected and unaffected family members were then taken. Family members 
were contacted by mail and were sent a letter of invitation, information sheet, consent form 
and questionnaire (see Appendix), inviting them to participate in the study.  Those 42 relatives 
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who completed and returned the consent form were enrolled in the study and were sent 
Oragene® DNA genotek saliva collection kits by mail. Returned saliva collection kits were 
stored at -20°C. 
 
2.4.4 Culture and harvest of MG-63 cells 
The human osteosarcoma MG-63 cell line was obtained from Dr Vehid Salih at the Eastman 
Dental Hospital, University College London.  MG-63 cells were cultured in Dulbecco’s modified 
Eagle medium (Invitrogen) supplemented with glutamax, 10% foetal bovine serum and 1% 
penicillin/streptomycin (10,000 units ml−1 penicillin and 10,000 μg ml−1 streptomycin) and 
were maintained at 33°C and 5% carbon dioxide. Cells were seeded at a density of 
approximately 1-2 x 105 cells per 75 cm2 flask (Nunc) and passaged by trypsinisation when 
confluency reached approximately 80%. Cells were transferred to 6 well plates before being 
harvested and homogenised using a QIAshredder column (Qiagen), prior to cDNA preparation. 
 
2.5 cDNA preparation 
2.5.1 RNA purification 
The human stapes samples were thawed and any excess medium surrounding the stapes was 
removed.  The stapes were viewed under a dissecting microscope and any attached connective 
tissue or dried blood was removed using forceps.  The three whole human stapes bones (one 
from an otosclerosis patient undergoing stapedectomy surgery and two from each ear of a 
single control individual) were dissected into suprastructure and footplate components under 
the microscope, which were then processed separately.  The suprastructures from both ears of 
the control individual were pooled prior to processing, as were the footplates. The stapes 
tissue was disrupted and homogenised using the PRO200® hand held homogeniser (Bio-Gen) 
in in 500µl QIAzol Lysis Reagent.  RNA was purified from the stapes using the RNeasy lipid 
tissue mini kit (Qiagen) according to the manufacturer’s protocol. An on column DNase digest 
was performed using RQ1 RNase-Free DNase (Promega).  
RNA was extracted from the homogenised human MG-63 cells using the RNeasy mini kit 
(Qiagen) in accordance with the manufacturer’s protocol. These samples served as positive 
controls during semi-quantitative and quantitative real time PCR assays to demonstrate 
successful amplification of the desired DNA fragment. 
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The RNA product was eluted in 30µl of ddH2O and the concentration was quantified using the 
Nanodrop® ND-1000 spectrophotometer (Thermo Scientific). Half the RNA product was 
archived at  -80°C while the other half was immediately reverse transcribed to cDNA. 
 
2.5.2 Reverse Transcription of RNA to cDNA 
Two alternative methods were used to convert RNA to cDNA: 
Method 1: Qiagen Omniscript Reverse Transcription kit 
RNA from the majority of human tissue samples was converted to cDNA using the Omniscript 
Reverse Transcription kit (Qiagen) with random primers according to the manufacturer’s 
protocol. The cDNA product was stored at -20°C. 
Method 2: Clontech SMARTer™ kit 
RNA from 12 selected human stapes samples (see chapter 5 table 5.1.) was converted to cDNA 
using the SMARTer™ kit (Clontech), according to the manufacturer’s protocol.  The cDNA 
product was stored at -20°C. The SMARTer™ kit is more expensive than the Omniscript kit, but 
has increased sensitivity for efficient conversion of small quantities of RNA to full length CDNA.  
This kit was therefore used only for the 12 RNA samples that would be sent for RNA-
sequencing. 
 
Total no. 
samples 
collected 
No. samples 
processed using 
Omniscript kit 
No. samples 
processed using 
Clontech kit 
Otosclerotic suprastructure samples 110 103 7 
Otosclerotic footplate samples 1 0 1 
Control suprastructure samples 10 7 3 
Control footplate samples 1 0 1 
 
Table ‎2.1 Table showing numbers of human stapes samples collected 
Table shows numbers of otosclerotic and control suprastructures and footplates processed using Omniscript and 
Clontech reverse transcription kits. The one control footplate sample and one of the control suprastructure samples 
consisted of structures pooled from both ears of the same individual. 
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2.6 Gene Expression Assays 
2.6.1 RNA-sequencing 
The RNA isolated from the suprastructures of 7 study participants with otosclerosis and the 
footplate from the stapes of one of these individuals was reverse transcribed to cDNA using 
the SMARTer™ kit (Clontech), according to the manufacturer’s protocol. In addition, RNA 
purified from the suprastructures of 3 additional control participants and the footplate RNA 
from one of these was also reverse transcribed using the SMARTer™ kit. The concentration of 
the cDNA generated using the Clontech SMARTer™ kit was quantified using the Nanodrop® 
ND-1000 spectrophotometer (Thermo Scientific) and was purified using the QIAquick PCR 
purification kit (Qiagen) according to the manufacturer’s protocol.  The product was eluted in 
50µl PE buffer. 2µl of the purified cDNA was sent to UCL Genomics for quality control using the 
Bioanalyzer Agilent 2100. Quality control is a crucial early step in the bioinformatics pipeline of 
RNA-Sequencing to ensure high quality sequences and bases in order to assure a reliable final 
result.  The 12 cDNA samples were then sent to Otogenetics Corp (Norcross, GA, U.S.A.) where 
cDNA fragmentation was performed on the samples and cDNA libraries constructed before 
high-throughput paired-end RNA sequencing using Illumina HiSeq 2000 was carried out. 
Paired-end 100 nucleotide reads were aligned to human genomic assembly hg19, which 
generated a read count for every transcript. 
 
2.6.2 Semi-quantitative Reverse Transcription Polymerase Chain Reaction  
For all cDNAs processed using the Omniscript kit, a GAPDH assay was performed to establish 
cDNA integrity. All PCR assays were conducted using MG-63 cDNA in addition to the stapes 
cDNA as positive controls and ddH20 as a control for background contamination. Reactions 
were set up on ice and contained approximately 400ng cDNA from each stapes sample or MG-
63 cell cDNA, 0.5µM each primer, 0.3mM dNTPs, an optimised concentration of MgCl2, 5 µl of 
5x green PCR buffer and 1.25U GoTaq polymerase (Promega) in a total volume of 20µl. Primer 
pairs were designed to span exon-exon junctions to avoid the amplification of genomic DNA 
(Table ‎2.2). Thermal cycling was performed under the following reaction conditions: 
Denaturation at 93°C for 15 seconds, annealing at optimum temperature for 30 seconds, 
extension at 72°C for 30 seconds, for up to 40 cycles, with an initial denaturation step of 93°C 
for 3 minutes. PCR reactions were carried out in capped 0.5ml thin walled Eppendorf tubes or 
96 well Eppendorf plates in an Eppendorf Mastercycler Gradient machine and resulting bands 
analysed by agarose gel electrophoresis (2.9).  
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Table ‎2.2 Primers used during semi quantitative RT-PCR assays       
* Reverse primer B for human RELN-001 (Csomor, et al. 2011)                                                                               
** Reverse primer E for human truncated RELN variant (Ovadia and Shifman 2011) 
 
2.6.3 Quantitative Real Time PCR (qRT-PCR)  
Taqman® gene expression assays were performed on human otosclerotic and control cDNA 
samples that had been processed using the Omniscript kit.  Real-time PCR was conducted using 
the ABI PRISM 7500 Sequence Detection System (Applied Biosystems) with primer/probe pairs 
obtained from Applied Biosystems. The reactions contained 50ng stapes or MG-63 cDNA, 5µl 
Taqman® Fast Universal PCR Mastermix (Applied Biosystems) in a total volume of 10µl. 
Thermal cycling was performed under the following reaction conditions: 95°C for 10 minutes 
followed by 45 cycles of 95°C for 15 seconds and 60°C for 1 minute.  
A Taqman® assay was performed for the detection of RELN-specific mRNA (chapter 6) on cDNA 
extracted from the 71 otosclerotic and 5 control stapes suprastructures that had been 
collected at the time of the study and on cDNA extracted from MG-63 cells. Assays were 
carried out in triplicate on all otosclerotic samples and 6 replicates were performed for control 
Primer name 
Forward or  
reverse 
primer 
Gene Primer sequence Amplicon 
hGAPDHF Forward GAPDH GGAAGGTGAAGGTCGGAGTCA 
 227 bp 
hGAPDHR Reverse GAPDH GAAGATGGTGATGGGATTTCCA 
RELN1F (A) Forward RELN (001) ACCATGTGGAGGTCGTCCTAGTA 
262 bp 
RELN1R (B)* Reverse RELN (001) CACTCGGTCTTGAGAAGGGCTTTC 
RELN2F (C) Forward RELN (002) GCAATACAGCGTCAACAACGG 
209bp 
RELN2R (D) Reverse RELN (002) GTTTGCGAGTGAGGACGACCT 
RELN2F (C) Forward 
Truncated 
RELN 
GCAATACAGCGTCAACAACGG 
241 bp 
RELN3R (E)** Reverse 
Truncated 
RELN 
CCTTCCTGAAATGGACATGG 
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samples and MG-63 cell cDNA. It was ensured that the Taqman® assay chosen was located in a 
region that could detect all RELN isoforms.  
In addition, Taqman® assays were performed for the detection of ASPN, FBLIM1, FKBP14, 
LAIR1, LUM and SPARCL1-specific mRNA, to validate the results of the RNA-sequencing study 
(chapter 5), on cDNA extracted from 81 otosclerotic and 5 control stapes. 10 additional stapes 
had been collected by the time that this study was performed since the RELN study. Assays on 
otosclerotic samples were performed once, as each otosclerotic sample was treated as a 
replicate. However, due to the small number of controls collected, assays on controls were 
carried out in triplicate.  
Taqman® assays were performed for detection of SERPINF1-specific mRNA (chapter 4) on 
cDNA extracted from 81 otosclerotic and 5 control stapes. Two assays were performed, one 
with a target located in the upstream region of the gene and another in the downstream 
region, in order to make a comparison between expression levels of specific exons. These 
assays were performed on 81 otosclerotic and 5 control stapes with assays on the control 
samples being performed in triplicate. On 3 otosclerotic samples with known mutations in the 
SERPINF1 gene, six replicates were performed.  
In all assays, eukaryotic 18s rRNA was used as the endogenous control. For Applied Biosystems 
assay ID numbers, see Table ‎2.3 
Gene Target exons 
Applied Biosystems 
Assay ID 
ASPN 7-8 Hs00214395 
FBLIM1 2-3 Hs00378472 
FKBP14 1-2 Hs00215735 
LAIR1 9-10 Hs00253790 
LUM 2-3 Hs00929860 
RELN 62-63 Hs01022646 
SERPINF1 3-4 Hs011006934 
SERPINF1 6-7 Hs011006937 
SPARCL1 10-11 Hs00949881 
 
Table ‎2.3 Table showing Applied Biosystems assay ID numbers for each Taqman® assay performed 
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2.7 Genomic DNA preparation from blood and saliva  
Blood was thawed at room temperature and genomic DNA was isolated using Illustra™ DNA 
Extraction kit BACC2 (GE Healthcare) according to the manufacturer’s protocol.  Saliva samples 
were thawed and genomic DNA was isolated using the DNA genotek prepIT™.L2P kit according 
to the manufacturer’s protocol. 
The DNA pellet was re-suspended in between 100µl and 400µl 0.1x TE buffer according to the 
size of the pellet, and placed on a rotator for 2 days at 4°C.  The gDNA was stored at -20°C. 
 
2.8 Detection of genomic variation 
2.8.1 Whole Exome Sequencing 
Whole Exome Sequencing was performed on 10 genomic DNA samples at The Wellcome Trust 
Sanger Institute, Cambridge, thanks to collaboration with Professor Karen Steel.  
Prior to sequencing, the concentration of the gDNA generated using the Illustra™ DNA 
Extraction kit BACC2 (GE Healthcare) or Oragene® DNA genotek kit was quantified using the 
Nanodrop® ND-1000 spectrophotometer (Thermo Scientific) and was purified using a DNeasy 
blood and tissue kit (Qiagen) according to the manufacturer’s protocol.  The product was 
eluted in 60µl EB buffer (Qiagen). The purified gDNA was sent to The Wellcome Trust Sanger 
Institute, Cambridge. After target enrichment, sequencing was performed using the Illumina 
HiSeq 2000 with 100-bp paired-end reads. Reads were mapped to the reference human 
genome (GRCh37_hs37d5) and both single-nucleotide polymorphism (SNPs) and insertions-
deletions (indels) were identified using SAMtools (http://samtools.sourceforge.net/). 
Following prioritisation of variants for subsequent analysis, variants of interest were confirmed 
in the probands of each family exome sequenced via genotyping assays including restriction 
endonuclease digests or Sanger sequencing (‎2.8.2). 
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2.8.2 Genotyping 
Two different genotyping methods were used to identify the presence of genomic variants 
within gDNA samples; Sanger sequencing and restriction endonuclease digests. For both 
techniques, the genomic region of interest, in most cases an exon containing known or 
predicted sequence variants, was amplified through semi-quantitative PCR prior to Sanger 
sequencing or restriction enzyme digests. 
 
2.8.2.1 Semi-Quantitative PCR 
For all gDNA samples, a GAPDH assay was performed to establish gDNA integrity and ddH20 
was used as a control for background contamination. Reactions were set up on ice and 
contained approximately 200ng gDNA from each blood or saliva sample, 0.5µM each primer, 
0.3mM dNTPs, an optimised concentration of MgCl2, 5 µl of 5x colourless PCR buffer and 1.25U 
GoTaq polymerase (Promega) in a total volume of 25µl. Primers were designed where possible 
in the introns surrounding the exon of interest and at least 50 bases away from the variant to 
be genotyped in order that they could also be used as sequencing primers  (Table ‎2.4). In some 
cases, where exons were large, it was necessary to locate the primers within the exon itself as 
an amplicon greater than 500 bases is not desirable for effective sequencing. In the case of 
TRIM17, two pairs of overlapping amplicons were designed in order to capture the full exonic 
sequence. Thermal cycling was performed under the following reaction conditions: 
Denaturation at 93°C for 15 seconds, annealing at optimum temperature for 30 seconds, 
extension at 72°C for 30 seconds, for up to 40 cycles, with an initial denaturation step of 93°C 
for 3 minutes. PCR reactions were carried out in capped 0.5ml thin walled Eppendorf tubes or 
96 well Eppendorf plates in an Eppendorf Mastercycler Gradient machine and resulting bands 
analysed by agarose gel electrophoresis (2.9). 
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Primer name 
Forward or  
reverse 
primer 
Gene Primer sequence Amplicon 
COL1A2F Forward COL1A2 ACTGAGAACCAGAGTCAACCAC 
506bp 
COL1A2R Forward COL1A2 GCCGTTTGCTCCAGGATTAC 
CYP2D6F Reverse CYP2D6 CTCCATCACAGAAGGTGTGAC 
505bp 
CYP2D6R Reverse CYP2D6 CTCACACCTCCCTAGTGCAG 
DNAH5F Forward DNAH5 GTTAGGGTGGAATAAGCCTCA 
469bp 
DNAH5R Reverse DNAH5 AAGAATGGAAGACGTACGTGG 
EGLN3F Forward EGLN3 GTACCATGCATTTGGAGTGG 
446bp 
EGLN3R Reverse EGLN3 CTGAGGTTAGGTTTGATATGCT 
ERCC6F Forward ERCC6 CTGGCTGTTCATCTTCCTGAGT 
443bp 
ERCC6R Reverse ERCC6 CTCACAGTAAGACATCTAAGC 
FOXK1F Forward FOXK1 ACCGTCTGAATGCGGAGGACA 
429bp 
FOXK1R Reverse FOXK1 ATGATCACTGGCTGGGCGCTGA 
FRYLF Forward FRYL CCACGTGGATTTGGATAAAGT 
505bp 
FRYLR Reverse FRYL GTGAACTATCCTTCTCCCTTAC 
FZD2F Forward FZD2 TCCTGTGCTCCATGTACGCA 
490bp 
FZD2R Reverse FZD2 AGCACCGACCAGGTGAGGAT 
GNGT1F Forward GNGT1 CAAGGCTAGTGTGCATTGC 
520bp 
GNGT1R Reverse GNGT1 GGATTGGGCTTGGCCAGAG 
LEPRE1F Forward LEPRE1  CAGTCATCTCCCACCAGGTCC 
376bp 
LEPRE1R Reverse LEPRE1 GGACCGCATCCTGTTCTCTCTG 
MIA3F Forward MIA3 CTGCAGCTACAGATTCTGAG 
416bp 
MIA3R Reverse MIA3 TACAAGTGCATCAGCTGTTGAG 
mir183F Forward mir183 GCAAGGCCAGAAGGTCAGCT 
473bp 
mir183R Reverse mir183 GCCAAGCAGATGGCACTGGTG 
PDLIM5F Forward PDLIM5 TGACCTCATGATCCGCCCA 
500bp 
PDLIM5R Reverse PDLIM5 TGACAACTACCAATCAGTCTC 
PTK6F Forward PTK6 CTCCCTGTGCTGGCTTCAG 
320bp 
PTK6R Reverse PTK6 GGGCTCGAGGCCAGAGGTC 
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SERPINF1Exon2F Forward SERPINF1  AGTGACTAGCCCTGCCCAAC 
309bp 
SERPINF1Exon2R Reverse SERPINF1  AAGCCTGGCCTGGAACCT 
SERPINF1Exon3F Forward SERPINF1  CGTGAGGAGACAGTCCCTGT 
345bp 
SERPINF1Exon3R Reverse SERPINF1  TCAGCCACGTTTACGCAGAGG 
SERPINF1Exon4F Forward SERPINF1  GCCTACTTGGGCTCTCAGCAGA 
311bp 
SERPINF1Exon4R Reverse SERPINF1  ACATGCCTCAGGCAACTTGG 
SERPINF1Exon5F Forward SERPINF1 TGCTGAGCGCTAAACCAGAAC 
323bp 
SERPINF1Exon5R Reverse SERPINF1  AGAATTGGAGACGCGCTCACC 
SERPINF1Exon5bF Forward SERPINF1  AGATGCTGGCTGGGAAGTCAG 
440bp 
SERPINF1Exon5bR Reverse SERPINF1  CTGAGATCGCACCACTGCACTC 
SERPINF1Exon6F Forward SERPINF1  CTGACAGCTAAGCTCCCTTGA 
369bp 
SERPINF1Exon6R Reverse SERPINF1  TGTAGACAGCTGTCGGATCTCA 
SERPINF1Exon7F Forward SERPINF1  CTGGATGAAGGACGAGACCA 
420bp 
SERPINF1Exon7R Reverse SERPINF1  AGCCCTTGCGTTCTGCTTAGC 
SMAP1F Forward SMAP1 ACATTGGTCTCTACCCGCTGG 
451bp 
SMAP1R Reverse SMAP1 GCATCTTAACCCTGTGATTCTC 
TRIM17aF Forward TRIM17 GACCCTGAATGCCCCACACCT 
419bp 
TRIM17aR Reverse TRIM17 CTGGGAGGCTCCATCAGCATG 
TRIM17bF Forward TRIM17 CAAGGGGACCAAGTACTTATCC 
586bp 
TRIM17bR Reverse TRIM17 GAGCCACAGATTCCTGTCATTC 
VPS53F Forward VPS53 AGTAGAGACCTGACCTCAGGTG 
299bp 
VPS53R Reverse VPS53 CAAGATGTGCCAAAAGCTGCTG 
ZNF225F Forward ZNF225 TACCCATCGTAGAGTCCACAGTGGA 
447bp 
ZNF225R Reverse ZNF225 TCTCTACTGTGGAGTCTCTGATGG 
 
Table ‎2.4 Primers used for RT-PCR during genotyping and Sanger sequencing 
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2.8.2.2 Sanger sequencing 
Sanger sequencing was performed by Source BioScience Life Sciences.  Approximately 100ng 
purified PCR product (2.10) was sequenced in each instance. Sequencing primers were in all 
cases either the forward or reverse primer that had been used during amplification of the exon 
or genomic region containing the variant to be genotyped. These primers are shown in 
Table ‎2.4.  
DNA sequencing chromatograms were visualized using Finch TV version 1.4.0 Geospiza©. 
During segregation analysis in otosclerosis families and identification of specific known variants 
in a cohort of familial otosclerosis probands, chromatograms were analysed for the presence 
of heterozygous variants by observation of a double peak on the chromatogram at the position 
of the known variant, indicating the presence of two variant alleles. Individuals were also 
checked for homozygosity of the variant at this site, although this was expected to be unlikely 
due to the rarity of the variants analysed. During investigation for the presence of unknown 
variants within an exon, the whole chromatogram representing the full exonic region was 
analysed by eye for the presence of double peaks indicative of a heterozygote. 
Chromatograms were also checked for the presence of homozygous variants for known 
common alleles within the exon, as these would not be easily visualised by a double peak.  
 
2.8.2.3 Restriction endonuclease digestion 
Restriction endonuclease digests were used to detect the presence of a specific variant within 
a PCR product.  Typically 1µg of PCR product was digested with 5 units of the appropriate 
enzyme in 1x of the appropriate restriction enzyme buffer in a total volume of 20µl. Reactions 
were typically left for 1-2 hours or overnight at 37°C unless a different optimal temperature 
was specified. Resulting DNA fragments were analysed by gel electrophoresis (2.9) against a 
digested sample from a known heterozygote which acted as a positive control. The restriction 
endonuclease digests performed are summarised in Table ‎2.5. 
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Gene Variant 
PCR 
amplicon 
length 
Restriction 
Endonuclease 
Fragment 
sizes  
wt 
Fragment  
sizes  
het 
Fragment  
sizes 
mutant 
CYP2D6 c.345delC 505bp DrdI 505bp 505+278+226bp 278+226bp 
DNAH5 c.7883T>G 469bp OliI 469bp 469+319+150bp 319+150bp 
EGLN3 c.496C>T 446bp AciI 308+138bp 446+308+138bp 446bp 
mir-183 c.81G>T 473bp AvaII 473bp 473+303+170bp 303+170bp 
PTK6 c.652A>T 320bp MlsI 207+113bp 320+207+113bp 320bp 
SERPINF1 c.441G>C 440bp TseI 314+126bp 440+314+126bp 440bp 
TRIM17 c.915C>G 419bp RsaI 334+85bp 419+334+85bp 419bp 
VPS53 c.107C>G 299bp PpuMI 182+117bp 299+182+117bp 299bp 
Table ‎2.5 Table showing predicted fragment sizes from restriction endonuclease digests  
Table shows the predicted fragment sizes for wild-type, heterozygous and homozygous mutant sequences with 
each restriction endonuclease. 
 
 
2.9 Agarose gel Electrophoresis 
DNA bands were visualised by agarose gel electrophoresis on 1.5-3% agarose gels, made using 
1x TAE buffer and 0.25µg/ml ethidium bromide. 1x DNA loading buffer was added to each 
sample where appropriate and was electrophoresed alongside 5µl 1kb or 100bp DNA ladder 
(Promega) at approximately 80mA for 30 minutes.  DNA bands were visualised by exposure to 
ultra-violet light using a 3UV™ Transilluminator GelDoc-It imaging system (Jencons-PLS). 
 
2.10 Purification of PCR products 
Specific PCR products were purified using either the QIAquick PCR purification kit (Qiagen) with 
a microcentrifuge, or the QIAquick 96 PCR purification kit (Qiagen) along with the QIAvac 96 
vacuum manifold and a vacuum pump, according to the manufacturer’s instructions. The 
purified PCR product was eluted in 30µl of Qiagen Buffer EB (10 mM Tris·Cl,pH 8.5). 
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2.10.1 Purification of PCR product from low melting point agarose gels 
Specific PCR products were recovered using standard agarose gel electrophoresis (2.9) with the 
use of low melting point agarose.  The gel was exposed to UV light under a TFX-20M UV 
Transilluminator (BDH) and the required bands excised using a scalpel.  PCR products were 
purified using the QIAquick gel extraction kit (Qiagen) with a microcentrifuge according to the 
manufacturer’s instructions. The purified PCR product was eluted in 30µl of Qiagen Buffer EB 
(10 mM Tris·Cl,pH 8.5). 
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3 Cohort Characteristics 
 
3.1 Overview 
Throughout this chapter, the data collected from the questionnaire responses of study 
participants will be analysed and evaluated in the context of the themes discussed in Chapter 1 
of this thesis. The analysis will be focussed on three key areas;  (i) the clinical characteristics of 
otosclerosis in the cohort members; (ii) exposure to environmental factors predicted to be 
involved in the disease process; and (iii) the frequency of other diseases and disorders in 
members of the cohort. This analysis will provide a general overview of the demographics of 
the cohort recruited, in order to establish whether the cohort is typical of a group of 
individuals with otosclerosis. It could also enable the identification of trends in the data and 
indicate reasons for susceptibility to this form of conductive hearing loss.  
 
3.2 Results  
3.2.1 Collection of DNA samples from study participants 
Patient recruitment was opened in July 2011 after ethical approval had been received from the 
London Bloomsbury Research Ethics Committee. As of July 2013, 263 otosclerosis patients had 
been recruited to this study. Human tissue samples collected include; 110 otosclerotic stapes 
suprastructures; one otosclerotic footplate; 11 control stapes suprastructures; and two control 
footplates. In addition, 138 blood samples and 127 saliva samples were collected from 
otosclerosis probands, totalling 263 genomic DNA samples. Saliva samples from 42 family 
members of selected probands with a strong family history of the condition were also obtained 
(Figure ‎3.1). 
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Figure ‎3.1 Bar graph showing numbers of stapes and genomic DNA samples collected  
 
3.2.2 Characteristics of the otosclerosis cohort 
Of the 263 study participants recruited, 186 were female and 77 male.  The cohort therefore 
displays a female to male ratio of 2.4:1. The average age of male particpants was 55, the 
average of female participants was 52 and the overall average for the cohort was 53. 
Each study participant was sent a questionnaire in the post (see Appendix). The questionnaire 
was completed and returned by 232 of the 263 participants, representing a questionnaire 
response rate of 88.2%. The questionnaire was designed to capture the characteristics of the 
cohort including their age of symptom onset, ethnicity and whether or not they have a strong 
family history of otosclerosis. It also collected details of participants’ experience of unilateral 
or bilateral hearing loss, tinnitus and vertigo.  
Of the 232 questionnaire respondents, 157 (67.7% of respondents) reported the first 
symptoms of hearing loss between the ages of 21 and 40, 11 (4.7% of respondents) were 
under the age of 10 at onset and just one (0.4% of respondents) was over the age of 61 
(Figure ‎3.2). 
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Figure ‎3.2 Bar graph showing age of hearing loss onset of questionnaire respondents  
 
A comparison of the age of hearing loss onset in males and females showed that a greater 
percentage of females exhibited symptoms at a young age (Figure ‎3.3). This difference was 
most marked in the 21-30 age range, where 35.1% of females developed symptoms in 
comparison to just 29.5% of males. In contrast, males were more likely to develop hearing loss 
at a more advanced age, in particular in the 41-50 age range where 18.0% of males developed 
symptoms, in comparison to 10.5% of females. However, when a Student’s two-tailed paired-
end t-test was conducted to compare difference in age of onset distribution between males 
and females, there was no significant difference(p=0.44). 
 
Figure ‎3.3 Bar graph showing age of hearing loss onset of male and female questionnaire respondents 
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The ethnicity of respondents was wide ranging. Of the respondents, 173 (74.6% of 
respondents) described themselves as British or Irish, 24 (10.3% of respondents) identified 
themselves as being of other European origin, 11 (4.7% of respondents) were of Asian origin, 
five (2.2% of respondents) of African or Caribbean origin and 19 respondents were of other 
ethnic origins (Figure ‎3.4). 
 
Figure ‎3.4 Pie chart showing ethnicity of questionnaire respondents 
 
Of the 232 respondents, 41 (17.7% of respondents) reported a strong family history of 
otosclerosis with two or more affected relatives. An additional 41 (17.7% of respondents) had 
some family history of the condition with just one affected relative. A further 97 (41.8% of 
respondents) reported a family history of other forms of hearing loss, including conditions 
resembling otosclerosis without formal diagnosis. No family history of hearing loss was 
reported by  52 respondents (22.4% of respondents) (Figure ‎3.5).  
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Overall, a greater proportion of female than male respondents had a strong family history of 
otosclerosis. However, a greater proportion of males than females reported just one affected 
relative. A substantially greater proportion of females than males reported a family history of 
other forms of hearing loss aside from otosclerosis, whilst a greater proportion of males than 
females indicated that they had no family history of hearing loss. One study participant was 
adopted into her family and so did not know about the relevant medical history of her 
biological relatives (Figure ‎3.5).  
 
 
Figure ‎3.5 Bar graph showing family history of hearing loss in male and female questionnaire respondents 
 
Analysis of the questionnaire responses showed that the majority of study participants 
experienced bilateral hearing loss, with 162 (69.8% of respondents) reporting hearing loss in 
both ears. Tinnitus symptoms were reported by 158 participants (68.1% of respondents).  A 
smaller proportion of the cohort,  72 respondents (31.0% of respondents), reported symptoms 
of vertigo (Figure ‎3.6).   
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Figure ‎3.6 Pie charts showing proportion of respondents with bilateral hearing loss, tinnitus and vertigo 
 
3.2.3 Environmental factors to which cohort members have been exposed 
The questionnaire also collected information on environmental factors that could have 
influenced a participant’s susceptibility to developing otosclerosis. This information included 
data on whether respondents had experienced measles, mumps or rubella infection and 
whether they had been vaccinated against these three viruses. The questionnaire also 
collected information in relation to periods of residence abroad, in order to identify 
respondents who had lived in countries with exceptionally high or low fluoride content in the 
drinking water. In addition, data was collected from women in relation to pregnancy, 
breastfeeding, use of oral contraceptives and hormone replacement therapy.  
Of the 232 questionnaire respondents, 125 had been infected by measles (53.9% of 
respondents), whilst 91 (39.2% of respondents) had received a vaccination against the virus 
(Table ‎3.1). Trends in the data showed that with decreasing age of respondents there was an 
increase in the number of cohort members who had received the measles vaccination. All 
participants under the age of 22 had been vaccinated against measles, whilst all respondents 
over the age of 82 had been infected with the virus (Figure ‎3.7).  Fewer respondents had been 
infected by mumps than measles, with 102 (44.0% of respondents) reporting infection. Of the 
respondents, 79 were vaccinated against mumps (34.1% of respondents). Rubella infection 
was the least common of the three viruses, with just 57 participants (24.6% of respondents) 
having been infected, although 104 (44.8% of respondents) were vaccinated against the virus. 
A large proportion of respondents did not know whether or not they had been infected by the 
viruses and an even larger proportion were unsure if they had received vaccinations 
(Table ‎3.1). 
 
162 
64 
6 
Bilateral Hearing Loss
Unilateral Hearing loss
Doesn't Know
158 
69 
5 
Tinnitus
No Tinnitus
Doesn't Know
72 
147 
13 
Vertigo
No Vertigo
Doesn't Know
 
 
80 
 
 Measles Mumps Rubella 
 Infection Vaccination Infection Vaccination Infection Vaccination 
Yes 125 91 102 79 57 104 
No 64 79 81 82 110 64 
Doesn't 
Know 
43 62 49 71 65 64 
 
Table ‎3.1 Table of the number of questionnaire respondents infected by and vaccinated for measles mumps and 
rubella viruses  
 
 
Figure ‎3.7 Bar graph showing percentage of respondents born in each decade vaccinated for and infected by 
measles 
 
27.8 
25.5 
55.7 54.5 
76.5 
100.0 100.0 
77.8 
63.9 
70.9 
47.5 
24.2 23.5 
0
10
20
30
40
50
60
70
80
90
100
1921-1930 1931-1940 1941-1950 1951-1960 1961-1970 1971-1980 1981-1990 1991-2000
P
er
ce
n
ta
ge
 o
f 
re
sp
o
n
d
en
ts
 
Year of birth 
% received measles vaccination
% infected with measles
 
 
81 
 
Analysis of the questionnaire responses identified the number of respondents who had lived 
abroad for a period of 5 years or more. This data was collected in order to identify potential 
links between fluoride content in drinking water and onset of otosclerosis. Table ‎3.2 shows 
that nearly 10% of the cohort have lived outside the UK within Europe during their lifetime, 
whilst nearly 16% have lived in non-European continents. 
 
Continent/region 
no. respondents who have lived 
abroad 
% respondents who have lived 
abroad 
Africa 8 3.45 
Asia 6 2.59 
Australia 10 4.31 
Caribbean 1 0.43 
Europe 22 9.48 
Middle East 4 1.72 
North America 7 3.02 
South America 1 0.43 
 
Table ‎3.2 Table of number and percentage of respondents who have lived outside the UK for over five years 
 
All consenting females were requested to complete some additional questions regarding 
pregnancy, breastfeeding, contraceptives and hormone therapy to establish any links between 
otosclerosis and hormones, as has been hypothesised in published literature on the topic. Of 
the 186 female study participants, 170 responded to the questionnaire circulated to all 
participants. Of these respondents, 118 (69.4% of female respondents) had been pregnant, 
with two pregnancies the most common number. Of the 118 respondents who had been 
pregnant, 98 (83.1%) had breastfed and 47 (39.8%) had noticed a deterioration in hearing 
during or shortly after their pregnancy (Figure ‎3.8). 
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Figure ‎3.8 Pie charts showing number of pregnancies in female respondents, number of months for which 
respondents had breastfed, and proportion of respondents who developed hearing loss during or after pregnancy 
 
Of all 170 female respondents, 126 (74.1% of respondents) had taken oral contraceptives with 
40% of these 126 having taken them for longer than 5 years (Figure ‎3.9).  
 
 
Figure ‎3.9 Pie chart showing number of years for which female respondents had taken oral contraceptives 
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Eighty individuals (47.1% of respondents) had experienced the menopause, with 25 (14.7% of 
respondents) having taken or currently taking hormone replacement therapy (HRT) (Table ‎3.3). 
 
No. years taking HRT No. respondents 
<1 7 
2-5 7 
6-10 6 
11+ 5 
 
Table ‎3.3 Table showing number of years for which questionnaire respondents had taken HRT 
 
3.2.4 Incidence of autoimmune disease and connective tissue disorders in 
cohort members 
The questionnaire also requested information regarding particpants’ medical history including 
conditions that may have links with otosclerosis. Data was collected on autoimmune 
conditions, broken bones and connective tissue disorders. It was found that 39.2% of the 232 
respondents of both genders had broken a bone at some point in their lifetime. History of an 
autoimmune condition was reported by 18.1% of respondents. This is approximately double 
the predicted prevalence of autoimmune conditions in the general population of 7.6-9.4%, a 
prevalence range derived from a large recent meta-analysis (Cooper and Stroehla, 2003) 
(Table ‎3.4). When a Chi squared test was performed to compare the prevalence of 
autoimmune  conditions in the otosclerosis cohort and the general population based on the 
greater 9.4% prevalence statistic derived form this meta-analysis, the difference was found to 
be highly significant (X2=20.6, df=1, p=5.64x10-6). In addition, a further four respondents (1.7% 
of respondents) reported a connective tissue disorder, including two cases of Osteogenesis 
Imperfecta and one case each of Osteomalacia and Plantar fasciitis. 
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Autoimmune condition 
no. 
respondents 
affected 
% of questionnaire 
respondents 
affected 
Prevalence in 
general 
population 
Unspecified Autoimmune Condition 21 9.05% n/a 
Bullous pemphigoid 1 0.43% 
Data 
unavailable 
Graves’ disease 2 0.86% 1.15% 
Lichen Sclerosus 2 0.86% 
Data 
unavailable 
Multiple Sclerosis 1 0.43% 0.06% 
Osteoporosis 14 6.03% 4.34% 
Sjogrens disease 1 0.43% 0.01% 
Total 42 18.10% 3.23% 
 
Table ‎3.4 Table of number and percentage of respondents who reported history of autoimmune conditions  
For data on the prevalence of the condition in the general population see (Cooper and Stroehla, 2003). 
 
3.3 Discussion of cohort characteristics 
3.3.1 Ascertainment of DNA from study participants 
Over the course of the two year recruitment period from July 2011 to July 2013, 263 
otosclerosis patients donated genomic DNA samples for the benefit of this research study. This 
is thought to be the second largest collection of genomic DNA samples from otosclerosis 
patients worldwide, second only to the largest collection held by the Department of Medical 
Genetics at the University of Antwerp in Belgium. In addition, the 110 otosclerotic stapes 
suprastructures collected during this study are thought to be the largest collection of non-
formalin-fixed otosclerotic stapes samples collected to date, consisting of more stapes samples 
than the largest published collection of 85 samples held at the University Medical School of 
Debrecen in Hungary. The combined genomic DNA and stapes collections for this study are 
thought to be the largest global collection of overlapping samples from the same individuals, 
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with both stapes cDNA and genomic DNA held from 110 otosclerosis patients. This collection 
therefore offers the first opportunity to validate the results of genetic studies by conducting 
gene expression studies to identify the impacts of genetic variants on gene expression in 
specific otosclerotic stapes. 
Recruitment for this study was initially slightly slower than expected, as initial predictions 
suggested that 100 stapes surgeries were performed per year at the Royal National Throat 
Nose and Ear hospital in London. In reality, this prediction had failed to account for the large 
number of patients with bilateral hearing loss who had both ears operated on during that 
time, so was an overestimate of the true number of participants who could be recruited.  To 
overcome this, recruitment was expanded to two new UK sites at the Sunderland Royal 
Hospital and the Freeman Hospital in Newcastle-upon-Tyne, where as of July 2013, the first 
consenting participants were recruited. This research study is now the first multi-centre study 
in the UK recruiting otosclerosis patients from around the country.  
During the recruitment phase of the study, a large number of probands reporting a strong 
family history of otosclerosis that also had large numbers of living affected relatives were 
recruited. Following successful attempts to contact both affected and unaffected family 
members, a total of 42 relatives were recruited from 16 unrelated otosclerosis families, in 
addition to the 16 probands from each of these families. This cohort is therefore extremely 
useful for investigations into genetic factors involved in familial otosclerosis.  
One obstacle encountered during sample collection for this study was a difficulty in gaining 
access to large numbers of control stapes as there are very few medical scenarios during which 
the stapes bone is removed routinely. As of July 2013, 11 control suprastructures and 2 control 
footplates had been collected which came predominantly from individuals undergoing total 
petrosectomy surgery or those receiving surgery following head trauma. There was also 
difficulty in gaining access to stapes footplates. The collection of footplates is not easy in the 
UK since the laser assisted stapedotomy procedure, which leaves the footplate in place during 
surgery, is the favoured surgical technique. However, it is important to compare gene 
expression in footplate and suprastructure as the footplate is the predominant location of the 
otosclerotic foci, where it is most likely that aberrant gene expression will occur in 
otosclerosis. To overcome this, a collaboration has been established with the University of 
Athens in Greece, where the stapedectomy surgery, during which the whole stapes is 
removed, is routinely performed.  This will enable access to be gained to large number of 
stapes footplates, which will be useful to validate any future gene expression studies 
conducted using stapes suprastructures. 
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3.3.2 Analysis of cohort characteristics 
The gender distribution of the cohort recruited displays a female to male ratio of 2.4:1.  This is 
roughly in line with reports from the 1930s which suggested that twice as many females as 
males are affected by otosclerosis (Davenport, 1933). However this fact has been widely 
disputed (Larsson, 1960, Morrison, 1967) with claims that the gender bias is not a true 
reflection of incidence but is caused by the fact that females are more likely to be seen in 
clinical practice, as women are more likely than men to consult their General Practitioner 
regarding hearing loss, resulting in more referrals to the clinic (Browning and Gatehouse, 
1992). The data collected from the otosclerosis cohort suggests that more women are being 
referred, but cannot provide evidence to clarify whether or not this is a true reflection of 
disease incidence.  
The data collected also suggests that the most common age of onset of hearing loss in the 
otosclerosis cohort is between the ages of 21 and 40.  This coincides with previous published 
reports of the average age of onset being in the 3rd decade of life (Gapany-Gapanavicius, 
1975). Eleven members of the cohort reported first experiencing hearing loss in childhood 
below the age of 10 and one member of the cohort was over age 61 at onset.  This data 
therefore supports the literature, suggesting that the condition may develop as early as 
infancy or as late as the sixth decade in rare cases. The age of onset data also shows an 
interesting gender distribution with a greater percentage of females exhibiting symptoms at a 
younger age than males, especially in the 21-30 age range where 35.1% of females develop 
symptoms in comparison to just 29.5% of males. Since this age range coincides with child-
bearing age in females and is also the age range at which females are most likely to be taking 
oral contraceptives, this difference in age distribution between the genders could provide 
support to previous studies that have suggested a hormonal role in disease pathogenesis 
(Vessey and Painter, 2001, Lippy et al., 2005, Podoshin et al., 1978). However, since there was 
not found to be a  statistical difference in age distribution between males and females, this 
trend may be coincidental. 
Ethnicity is predominantly British or Irish in the otosclerosis cohort with three quarters of 
study participants describing themselves as such. According to the 2011 UK census, 47.1% of 
London’s population describe themselves as British or Irish. Therefore this cohort has 
significantly more British or Irish individuals than would be expected from a randomly selected 
cross-section of London’s population.  This may be because otosclerosis is particularly common 
in Caucasians, affecting approximately 0.3-0.4% of the population (Declau et al., 2007a), and 
less common in other ethnic groups including black African and Oriental populations (Declau et 
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al., 2007a). Alternatively, it may reflect the ethnic composition of the catchment area of the 
Royal National Throat Nose and Ear Hospital which is located in Islington in North London, a 
borough which has a less diverse ethnic population than some other London boroughs.   
In total, 35% of questionnaire respondents reported a positive family history of otosclerosis. 
This is lower than the percentage that would have been expected from consulting the 
published literature which estimates familial cases to comprise 50% of all reported incidences 
of otosclerosis. However, despite the fact that 50% is the figure cited in review articles (Thys 
and Van Camp, 2009), the data upon which it is based originates from the 1970s and 80s with 
no evidence in the current literature to substantiate it. The data collected during this study 
could therefore provide an indication for current incidence figures for familial otosclerosis. 
However, it must be considered that there may have been some individuals who reported a 
family history of hearing loss other than otosclerosis who had a family member with hearing 
loss due to undiagnosed otosclerosis. It is therefore likely that the figure of 35% is an 
underestimate of the true incidence of familial cases of otosclerosis.  
The data collected from the otosclerosis cohort regarding the proportion of individuals 
experiencing bilateral hearing loss, tinnitus and vertigo is slightly lower than has been 
presented in the published literature, with roughly 70% of the cohort experiencing bilateral 
loss and tinnitus, and with fewer reporting symptoms of vertigo. When considering bilateral 
hearing loss in the cohort, it is important to be aware that this statistic is not a true indication 
of the proportion of the cohort who will experience bilateral loss throughout their lifetime. 
Since the questionnaire is issued to patients shortly after a clinic visit, it is likely that many of 
these will be patients having their first visit who have only recently developed symptoms, and 
since otosclerosis usually develops unilateral initially, it is possible that these individuals could 
go on to develop bilateral loss in the future. It therefore likely that the true incidence of 
bilateral loss in the cohort would be slightly higher, which may bring the percentage up to a 
figure more similar to the predicted 70-85% as suggested by the literature (Emmett, 1993). 
Since the questionnaire was not completed by a control population, statistical analyses 
performed on the data collected was limited. This is because is was not possible to compare 
the questionnaire responses of otosclerosis study participants with  a population of unaffected 
individuals. This must be taken into consideration when evaluating the outcomes of the 
questionnaire analysis. 
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3.3.3 Environmental factors involved in otosclerosis development 
The questionnaires sent to study participants included questions to collect information on 
exposure to measles, mumps and rubella infection and vaccination against these viruses. This 
data was collected because a large number of studies in the past have resulted in the 
publication of conflicting reports linking viral infection and the development of otosclerosis  
(Arnold and Friedmann, 1987), McKenna et al., 1989(Niedermeyer et al., 1994, McKenna et al., 
1996). By gathering data on incidence of viral infection and vaccination, it was therefore hoped 
that the cohort could be analysed to identify whether it was overrepresented by those who 
had been infected or vaccinated against these viruses compared to the general population. 
Unfortunately, the data collected during this study is incomplete, as a large proportion of 
respondents were unsure of whether or not they had been infected or had received 
vaccination against these viruses in the past. This was particularly true in regards to 
vaccination, possibly because in the UK vaccinations are carried out at a young age so were not 
within memory of the cohort members. Despite this limitation in data collection, the 
proportion of cohort members who had been infected by the measles virus appeared to be 
high at 53.9%, even when those who did not know whether or not they had been infected 
were excluded from the analysis. However, when considering whether 53.9% is greater than 
the proportion of individuals that would be expected to have been infected by measles in the 
general population, the age distribution of the cohort must be considered. This is because 
older cohort members are more likely to have been exposed to measles infection than younger 
members, as a result of the reduction in incidence of measles following the introduction of the 
vaccination programme in the UK in 1970. Therefore given that 78% of the cohort were born 
prior to 1970, it is not surprising that 53.9% of the cohort had been infected with the measles 
virus.  
Since the risk of developing measles fluctuates each year based on vaccination uptake rates, it 
is extremely difficult to measure the general population risk of being infected by measles. It is 
therefore not possible to compare the incidence of infection in the otosclerosis cohort, which 
includes individuals born over a time period spanning eight decades, with incidence figures for 
the general population. As a result, it is not possible to establish from this data whether the 
otosclerosis cohort is overrepresented for those who had been infected or vaccinated in the 
past. This is a difficulty that has been encountered by many research groups investigating the 
link between viral infection and otosclerosis and may partly explain why the role of viral 
infection in otosclerosis aetiology is yet to be elucidated. 
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In addition to gathering information on viral infection and vaccination, the questionnaires sent 
to study participants also attempted to collect data on the exposure of participants to fluoride 
ions in their drinking water. Fluoride is a naturally occurring ion in ground water which can be 
found at particularly high concentrations on the West coast of the USA, Argentina, some parts 
of Northern and Eastern Africa, Pakistan and regions of both Northern and Southern India, as 
well as various parts of China. In many developed countries, it is added to the water supply 
due to its known dental benefits in children. Fluoride is known to inhibit bone resorption and 
has thus been suggested to contribute to otosclerosis when present at low levels in the 
drinking water (Daniel, 1969) although not all studies support this theory (Vartiainen and 
Vartiainen, 1997a). Fluoride therapy has also been used as a treatment to slow the progression 
of hearing deterioration in otosclerosis patients with a recent review of the literature 
concluding that there is some evidence to suggest that sodium fluoride may be of benefit to 
preserve hearing in otosclerosis patients (Cruise et al., 2010). The questionnaire was designed 
in an attempt to capture information on where study participants had previously lived, in order 
to work out whether or not they had been exposed to low levels of fluoride during their 
lifetime. However, no particular country or region emerged from the data collected as being 
over-represented as a prior residence of cohort members. Since fluoride concentrations 
fluctuate within localised regions depending on the natural fluoride concentration in ground 
water and the varying choices made by local authorities on whether or not to fluoridate water 
supplies, it is extremely difficult to measure a person’s lifetime exposure to fluoride. This 
limitation may explain why despite a promising link between otosclerosis and fluoride based 
upon clinical evidence suggesting that fluoride treatment is beneficial in slowing down 
progression of otosclerosis, no research has been published in the past decade to investigate 
exposure to fluoride in drinking water and development of otosclerosis. 
A set of additional questions were asked specifically to female questionnaire recipients in 
order to gather data on pregnancy and use of both oral contraceptives and hormone 
replacement therapy in females with otosclerosis. These questions were included in the 
questionnaire due to the discrepancy in prevalence of otosclerosis between males and females 
and also due to the fact that otosclerosis often manifests after or during pregnancy, with many 
women reporting early symptoms shortly after giving birth and or during breastfeeding, 
although this evidence is somewhat contradictory (Vessey and Painter, 2001, Lippy et al., 
2005). The data collected from the questionnaire appears to be fairly representative of a 
cohort of adult women, however it is noteworthy that roughly 40% of women in the cohort 
who had been pregnant reported to experience changes in their hearing ability during or 
shortly after their pregnancy. This could indicate a potential link between hearing 
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deterioration in females with otosclerosis and hormonal changes during pregnancy. Despite 
this, it must be taken into account that the average age of onset of otosclerosis coincides with 
the typical child-bearing age of women in the UK, which is supported by the age of onset data 
collected during this study where a higher proportion of females than males reported onset of 
symptoms between the ages of 21 and 30. Therefore it is difficult to establish whether 
pregnancy is involved in development of otosclerosis or if any correlation seen is coincidental.  
 
3.3.4 Otosclerosis as an autoimmune condition 
The questionnaire completed by study participants also included questions designed to gather 
information on autoimmune conditions and other connective tissue disorders in otosclerosis 
patients. Analysis of data collected indicates that the cohort is overrepresented by those 
experiencing autoimmune disorders in comparison to the general population, with 18.1% of 
questionnaire respondents reporting an autoimmune condition compared to a predicted 7.6-
9.4% in the general population. When a Chi squared test was performed, it was found that 
there was a significant difference in prevalence figures of autoimmune diseases in the 
otosclerosis cohort compared to the general population. To perform this statistical test, 
prevalence data from the largest recent meta-analysis (Cooper and Stroehla, 2003) was used 
to estimate prevalence in the general population. The largest percentage in the prevalence 
range  of 9.4% was used to ensure that calculations were conservative. 
One autoimmune condition of particular interest is Sjogren’s disease, which was reported by 
one of the questionnaire respondents, resulting in a cohort frequency of 0.43% which is 
substantially higher than the 0.01% reported frequency in the general population (Cooper and 
Stroehla, 2003). Sjogren’s disease is a progressive systemic autoimmune condition that affects 
the exocrine glands resulting in dryness of the skin, nasal passages and genitals. It frequently 
occurs in individuals with other systemic connective tissue diseases (Theander and Jacobsson, 
2008) including Bullous Pemphigoid (Yamamoti et al., 1998), a condition reported by another 
cohort member, which is characterised by production of autoantibodies against collagen XVII. 
Sjogren’s disease is more common in women than men, with nine in ten individuals with the 
condition being female, and most frequently occurs roughly around the time of menopause. It 
is thought that it may be caused by activation of the transcription factor NFκB, which results in 
the upregulation of the human leukocyte antigen in the epithelial tissues of patients. Sjogren’s 
disease has also been reported repeatedly in individuals with the common connective tissue 
condition Plantar Fasciitis, which affects another cohort member, and which occurs when a 
tight band of connective tissue develops around the arch of the foot.  
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In addition to Sjogren’s disease and its related conditions, the cohort is also over-represented 
by individuals with other systemic autoimmune conditions including Multiple sclerosis which 
affects 0.43% of questionnaire respondents compared to 0.06% of the general population, and 
Osteoporosis which affects 6.03% of questionnaire respondents compared to 3.34% of the 
general population. In addition, 21 additional cohort members reported an autoimmune 
condition but did not specify which one. Since multiple autoimmune conditions often occur 
concomitantly in a single individual, the over-representation of autoimmune conditions in the 
otosclerosis cohort is suggestive that otosclerosis may itself have an autoimmune pathology. 
 
 
In summary, the otosclerosis cohort recruited during this study has provided the largest stapes 
tissue bank worldwide for gene expression studies and is the first instance of a large collection 
of stapes and genomic DNA samples from overlapping individuals. The cohort recruited tends 
to display characteristics in line with what would be expected from the published literature. 
However, the information gathered regarding exposure to environmental agents thought to 
play a role in otosclerosis was less informative than had been hoped, as it is very difficult to 
measure a person’s exposure to their environment, an issue that has been encountered by 
other research groups. Despite this, a large proportion of female cohort members reported 
hearing deterioration during or shortly after pregnancy suggesting that the link between 
hormones and otosclerosis is worth future investigation. In addition, the cohort appeared to 
be over-represented by individuals reporting autoimmune conditions, suggesting that perhaps 
a mechanism of autoimmunity may be involved in development of otosclerosis. 
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4 Whole Exome Sequencing (WES) 
identifies novel genetic variants that 
segregate with otosclerosis in families 
 
4.1 Introduction 
Whole Exome Sequencing (WES) is a powerful Next Generation Sequencing (NGS) technique 
involving targeted sequencing of the exome; the protein coding portion of the human genome. 
When accompanied by an effective variant prioritisation strategy, WES can be used to identify 
genetic variants involved in monogenic inheritance of Mendelian traits (Bamshad et al., 2011). 
The first study to employ this technique was a proof-of concept study which successfully 
identified  the causal mutation within the MYH3 gene known to underlie the rare autosomal 
dominant disorder Freeman-Sheldon syndrome (Ng et al., 2009). Since its publication in 2009, 
more than 100 additional genes involved in various monogenic disorders have been 
characterised through use of this technique (Rabbani et al., 2012). WES is based on the 
principle that that the exome constitutes approximately 1% of the genome but accounts for 
about 85% of disease causing mutations in Mendelian disease (Cooper, 1998). Therefore 
focusing solely on the exome rather than the entire genome is a quick and cost-effective 
approach for identification of pathogenic variants.  
During WES, a library of short fragments of DNA are prepared from genomic DNA, which are 
sequenced in millions of parallel reactions before being mapped to a reference genome based 
on the sequence alignment. This enables variant calling of coding variants. These variants are 
then subjected to a stepwise prioritisation process (Figure ‎4.1) which ensures that only those 
shared by affected family members but absent in unaffected family members are retained. 
Rare variants and those predicted to have a damaging effect on the resulting protein are 
prioritised, with the aim of identification of disease causing mutations within candidate genes. 
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Figure ‎4.1 Variant prioritisation following WES  
Flow chart showing variant prioritisation to identify disease causing variants within candidate genes (from 
(Biesecker, 2010)). 
 
Prior to the introduction of WES, the traditional approach to gene identification for Mendelian 
traits was through use of linkage analysis studies. However, the success of these studies was 
limited due to the issue of variable penetrance and the requirement to recruit large numbers 
of affected family members (see Chapter 1 section 1.7.2.1). In addition, the NGS methods 
available, such as Whole Genome Sequencing (WGS,) were too costly for the majority of 
research groups and were both slow and labour-intensive, generating vast quantities of data, 
which led to a wealth of bioinformatics obstacles (Wang et al., 2013). Although these 
techniques have many useful applications, the introduction of WES has offered an attractive 
alternative option for identification of pathogenic variants, which is increasing in popularity 
amongst many research groups.  With WES, it is possible to identify disease causing variants 
within small affected families with as few as two affected members, giving this NGS technique 
wider applications than traditional linkage analysis. It is also a more cost-effective option than 
WGS, at approximately one sixth of the cost. This reduced cost means that it is possible to 
perform WES on larger numbers of family members than would be possible for WGS, which 
increases statistical power of the study, making the identification of a disease causing variant 
more likely.  In addition, WES is less labour-intensive than WGS meaning that results can be 
made available rapidly with fewer bioinformatics obstacles (Majewski et al., 2011). 
However, there are also clear limitations for the use of WES for identification of disease-
causing genes. Our current knowledge of the human genome limits the use of this technique, 
as disease causing variants located within, as yet, unidentified genes, will be overlooked during 
this approach. Similarly, variants located in non-coding regulatory regions of the genome 
including transcriptional promoter and enhancer elements, as well as those that regulate 
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alternative splicing may also be missed. In addition, this technique may not be ideal for 
investigating structural variation within genomes including translocations and inversions, as 
well as copy number variants and variation involved in triplet repeat disorders (Wang et al., 
2013). WES cannot be used to identify mitochondrial variation as it focuses on the protein-
coding region of chromosomes only. Furthermore, for conditions that exhibit variable 
penetrance, problems may be encountered during segregation analysis that follows WES, due 
to difficulties in discriminating between phenotypically unaffected family members who may 
or may not possess the disease causing mutation (Majewski et al., 2011).  
To date, no research has been published using WES for gene discovery in otosclerosis. Here it 
is used to identify novel genetic variants within four families exhibiting monogenic inheritance 
of familial otosclerosis. The two greatest challenges faced when performing WES were the 
difficulty in selection of the best possible individuals for sequencing, as well as the analysis, 
interpretation and filtering of large numbers of variants. In this chapter, strategies for selecting 
appropriate samples to be sequence are discussed, followed by a description of how variants 
were identified, annotated and prioritised. The individuals selected for sequencing and variant 
prioritisation strategy employed was just one of many possible options, and was decided upon 
as the most likely strategy to yield the desired result.  
The prioritisation steps are based on a series of assumptions that can be made about the 
disease causing variant, which may appear overly stringent in comparison to other research 
techniques, as it is possible that the true disease causing mutation could be eliminated at any 
stage of the filtering process. However, it is crucial to use stringent filters initially in order to 
narrow down the large number of variants to a small pool of those most likely to be disease 
causing.  If no variants within good candidate genes were identified at the end of the process, 
reduced-stringency filters would be applied, in what is an iterative process.  
This chapter is divided into two parts.  Part I will describe the identification of all variants 
within individuals who have been sequenced, followed by prioritisation of candidate variants 
that segregate with familial otosclerosis, whilst Part II will involve further analysis performed 
on the most interesting candidates to emerge from Part I. Due to the step-wise nature of this 
analysis, the results and discussion sections will be combined in each part of this chapter, as it 
is essential to interpret the results at each stage in order to make decisions on how best to 
proceed. A general discussion section will summarise the findings at the end of the chapter. 
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Whole Exome Sequencing Part I 
Identification of rare variants that 
segregate with familial otosclerosis 
 
4.2 Identification of ten individuals for WES 
WES was performed at the end of year one of this research project at the Wellcome Trust 
Sanger Institute in Cambridge. In order to obtain genomic DNA samples from appropriate 
otosclerosis families for sequencing, probands that reported a strong family history of 
otosclerosis in their questionnaire responses were prioritised for family recruitment.   This 
ensured that genomic DNA was collected from sufficient numbers of families for WES.  
At the end of year one, sixteen otosclerosis families had been recruited. This included the 
recruitment of thirty five individuals with confirmed otosclerosis based on confirmation of 
otosclerosis during surgery or audiometric analysis along with physical examination. It also 
included one individual with presumptive otosclerosis who was not able to confirm a diagnosis 
but who was presumed to be affected based on reported symptoms characteristic of 
otosclerosis that strongly indicated the presence of the condition in this family member. In 
addition, four of the individuals reported symptoms of hearing loss that were caused by other 
hearing conditions including presbycusis, or had undiagnosed hearing loss. For this reason it 
was not possible to exclude the possibility of otosclerosis in these individuals. Eighteen 
unaffected family members were also recruited who had not reported any prior symptoms of 
hearing loss. 
In total ten individuals across four of these sixteen families designated A (Figure 4.2), B Figure 
4.3), C (Figure 4.4) and D (Figure 4.5)were selected for WES, to give the best possible chance of 
identifying the disease causing variant.  
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These four families were prioritised for WES based on the following criteria: 
 The family appeared to exhibit clear monogenic inheritance of otosclerosis 
 Otosclerosis was present in multiple generations of the family 
 The family included multiple living affected relatives  
 It was possible to secure genomic DNA samples from multiple affected and unaffected 
family members 
 Families from which stapes cDNA had been obtained were prioritised where possible 
Families A, B, C and D are described in sections ‎4.2.1, ‎4.2.2, ‎4.2.3 and ‎4.2.4 respectively. 
 
4.2.1 Family A 
Family A is of Caucasian origin living in the UK. The mode of otosclerosis inheritance in this 
family is consistent with an autosomal dominant pattern (Figure ‎4.2). Autosomal dominant 
inheritance is assumed due to the presence of either confirmed or presumptive otosclerosis in 
three of five siblings in generation III, in addition to one confirmed case in generation IV. In this 
family, it appears that otosclerosis is inherited from two sisters in generation II, for which the 
hearing status is unknown. Two living affected individuals within this family have confirmed 
otosclerosis, both of whom were selected for WES (Table ‎4.1). These individuals are the 
proband (IV:3) and her maternal uncle (III:2) who would be expected to share 25% of their 
variants. The probands mother (III:1) is the case of presumptive otosclerosis previously 
mentioned, where otosclerosis is presumed but cannot be confirmed. This individual reported 
to have undergone bilateral surgery for hearing loss, which is strongly suggestive of 
otosclerosis as there are few other scenarios under which bilateral hearing loss surgery would 
be performed. This combined with analysis of the family pedigree which suggests that this 
individual is likely to have passed the disease causing variant on to her affected daughter 
(IV:3), indicates that otosclerosis is likely in this individual. The proband’s daughter (V:1) 
reported recent symptoms of hearing loss but audiometric analysis was unable to provide a 
diagnosis. It is therefore not possible to rule out hearing loss in this individual. The age of 
hearing loss onset ranges between the age ranges of age 11-20 and 21-30 in this family.  
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Figure ‎4.2 Pedigree of Family A 
Square=male; circle=female; slash=deceased individual; open symbol=clinically unaffected; solid symbol=hearing 
impairment; black symbol=confirmed otosclerosis; dark grey symbol=presumptive otosclerosis; light grey 
symbol=other hearing loss; arrow=proband 
 
Family 
member 
Age at 
recruitment 
Gender Hearing status 
Age range at 
hearing loss onset 
Selected for WES 
III:1 78 Female Presumptive 
otosclerosis 
unknown No 
III:2 64 Male 
Confirmed 
Otosclerosis 
21-30 Yes 
IV:1 54 Male Unaffected n/a No 
IV:2 53 Male Unaffected n/a No 
IV:3 
(Proband) 
48 Female 
Confirmed 
Otosclerosis 
11-20 Yes 
V:1 27 Female Undiagnosed 
hearing loss 
21-30 No 
 
Table ‎4.1 Table showing demographics of members of family A 
 
 
98 
 
4.2.2 Family B 
Family B is of Caribbean origin from a small island in St Vincent and the Grenadines (details 
with-held to protect identity of family). The proband describes herself as of black Caribbean 
origin with her maternal family being of French origin, whilst her paternal grandmother is of 
black Carib origin and paternal grandfather of Scottish origin. 
The family appears to exhibit autosomal dominant inheritance of otosclerosis with variable 
penetrance (Figure ‎4.3). This assumption has been made due to presence of otosclerosis 
symptoms in close to 50% of the offspring of a single generation despite neither of their 
parents exhibiting symptoms. However, since the family comes from a small island population 
of approximately 4,500 people and since neither of the proband’s parents experienced 
otosclerosis symptoms, autosomal recessive inheritance cannot be ruled out. Although DNA 
from only a single generation of affected individuals is available in this family, they were 
selected as a good family for WES because the inheritance pattern is consistent with 
monogenic inheritance. In addition they were prioritised because the stapes of the proband 
was one of those RNA sequenced (chapter 5), the results of which it was assumed could assist 
with the identification of the pathogenic variant in this family.  
Three living affected individuals within this family have confirmed otosclerosis, two of whom 
were selected for WES along with one unaffected individual within the family (Table ‎4.2). Since 
the only suitable affected individuals for WES in this family are siblings who share 50% of their 
variants, it was decided to also select unaffected sibling III:5, in order to assist the variant 
prioritisation process following WES. Unaffected individual III:5 was selected in preference to 
individual IV:1 as this individual is younger than the age at which some of his relatives 
developed symptoms, so it is possible this individual could go on to develop symptoms in the 
future (Table ‎4.2). In addition, III:5 was selected in preference to II:1 as it was expected that it 
would be more beneficial to sequence an unaffected family member from the side of the 
family in which otosclerosis occurs. There was no great benefit in selecting III:5 in preference 
to III:6 but was chosen for the sole reason that a greater yield of genomic DNA was obtained 
from individual III:5. The selection of an unaffected individual raises some concerns regarding 
variable penetrance, especially because the father in this family appears not to have 
otosclerosis despite the condition seemingly being passed down the paternal line. His age at 
death is unknown. Symptom onset is variable in this family and ranges from age ranges 11-20 
to 41-50.  
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Figure ‎4.3 Pedigree of Family B 
Square=male; circle=female; slash=deceased individual; open symbol=clinically unaffected; solid symbol=hearing 
impairment; black symbol= confirmed otosclerosis; light grey symbol=other hearing loss; arrow=proband 
 
Family 
member 
Age at 
recruitment 
Gender Hearing status 
Age range at 
hearing loss onset 
Selected for WES 
II:1 87 Female Unaffected n/a No 
III:1 67 Male Presbycusis 61+ No 
III:2 65 Female 
Confirmed 
Otosclerosis 
41-50 Yes 
III:3 
(Proband) 
63 Female 
Confirmed 
Otosclerosis 
21-30 Yes 
III:4 62 Male 
Confirmed 
Otosclerosis 
11-20 No 
III:5 60 Female Unaffected n/a Yes 
III:6 59 Male Unaffected n/a No 
IV:1 35 Male Unaffected n/a No 
 
Table ‎4.2 Table showing demographics of members of family B 
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4.2.3 Family C 
Family C is of Caucasian origin and exhibits an otosclerosis inheritance pattern consistent with 
that of autosomal dominant inheritance. This can be assumed due to the presence of multiple 
affected family members in successive generations (Figure ‎4.4). The hearing status and age at 
death of generation I is unknown but it can be assumed that at least one of the individuals in 
this generation possessed the disease causing variant, as it would be very unlikely that two of 
their offspring in generation II would develop a spontaneous mutation leading to the disease 
phenotype.  Three living affected individuals within this family have confirmed otosclerosis, 
two of which (III:1 and II:3) were selected for WES (Table ‎4.3). These two individuals were 
selected in preference to individual II:4, as they were the two most distantly related affected 
individuals in the family, who would be expected to share just 25% of their variants. This 
meant that more variants could be eliminated at the first stage of the filtering process, than if 
only one of these individuals was selected along with II:4. Family member II:1 has presbycusis 
and member III:2 has recently reported symptoms of hearing loss at age 45, which has not 
been diagnosed. Since symptom onset ranges from age ranges 21-30 to 31-40 in this family, it 
is possible that individual III:2 could be experiencing the first symptoms of otosclerosis, as 
although he would be the oldest reported case of symptom onset in this family, he is only 5 
years older than the oldest reported case to date.  
 
 
Figure ‎4.4 Pedigree of Family C 
Square=male; circle=female; slash=deceased individual; open symbol=clinically unaffected; solid symbol=hearing 
impairment; black symbol=confirmed otosclerosis; light grey symbol=other hearing loss; arrow=proband 
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Family 
member 
Age at 
recruitment 
Gender Hearing status 
Age range at 
hearing loss onset 
Selected for 
WES 
II:1 83 Female Presbycusis 61+ No 
II:2 81 Male Unaffected n/a No 
II:3 78 Female 
Confirmed 
Otosclerosis 
21-30 Yes 
II:4 74 Male 
Confirmed 
Otosclerosis 
31-40 No 
II:5 7th decade Female Unaffected n/a No 
III:1 
(Proband) 
46 Female 
Confirmed 
Otosclerosis 
21-30 Yes 
III:2 45 Male 
Undiagnosed 
hearing loss 
41-50 No 
III:3 41 Female Unaffected n/a No 
 
Table ‎4.3 Table showing demographics of members of family C 
 
4.2.4 Family D 
Family D is of Portuguese origin from a small rural region in Portugal (details with-held to 
protect identity of family). It appears that all family members are the descendants of two 
brothers for whom the disease status is unknown. Although this family appears to show 
autosomal dominant inheritance, the multiple consanguineous marriages in the family may be 
affecting the apparent inheritance pattern so autosomal recessive inheritance cannot be ruled 
out (Figure 4.5). The large numbers of individuals with confirmed or presumptive otosclerosis 
in this family suggests high penetrance of the disease causing allele, providing a strong 
rationale for monogenic inheritance in this family. Three living affected individuals (IV:2, V:1 
and V:3) have confirmed otosclerosis, all of whom were successfully recruited and selected for 
WES (Table ‎4.4). Individual IV:1 who has presbycusis and unaffected individual V:2 were also 
recruited. Intermarriage within the family means that the siblings and their parents may share 
more than 50% of their variants. Therefore three affected family members were chosen to 
assist with the filtering process to ensure the best possible chance of identifying the 
pathogenic variant. The proband in this family developed symptoms under the age of 10, 
however age of onset data is not available for the remainder of the family. 
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Family 
member 
Age at 
recruitment 
Gender Hearing status Selected for WES 
IV:1 75 Female Presbycusis No 
IV:2 81 Male Otosclerosis Yes 
V:1 
(Proband) 
43 Female Otosclerosis Yes 
V:2 4th decade Male Unaffected Yes 
V:3 46 Male Otosclerosis No 
 
Table ‎4.4 Table showing demographics of members of family D 
 
In this family there are two incidences, on either side of the family, in which multiple siblings 
have died in infancy or had severe disability. Although this could be due to an unrelated 
autosomal recessive genetic condition, which would not be surprising given the number of 
consanguineous marriages in the family, it is also possible that an allele leading to otosclerosis 
could be being selected for over a lethal allele.  In addition, this family also has a range of 
other symptoms which are suggestive of a potential systemic connective tissue disorder. These 
symptoms include double jointedness, joint pain and muscular aches which are often triggered 
by illness or infection, hyperflexibility, temporomandibular joint dysfunction, weakness in the 
hip joints, carpal tunnel syndrome, scoliosis with old age, itchy skin after sun exposure, bad 
scarring, frequent miscarriages, arthritis and gastrointestinal problems. Since otosclerosis is 
known to co-occur with a number of systemic connective tissue disorders, it is therefore 
possible that this family has a connective tissue disorder that manifests coincidently with 
otosclerosis, or of which otosclerosis is a symptom. The literature suggests two possible 
genetic disorders which could explain the symptoms of this family; Ehlers-Danlos syndrome 
(Byers and Murray, 2012) and Buschke-Ollendorff syndrome (Schena et al., 2008). Genes that 
have been implicated in both conditions could assist with the variant prioritisation process 
following WES to help identify the pathogenic variant in family D. 
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4.3 WES in ten familial otosclerotic cases 
WES was performed on the genomic DNA isolated from each of the ten individuals selected. 
After target enrichment, the whole exome DNA library from each participant was sequenced 
using Illumina HiSeq 2000 with 100bp paired-end reads. This technology involves random 
fragmentation of the genomic DNA which is then attached to an optically transparent surface 
prior to fragment extension and amplification to produce a flow cell which contains thousands 
of copies of the DNA template. These templates were then sequenced in millions of parallel 
reactions using sequencing-by-synthesis (SBS) technology which ensures highly accurate base 
calling, before being mapped to the reference human genome (GRCh37_hs37d5) based on the 
sequence alignment. Both single-nucleotide polymorphism (SNPs) and insertions-deletions 
(indels) were identified using SAMtools (http://samtools.sourceforge.net/) and GATK 
(http://www.broadinstitute.org/gatk/), although the data reported here refers only to 
SAMtools. A mean of 16.5 Gb of sequence was generated per sample with an average of 
96.16% of the bases mapping to the reference genome at a coverage of at least 10x. The mean 
depth of coverage was 178.5x. On average 89,656 exonic variants were identified in each of 
the ten individuals exome sequenced. The number of variants identified was slightly higher in 
the family of Caribbean origin (family B) at 93,972 variants than in the three Caucasian families 
(families A, C and D) in which an average of 88,217 variants were mapped per individual. This 
may be because the reference genome against which variants are mapped is not derived from 
a single individual but from a collection of DNA from anonymous individuals of primarily 
European origin assembled in a mosaic haploid genome (Chen and Butte, 2011), so would be 
expected to have fewer variants in common with non-Caucasian genomes. Of all the variants 
mapped, 93.7% met a quality score threshold of 30. Since quality scores measure the 
probability that a base is called incorrectly, and the quality score of any given base (Q) can be 
defined by the equation Q=-10log10(e) where e is the predicted probability of an incorrect base 
call, a quality score of 30 represents an  error rate of 1 in 1000 which represents a base call 
accuracy of 99.9%. 
The sequencing facility at the Wellcome Trust Sanger Institute supplied data files consisting of 
a list of all variants mapped per individual including SNPs and indels. All SNPs identified were 
annotated with numerous data fields which are summarised in Table ‎4.5. All indels identified 
were annotated with the same data fields with the exception of all 1000 Genome Project 
frequency data, 500 Exomes Project frequency data, and the predicted effect of variants based 
on PolyPhen and SIFT softwares. 
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Field name Explanation of field name 
CHROM Chromosome number 
POS 1-based position of variant. For indels, this is position preceding the indel 
ID Variant identifier, usually the dbSNP rsID where applicable 
REF Reference sequence at POS involved in variant. For a SNP, it is a single base 
ALT Comma delimited list of alternative sequence(s) 
QUAL Phred-scaled probability of all samples being homozygous reference 
FILTER Semicolon delimited list of filters that the variant fails to pass 
INFO-1000G Allele presence in the 1000 Genomes Project 
INFO-1000G_AF Allele frequency in the 1000 Genomes Project 
INFO-500e1012 Allele presence in the 500 Exomes Project 
INFO-AC1 EM estimate of the site allele count of the strongest non-reference allele 
INFO-AF1 EM estimate of the site allele frequency of the strongest non-reference allele 
INFO-AF_AFR Allele frequency in African population of 1000 genomes project 
INFO-AF_AMR Allele frequency in Ad Mixed American population of 1000 genomes project 
INFO-AF_ASN Allele frequency in East Asian population of 1000 genomes project 
INFO-AF_EUR Allele frequency in European population of 1000 genomes project 
INFO-AF_MAX Maximum allele frequency in the 1000 genomes project populations 
INFO-Condel Consensus deleteriousness score of missense mutations predicts the allele to be 
deleterious or neutral 
INFO-DB Allele presence in dbSNP 
INFO-DP The number of reads covering or bridging POS 
INFO-DP4 Number of 1) forward ref alleles; 2) reverse ref; 3) forward non-ref; 4) reverse 
non-ref alleles, used in variant calling 
INFO-FQ 
Consensus quality. If positive, FQ equals the phred-scaled probability of there 
being two or more different alleles. If negative, FQ equals the minus phred-scaled 
probability of all chromosomes being identical. 
INFO-INDEL Indicating the variant is an INDEL 
INFO-MQ Mapping quality score based on Phred-scaled liklihood 
INFO-PV4 P-values for 1) strand bias; 2) baseQ bias; 3) mapQ bias; 4) tail distance bias  
INFO-PolyPhen PolyPhen software prediction that the allele is damaging or benign 
INFO-SIFT SIFT software prediction that the allele is deleterious or tolerated 
INFO-VAA The resulting amino acid change 
INFO-VCQ The variant is synonymous, nonsynonymous, intronic or located within a splice 
site  
 
Table ‎4.5 Table of annotated data fields for WES variants 
Table shows annotations supplied in documentation from the Wellcome Trust Sanger Institute for each of the 
variants identified during WES 
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4.4 Systematic step-wise prioritisation of variants 
A series of sequential prioritisation steps were devised to identify a shortlist of genes 
containing those variants, which were most likely to be involved in the disease process in each 
family. These steps are illustrated in Figure ‎4.6 and are each described in detail in the text 
below.  
 
Figure ‎4.6 Schematic showing the step-wise variant prioritisation process employed following WES.  
Steps highlighted in grey were applicable only to specific families, which is discussed in detail in the accompanying 
text below. 
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4.4.1 Retain variants shared amongst affected family members 
The first stage of the filtering process was based on the assumption that the disease causing 
variant would be shared by all affected members of each family. Therefore only SNPs and 
indels which were present in all affected sequenced persons in each family were retained, 
leaving on average 59,511 retained variants per family (Table 4.6).  
 
4.4.2 Retain rare variants 
The second stage of filters involved the assumption that a disease causing variant would likely 
be present at a low frequency in the general population. Since the incidence of otosclerosis is 
approximately 0.003-0.004 in the Caucasian population (Declau et al., 2007) and 
approximately half of all cases occur within families, together with the fact that most cases of 
familial otosclerosis are inherited in an autosomal dominant pattern suggesting that variants 
are likely to be heterozygous in affected family members, it can be predicted that the allele 
frequency of a familial otosclerosis variant in the general population would be approximately 
0.0015-0.002. Since linkage analysis has identified multiple otosclerotic loci, suggesting that 
familial otosclerosis is highly heterogeneous, it is likely that the frequency of a specific familial 
variant would be even less common in the general population in reality. Based upon this 
assumption, the frequency of the shared SNPs in each family were compared with frequency 
data from the 1000 Genomes Project (http://www.1000genome.org September 2011 release). 
The 1000 Genomes Project is a database of variants collected from sequencing the genomes of 
large numbers of healthy individuals of different ethnic origins. For the three Caucasian 
families (families A, C and D) all SNPs present in the 379 European genomes in the 1000 
Genomes Project with an allele frequency greater than 0.02 were eliminated. A cut off 
frequency of 0.02 was selected as this is at least 10x greater than the frequency that would be 
expected of a familial otosclerosis causing variant, and it is essential to be conservative when 
eliminating variants in order to minimise the chances of eliminating the disease causing 
variant. In the Caribbean family (family B) all SNPs present in the 246 African genomes in the 
1000 Genomes Project, the closest ethnically matched cohort, at the same allele frequency of 
0.02 were eliminated.  
The datasets from the three Caucasian families were then subject to a second round of 
filtering by eliminating all SNPs present in the 500 Exomes Project database 
(http://www.sanger.ac.uk/research/projects/metabolicdisease/).  This is a European cohort so 
was not suitable for filtering of the family B dataset.   
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Since frequency data on insertions and deletions was not yet available in either of these two 
databases, it was not possible to filter frequencies for indels. Following these filters, an 
average of 5,044 variants remained per family (Table 4.6). 
 
4.4.3 Retain coding variants 
The next stage of filtering was based on the assumption that a disease causing variant would 
likely have a direct impact on the protein it encodes. It was therefore assumed that any 
synonymous variants that do not cause an amino acid change could be excluded from the 
analysis. Similarly, variants located within non-coding genes or transcripts are unlikely to be 
pathogenic so were also excluded. However, it is possible that pathogenic variants may reside 
within non-coding transcripts, particularly in the case of microRNAs which are non-coding 
RNAs that play a role in transcriptional and post-transcriptional regulation. For this reason, an 
exception was made for variants located within microRNAs. Following the elimination of all 
synonymous and non-coding variants, with the exception of microRNAs, each dataset was left 
with an average of 429 variants (Table 4.6).  
 
4.4.4 Exclude variants present in unaffected family members (Family B 
only) 
In family B, since WES was also performed in an unaffected family member (Table 4.6), an 
additional level of filtering was then possible as it can be assumed that the unaffected family 
member will not possess the disease causing variant. As a result, remaining variants in this 
family that were present in individual III:5 were eliminated from the dataset.  This resulted in 
314 retained variants in family B.  Caution was taken when choosing to filter against the 
variants present in individual III:5 because this family exhibits variable penetrance. However, 
since individual III:5 is 60 years old, a decade older than the oldest reported age of onset in this 
family, it was decided that it was unlikely that she would develop otosclerosis in the future. 
Therefore filtering out variants present in individual III:5 was performed, with a view to return 
to this stage in the filtering process if no suitable candidates survived the remaining filters 
(Table 4.6).  
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4.4.5 Retain variants present within otosclerosis candidate genes  
At this stage, two different filtering techniques were employed in parallel on the remaining 
variants; a candidate gene filtering process and a non-candidate gene filtering process.  The 
purpose of the candidate gene filters was to ensure that any variants located within a list of 
494 candidate genes that had previously been implicated in otosclerosis through other studies 
were prioritised. These included all genes identified or investigated in the published literature 
through association studies, gene expression studies and within the eight loci identified 
through linkage analysis, as well as a list of genes known to be involved in other connective 
tissue disorders. It also included the 176 genes found to be dysregulated in the RNA 
sequencing study (chapter 5).  A complete list of these 176 dysregulated  genes can be found in 
the Appendix. On average 27 retained variants per family were located within genes in the 
candidate gene list (Table 4.6). 
 
4.4.6 Retain variants predicted to have a damaging effect on the gene 
product  
The non-candidate gene filtering process was carried out in parallel to ensure that other 
variants of interest, which had not been previously implicated in otosclerosis through other 
studies, were not overlooked.  This was crucial to avoid any bias that would be introduced by 
using solely a candidate gene approach.  The non-candidate filtering process was carried out in 
two stages. First it involved the use of two prediction tools Polyphen II and SIFT, to predict how 
likely the variant was to have a damaging effect on the resulting protein. This software uses an 
algorithm to predict whether the variant in question is likely to be damaging or benign.  
Therefore only SNPs predicted to be damaging were retained.  
 
4.4.7 Exclude variants present within the dbSNP database 
The second stage of the non-candidate gene filtering process involved retaining only those 
variants that were absent in the database dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). dbSNP 
is a public database containing information on all known human SNPs.  Unlike the 1000 
Genomes Project and 500 Exomes Project, dbSNP contains not only data from healthy 
individuals, but also from people with disease. There is therefore a small possibility that this 
database could contain variants from individuals with otosclerosis, so caution should be taken 
when applying this filter.  Despite this risk, dbSNP was used as a final robust filter, with a view 
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to return to this stage in the filtering process if no suitable candidates survived the remaining 
filters. On average, 38 variants survived the non-candidate gene filtering process (Table 4.6). 
 
4.4.8 Exclude homozygous alleles (Families A and C only)  
The retained variants from both filtering strategies were then subjected to two further filters. 
For families A and C where an autosomal dominant inheritance pattern could be assumed with 
confidence, all homozygous alleles were excluded.  It was possible to make this assumption as 
in an autosomal dominant disorder, only one copy of the disease causing variant is required to 
result in the disease phenotype. Due to the heterogeneous nature of familial otosclerosis, a 
specific familial otosclerosis variant would be expected to be rare and therefore unlikely to be 
homozygous in the affected family members. It can therefore be expected that all affected 
individuals in both families would be heterozygous for the disease causing variant. This was 
not a suitable filter for families B and D due to the small possibility of the condition exhibiting 
an autosomal recessive inheritance pattern in these families. It is therefore possible that the 
disease causing variant could be homozygous in affected members of these families. 
 
4.4.9 Exclude variants present in an “in-house” WES database 
Finally all variants were subject to filtering against an “in-house” WES database.  This database 
consisted of 20 individuals with presbycusis who had undergone the same WES process at the 
Wellcome Trust Sanger Institute in Cambridge and in whom otosclerosis could be ruled out 
from analysis of audiometric data.  Eliminating any variants present in this cohort removed 
common sequencing artefacts from the data. 
 
Following the filtering process, the number of potential variants had been narrowed down to 
just 144 variants; 30 in family A , 56 in family B, 23 in family C and 35 in family D (Table 4.6).  
Just one of these variants, a c.915C>G SNP within a gene called TRIM17 in family C, survived 
both the candidate and non-candidate gene filtering strategies. 
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4.5 Variant filtering for segregation analysis 
An additional variant filtering strategy was then performed to identify the best possible 
candidates for segregation analysis in each of the four families. In order to ensure that the 
variants most likely to be involved in the disease process were selected, all variants were 
annotated by gathering further information from five online databases. These are illustrated in 
Table ‎4.7. These annotations revealed that the 144 prioritised variants were enriched for 
genes known to be involved in bone maintenance and development, with 8% of variants 
located in genes involved in these functions. This was also true of genes known to be involved 
in deafness with 5% of all variants being located in genes implicated in a form of hearing loss. 
In addition, the dataset was also found to be highly enriched for variants predicted to be 
located within peroxisome proliferator-activated receptor (PPAR) binding sites within families 
B and D.  PPARs are a subfamily of nuclear receptors with a variety of functions including 
control of bone turnover and regulation in bone cell differentiation in mesenchymal and 
hematopoietic cell lineages. Of the 56 retained variants in family B, two were predicted to be 
located within PPARγ and one within PPARβ binding sites, whilst in family D, two of the 35 
variants were located within PPARγ binding sites.   
 
Website name Website address Annotation derived 
Gene Cards www.genecards.org Function of gene 
JAX lab  
(Jackson Lab - Mouse Genome 
Informatics) 
www.informatics.jax.org Mouse models of mutations 
within gene 
OMIM  
(Online Mendelian 
Inheritance in Man) 
www.ncbi.nlm.nih.gov/omim Role of gene in human disease 
SNP NEXUS www.snp-nexus.org 
Location of variant within 
predicted transcription factor 
binding sites 
NHLBI  
(U.S. National Heart Lung and 
Blood Institute database) 
www.nhlbi.nih.gov Frequency of variant in NHLBI 
cohort 
 
Table ‎4.7 Table of websites used during annotation of variants and genes  
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In order to prioritise variants for segregation analysis, each variant was ranked according to a 
list of set criteria that were based upon these annotations. Variants were given high rankings if 
located within a gene with a known biological role involved in bone development or 
maintenance, or known to be involved in conductive hearing loss, based on the annotations 
derived from the Gene Cards and JAX lab websites. This ensured that variants located within 
genes most likely to have an impact on bone growth or conductive hearing loss were included 
in further analysis as it would be expected that these genes would be the most likely to play a 
role in otosclerosis pathogenesis. Genes known to be involved in systemic connective tissue 
disorders when mutated according to the OMIM website were also ranked highly, as it was 
expected that a gene involved in another connective tissue disorder would be more likely than 
other genes to be involved in otosclerosis. Genes involved in connective tissue disorders were 
given especially high rankings in family D, as this family appears to have a range of symptoms 
suggestive of a wider connective tissue disorder. Other prioritisation criteria included variants 
that were located within a PPAR binding site as predicted by SNP NEXUS, or variants that were 
absent or rare in the NHLBI cohort which contains SNPs identified through a number of studies 
in individuals with heart, lung or blood conditions.  
In addition to these annotations, variants were also given a high ranking if they were known to 
be located within a highly conserved region of a gene or if they had been found to be 
significantly dysregulated in otosclerotic stapes in the RNA sequencing study (chapter 5).  
Conservation was measured using the online software GERP 
(http://mendel.stanford.edu/SidowLab/downloads/gerp/), which estimates conservation by 
identifying constrained elements in multiple species alignments.  A GERP value greater than 
2.5 indicates conservation of the variant. Highly conserved variants were prioritised as it is 
more likely that a variant conserved between species is crucial for proper gene function, since 
a variant compromising the function of a gene would act as a selection pressure during 
evolution, resulting in its elimination. The location of variants within genes dysregulated in 
otosclerotic stapes based on the RNA sequencing study data was also taken into account as it 
is likely that an otosclerosis causing variant will have an impact on the structure or function of 
the gene it encodes within the stapes. Of the 144 variants identified during the prioritisation 
process, 7% were located within genes significantly up-regulated and 4% within genes 
significantly down-regulated in otosclerotic stapes compared to control stapes. The RNA 
sequencing data was particularly useful for ranking the variants in family B, as the stapes from 
the proband in this family was one of the otosclerotic stapes sequenced.  Therefore variants in 
genes that were significantly dysregulated in this particular stapes compared to controls were 
strongly prioritised. In addition, variants encoding premature stop codons and frameshift 
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mutations, as well as those predicted have a strong damaging effect on the resulting protein 
based on predictions from Polyphen and SIFT, were prioritised, as it would be expected that 
these would have the greatest effect on the encoded protein product. 
Due to concerns regarding the subjectivity of candidate variant selection at this stage, ranking 
of variants was performed independently by both Joanna Ziff and Sally Dawson, before a list of 
candidates was agreed upon. Based on the ranking criteria, it was decided that the 23 best 
candidate variants would be prioritised for segregation analysis in the first instance, with a 
second round of variants selected if no good segregating causal genes were identified. The 
variants selected for segregation analysis in each family are summarised in Table 4.8 and Table 
4.9 and are further detailed at the start of each family section in Table 4.10, Table 4.12, Table 
4.14 and Table 4.16.  
All 23 variants were successfully validated by Sanger sequencing or restriction endonuclease 
digests of the proband of each family, indicating the high quality of the variant calling method. 
However variant c.1300G>A in hedgehog interacting protein-like 2 (HHIPL2) in family B was 
found to be homozygous in the proband through RFLP genotyping, whilst the WES data 
suggested that it was heterozygous.  This variant is further discussed in section ‎4.8. 
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4.6 Rationale for segregation analysis and confirmation 
of a causal role  
Segregation analysis was performed for the 23 top priority variants in the remaining family 
members, to identify which of these variants segregated with the disease in each relevant 
family. Since it could be assumed that all affected family members would share the disease 
causing variant, segregation analysis was used to eliminate any variants that were absent in 
additional affected family members from further analysis. Similarly, variants present in 
unaffected family members could also be eliminated from further analysis. However, due to 
variable penetrance of otosclerosis, it is possible that unaffected family members may possess 
the disease genotype without displaying otosclerosis symptoms.  For this reason it was decided 
that if just one unaffected family member possessed the variant, it would not be sufficient to 
eliminate it from further analysis.  However, if more than one unaffected individual possessed 
the variant, it was decided that it was appropriate to assume that it was unlikely to be disease 
causing and thus eliminate it from further analysis.  In addition, when performing segregation 
analysis, the age of the family members and age of symptom onset in the family had to be 
considered.  Since otosclerosis is an adult onset condition, it is possible that some family 
members with the disease genotype but no symptoms may go on to develop otosclerosis in 
the future.  For this reason, if a family member younger the maximum age of disease onset in 
the family possessed the variant, it was not eliminated from further analysis, unless two 
additional unaffected family members also possessed the variant. 
Identifying a rare nonsynonymous variant that segregates with a disease in a family exhibiting 
monogenic inheritance of a Mendelian trait, may indicate a possible role for the variant in the 
disease process. However, this evidence alone is not sufficient to indicate that the variant is 
disease causing, even if it is located within a gene with a predicted biological role relevant to 
the phenotype. Further evidence is essential in order to implicate the variant in disease 
pathogenesis. The best evidence to support this would be to identify the same rare variant 
within an unrelated family also exhibiting monogenic inheritance of the disease, or identifying 
alternative pathogenic variants within the same gene. For this reason, those variants that 
survived segregation analysis were  genotyped in 53 additional unrelated probands, in addition 
to the 4 familial probands, who had been recruited to the study, each of whom had reported a 
strong family history of otosclerosis in their questionnaire responses.  
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4.7 Genotyping in Family A 
In family A, four variants were prioritised for segregation analysis.  These are illustrated in 
Table 4.10. 
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Genotyping was performed for each of these variants in all members of family A through 
Sanger sequencing. All four of these variants were detected in both confirmed cases of 
otosclerosis in individuals III:2 and IV:3, as well as in the presumptive case of otosclerosis in 
individual III:1 (Table 4.11). However, due to the presence of each variant in at least one 
unaffected family member, none of the four variants fully segregated with the disease. 
Unaffected individual IV:1 was heterozygous for SNP c.227G>T in FRYL and duplication 
c.1224_1226dupCAT in SMAP1, while unaffected individual IV:2 was heterozygous for SNP 
c.7883G>T in DNAH5 and c.652A>T in PTK6. Neither individual IV:1 or IV:2 has otosclerosis 
symptoms and at ages 54 and 53 respectively, are substantially older than the oldest reported 
age of onset in this family, which is at age 30. However due to variable penetrance, none of 
these genes were ruled out on the basis of just one unaffected individual possessing the 
variant. Family member V:1, who has symptoms of hearing loss but whose audiogram is not 
suggestive of otosclerosis, is heterozygous for the variants in FRYL and PTK6, however is 
uninformative for the purpose of segregation analysis as at age 27, she is younger than the 
maximum age of symptom onset in this family. 
 
4.7.1 Genotyping variants that segregate with otosclerosis in family A in an 
otosclerosis cohort  
All four variants were genotyped in a cohort of 56 additional unrelated individuals, each 
reporting a family history of otosclerosis. Variant c.7883T>G in DNAH5 and c.652A>T in PTK6 
were genotyped through restriction endonuclease digests using OliI and MlsI respectively (see 
Appendix), but neither variant was detected in any additional probands within the cohort, 
resulting in cohort allele frequencies of 0.0088 (Table 4.11). SNP c.227G>T in FRYL and the 
1224_1226dupCAT duplication in SMAP1 were genotyped through Sanger sequencing due to 
no appropriate restriction endonuclease for RFLP genotyping. The variant in FRYL was not 
identified in any additional probands and no other variants were identified in the cohort within 
FRYL exon 6, the exon in which the variant in family A was located. However the three base 
CAT duplication found in the affected members of family A (Figure ‎4.7A) and which results in a 
duplication of amino acid 408, was found in two other members of the cohort in a 
heterozygous state and in one other member of the cohort in a homozygous state resulting in 
a cohort allele frequency of 0.044 (Figure ‎4.7B and Table 4.11).    
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A.
 
Chromatogram of a heterozygote for the CAT duplication c.1224_1226dupCAT in SMAP1 
B.
 
Chromatogram of a homozygote for the CAT duplication c.1224_1226dupCAT in SMAP1 
 
Figure ‎4.7 Chromatograms showing c.1224_1226dupCAT in SMAP1 
(A) Chromatogram of the genotype of the proband in family A showing the heterozygous three base CAT duplication 
in exon 10 of the SMAP1 gene. (B) Chromatogram of the genotype of the additional cohort member who is 
homozygous for the three base CAT duplication in exon 10 of the SMAP1 gene (Reverse complement of original 
sequence with reverse primer shown for clarity). 
 
Each of the three additional study participants in whom the c.1224_1226dupCAT duplication 
had been identified were contacted, in an attempt to recruit additional affected family 
members for genotyping. Two of these individuals had no living affected relatives with the 
condition, but one of the heterozygous probands had an affected son with a confirmed 
otosclerosis diagnosis who was successfully recruited. Sanger sequencing showed that he was 
also heterozygous for the three base duplication. 
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Sanger sequencing also revealed an additional variant within exon 10 of SMAP1, the exon in 
which the variant in family A is located. This nonsynonymous c.1247T>C SNP is present in the 
cohort at a frequency of 0.510 and causes amino acid change from methionine to threonine. 
However this SNP is very common and is present in the European cohort of the 1000 Genomes 
project database at a frequency of 0.505. It was therefore assumed that it was too common to 
be a possible disease causing variant and therefore eliminated from further analysis 
 
4.7.2 Discussion of variants segregating with otosclerosis in family A 
Following segregation analysis of the four variants prioritised in family A within DNAH5, FRYL, 
PTK6 and SMAP1, all were found to segregate with otosclerosis in most family members with 
the exception of a single heterozygous unaffected individual in each case. Due to the issue of 
variable penetrance, none of these genes were ruled out as possible causative variants. It is 
possible that any of these four variants may contribute to disease pathogenesis in this family. 
However, only one of these variants, the CAT duplication.1224_1226dupCAT in SMAP1, was 
identified in other members of the otosclerosis cohort 
The identification of the duplication c.1224_1226dupCAT in SMAP1 in additional unrelated 
individuals with otosclerosis suggested that this was the most likely of the four candidates to 
be involved in otosclerosis. This three base pair duplication results in duplication of amino acid 
408 in a specific SMAP1 isoform known as SMAP1-003 (ENST00000370452), which is located 
on chromosome 6q13.  It is located in exon 10 of 11 of SMAP1-003, an exon which is unique to 
this specific SMAP1 protein coding transcript. SMAP1 is a GTPase activating protein that plays a 
role in endocytosis. It encodes a protein similar to the mouse stromal membrane-associated 
protein-1, suggesting that it may be involved in the stimulatory activity of stromal cells, the 
connective tissue precursor cells in the bone marrow that go on to differentiate into 
osteoblasts. It is therefore possible that aberrant expression of this SMAP1 isoform as a result 
of a mutation, could interfere with the bone remodelling process, suggesting a potential role 
for SMAP1 in the aetiology of otosclerosis.  
SMAP1 is located within the OTSC7 region identified by Guy VanCamp’s research group at the 
University of Antwerp within a Dutch family through linkage analysis (Thys et al., 2007b). The 
OTSC7 region mapped in this family is the smallest of the eight published otosclerotic loci, 
containing just 22 protein coding genes. This suggests that this Dutch family has a mutation in 
the immediate region surrounding SMAP1 that segregates with otosclerosis. It is therefore 
possible that this family also has a variant within SMAP1. It would be useful to genotype this 
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Dutch family to identify whether or not they possess this variant or another variant within the 
gene, which could indicate that variants in SMAP1 are over-represented in families with 
otosclerosis. Having said this, a second otosclerosis family of Greek origin was also mapped to 
this region through linkage analysis, but the overlap between the critical regions of these two 
families did not contain the SMAP1 gene. Whilst it is possible that different genes were 
responsible for the disease in each of these families due to the heterogeneous nature of 
otosclerosis, it is likely that the disease causing gene in these families is located within the 
overlapping region, and therefore a gene other than SMAP1 is responsible for pathogenesis. 
In total, in the cohort of 57 unrelated probands, which includes the probands from all four 
families plus an additional 53 probands, duplication c.1224_1226dupCAT was found to be 
homozygous in one and heterozygous in three unrelated individuals with a strong family 
history of otosclerosis.  The minor allele frequency within the cohort was therefore 0.044. 
However, following genotyping it was found that this duplication is more common in the 
general population than was initially expected, with a minor allele frequency of 0.03 based on 
data from the European cohort within the 1000 Genomes Project (www.1000genome.org). 
This was missed during the initial variant prioritisation process as at that time, frequency data 
for insertions and deletions was not available. Had this been known, this duplication would not 
have survived the 0.02 frequency cut off threshold required to qualify the variant for 
segregation analysis. In addition, analysis of the RNA sequencing data (chapter 5) shows that 
SMAP1 exon 10, the exon in which duplication c.1224_1226dupCAT is located, is not detected 
in any of the otosclerotic or control stapes samples. Since this exon is unique to transcript 
SMAP1-003, it indicates that this transcript is not expressed in the adult human stapes. This 
suggests that it is unlikely that the protein encoded by this transcript is involved in the 
development of otosclerosis, as it would be expected that any transcript involved in the 
disease process would be likely to be expressed in human stapes bones.  
Despite this, the variant should not be ruled out as having possible involvement in otosclerosis. 
It is present in the cohort at a frequency 1.5x greater than that in the general population and 
was found in a homozygous state in one individual in the cohort, the odds of which are just 
0.0009 in the general population. In addition, it was also found to be present in the affected 
son of one of the additional heterozygous individuals in the cohort. Although it is unlikely that 
this duplication is causative, it is possible that it could be a disease susceptibility factor which, 
when combined with other variants, could result in the otosclerosis phenotype.  
For future analysis of family A, it would be necessary to decide whether to further follow up 
any of the four segregating variants in DNAH5, FRYL, PTK6 or SMAP1, or whether to identify 
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additional variants that were not initially prioritised for segregation analysis. To follow up the 
segregating variants, it would be necessary to recruit a larger cohort of familial probands in the 
hope of identifying one of these variants within an additional unrelated family, which would 
support the evidence for a role of the variant in disease pathology.  Alternatively, further 
Sanger sequencing could be performed on the remainder of the genes to identify if any 
additional variants within each gene were present within the cohort. This could provide 
supporting evidence for a role of these genes in otosclerosis pathogenesis.  
Since none of these genes fully segregated with the disease in family A, in addition to the fact 
that the variants in DNAH5, FRYL and PTK6 were not identified in any additional cohort 
members, combined with the lack of evidence to implicate SMAP1 in disease pathogenesis, 
suggests that it would be desirable to prioritise additional variants for segregation analysis and 
follow up genotyping in the remainder of the otosclerosis cohort, in the hope of identifying the 
disease causing variant in family A. 
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4.8 Genotyping in Family B 
In family B, a large number of good candidate variants were identified during step-wise 
prioritisation and filtering, of which eight were prioritised for segregation analysis (Table 4.12). 
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In family B, all variants with the exception of SNP c.3304C>A in ACE were identified in all 
affected family members; III:2, III:3 and III:4 during Sanger sequencing (Table 4.13). The ACE 
variant did not segregate with otosclerosis in the family, as affected individual III:4 was wild-
type for the variant. In addition, variant c.1626G>A within LEPRE1 and c.707A>G in MIA3 were 
ruled out of further analysis, as both were heterozygous in individual II:1, the 87 year old 
unaffected mother of the three affected siblings, who it was assumed could not possess the 
disease causing variant as the trait appears to have been passed down the paternal line. The 
variants in both of these genes were also present in at least two of the proband’s unaffected 
siblings, suggesting that they are unlikely to be causative variants within this family. SNP 
c.1300G>A in HHIPL2 was also ruled out of further analysis as the G/G genotype of individual 
III:5 appears to be inaccurate given the A/A genotype of her mother, individual II:1, as it would 
be expected that individual III:5 would possess at least one A allele inherited from her mother 
(Table 4.13). Due to the large number of other variants analysed in this family, it would be very 
unlikely that the maternity of this individual would need to be questioned or that there had 
been a mix up in the samples when genotyping. In addition, since the WES data did not match 
with the RFLP genotyping data for this variant, it would appear that this this SNP is located 
within a region prone to sequencing or mapping artefacts. Deletion c.345delC in CYP2D6 was 
found to be heterozygous in unaffected individual III:1 who has presbycusis, but since 
otosclerosis exhibits variable penetrance in this family, the deletion in CYP2D6 was not ruled 
out of further analysis. SNP c.601G>A in SERPINF1, c.107C>G in VPS53 and variant c.1291C>A 
in ANKS1A fully segregated with the family with the exception of unaffected member IV:1, who 
at age 35 is younger than the oldest reported age of onset in this family at age 50 (Table 4.13).   
 
4.8.1 Genotyping variants that segregate with otosclerosis in family B in an 
otosclerosis cohort  
The variants in SERPINF1, VPS53, ANKS1A and CYP2D6 were genotyped in a cohort of 56 
additional unrelated individuals with familial otosclerosis. The variants in ANKS1A, CYP2D6 and 
VPS53 were genotyped using TseI, DrdI and PpuMI respectively through restriction 
endonuclease digests (see Appendix).  However, the variants were not detected in any 
additional probands, resulting in a cohort allele frequency of 0.0088 in each case (Table 4.13). 
The c.601G>A nonsynonymous SNP in SERPINF1 was genotyped through Sanger sequencing 
(Figure ‎4.8), due to no appropriate restriction enzyme for RFLP genotyping, but was also not 
identified in any additional probands.  
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Figure ‎4.8 Chromatogram showing heterozygote for variant c.601G>A in SERPINF1 
Chromatogram of the genotype of the proband in family B showing the heterozygous G>A SNP in exon 5 of the 
SERPINF1 gene. 
 
4.8.2 Discussion of variants segregating with otosclerosis in family B 
It is possible that any of the four segregating variants in SERPINF1, VPS53, ANKS1A and CYP2D6 
may contribute to disease pathogenesis in this family, however, none were found in any 
additional members of the cohort. Despite this, the role of the protein encoded by SERPINF1 
as well as the location of the c.601G>A SNP within this gene suggests that it is potentially an 
excellent candidate variant within this family.  
SERPINF1 encodes PEDF (Pigment epithelium-derived growth factor) also known as Caspin, a 
50kDa protein which is 418 amino acids in length. PEDF is a neutrotrophic protein that is 
known to induce neurodifferentiation in retinoblastoma cells. It is a potent inhibitor of 
angiogenesis and lacks the serine protease inhibitory activity that is characteristic of most 
other members of the SERPIN gene family. PEDF is known to be highly expressed in collagen 
rich tissues including bone, cornea and cartilage. 16 unique variants located within this gene 
have been reported within individuals with the connective tissue disorder Osteogenesis 
Imperfecta (OI) type VI (www.oi.gene.le.ac.uk). Patients with OI frequently experience 
conductive hearing loss similar to that of otosclerosis, which has led researchers to postulate 
that otosclerosis may be a localised manifestation of OI (Weber, 1930). PEDF is not detected in 
the serum of individuals with OI type VI but is in those with other forms of the condition 
(Rauch et al., 2012), suggesting that mutations in this gene may affect its expression in certain 
tissues. If this is the case, then it is possible that the family B mutation could affect the 
expression of PEDF in the stapes, since bone is a collagen rich tissue in which PEDF is normally 
highly expressed.  There is therefore a possible role for the SERPINF1 gene in the disease 
process in otosclerosis. 
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Further evidence of a role for SERPINF1 in otosclerosis pathogenesis is the location of the SNP 
within the gene. SNP c.601G>A results in an amino acid change from aspartic acid 201 to 
asparagine and is located within a region that encodes an acidic part of the PEDF protein, 
where one aspartic acid residue and two glutamic acid residues are located within a five amino 
acid region.  Acidic negatively charged regions of this protein are known to interact directly 
with positively charged regions on collagen genes (Meyer et al., 2002). Since the SNP in family 
B, causes a change from an acidic residue to a neutral one, it is possible that the variant could 
inhibit interactions between PEDF and collagen, which could result in effects on the bone 
matrix, of which collagen is the predominant component. In addition, the variant in family B is 
also located within a predicted NFκB binding site. The receptor activator of NFκB (RANK) also 
plays an important role in the rate of bone turnover as it is expressed on the surface of pre-
osteoclasts which compete with osteoprotegerin (OPG), a protein secreted from osteoblasts, 
for binding to the RANK ligand on the surface of pre-osteoblasts. It is therefore possible that a 
variant within an NFκB binding site could have an impact on the NFκB signalling pathway, 
which could result in an imbalance in osteoblastogenesis relative to osteoclastogenesis, 
suggesting another potential way in which the family B mutation could lead to disease. 
Furthermore, there is also evidence that this c.601G>A SNP may affect expression of various 
PEDF isoforms (see Chapter 4 Part II).  For these reasons, this SNP is an excellent otosclerosis 
candidate variant in family B. 
In family B, it is not possible to rule out any of the four segregating variants for a role in 
otosclerosis pathophysiology. However, since the 601G>A SNP in SERPINF1 is such a good 
candidate, it was decided that its role in otosclerosis aetiology would be further investigated as 
the top priority for this family, in preference to any of the other variants. Further analysis of 
SERPINF1 is discussed in more detail in Chapter 4 Part II.  
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4.9 Genotyping in Family C 
In Family C, step-wise prioritisation of variants and filtering generated the smallest number of 
good otosclerosis candidate variants of all the four families. Four variants were prioritised for 
segregation analysis (Table 4.14), including the variant in TRIM17, which was the only variant 
to survive both candidate and non-candidate gene filtering strategies. 
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In Family C, all four of these variants were identified in the three affected family members; II:3, 
II:4 and III:1 through Sanger sequencing. However, variant c.2913G>C in ERCC6 and c.915C>G 
in PDLIM5 were ruled out as each variant was also present in two or more unaffected family 
members. Since otosclerosis exhibits variable penetrance, the presence of a variant in more 
than one affected relative is suggestive that this variant is not involved in disease 
pathogenesis. Variant c.496C>T in EGLN3 was found to be heterozygous in just one unaffected 
family member and c.915C>G in TRIM17 segregated fully with the disease (Table 4.15).  In this 
family, individual III:2 who reported early symptoms of hearing loss, is uninformative for the 
purpose of segregation analysis. This is because it is not known whether this individual has 
otosclerosis or another hearing condition. 
 
4.9.1 Genotyping variants that segregate with otosclerosis in family C in an 
otosclerosis cohort  
Genotyping was performed in a cohort of 56 additional unrelated individuals with familial 
otosclerosis for the segregating variants in EGLN3 and TRIM17. Both variants were genotyped 
using restriction endonuclease digests (see Appendix). Enzyme AciI was used to detect the 
presence or absence of the variant in EGLN3 and RsaI for the variant in TRIM17. However, 
neither variant was identified in any of the additional cohort members, resulting in a cohort 
allele frequency of 0.0088 for both variants (Table 4.15).  
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4.9.2 Discussion of variants segregating with otosclerosis in family C 
Following segregation analysis of variants identified in family C, the variant in TRIM17 was 
found to fully segregate with otosclerosis in all family members and EGLN3 with all but one 
heterozygous unaffected individual, which due to the issue of variable penetrance, was not 
ruled out as a possible causative variant. It is possible that either of these variants may 
contribute to disease pathogenesis in this family, however, neither was identified in additional 
members of the cohort. Despite this, the c.915C>G variant within TRIM17 remains a very good 
candidate in this family.  
Variant c.915C>G has not previously been reported in the literature and results in the 
introduction of a premature stop codon at amino acid 305 of the TRIM17 protein.  This variant 
was the only one of the 144 surviving the variant prioritisation process across all four families 
to meet the criteria of both the candidate gene and non-candidate gene filtering strategy. It is 
located within the OTSC10 region, which was identified by Guy VanCamp’s research group at 
the University of Antwerp (Schrauwen et al., 2011). It is therefore possible that this family 
could also possess a variant within TRIM17, however, since OTSC10 is one of the larger of the 
eight published otosclerotic loci, containing 148 protein coding genes, this is not necessarily 
the case. Despite this, since this SNP was the only prioritised variant found to segregate fully in 
family C, it is a strong candidate for this family. 
TRIM17 is a member of the Tripartite Motif family. These genes tend to play a role in protein 
degradation and are related to one another through their structures which contain a number 
of similar functional domains. TRIM proteins have E3 ubiquitin ligase activity and play key roles 
in regulating signalling cascades involved in immune responses. TRIM17 contains three zinc-
binding domains, a RING type zinc finger at residues 16-65, a B-box type zinc finger at residues 
94-135, a coiled-coil region at 196-221 and an SPRY domain at residues 348-477 (Ogawa et al., 
1998) . Since the TRIM17 transcript is prematurely truncated at amino acid 305 in individuals 
possessing the SNP, affected members of family C are therefore missing the SPRY domain, a 
protein interaction module that recognises specific protein partners rather than a consensus 
sequence (Woo et al., 2006). Little is currently known about SPRY domains but they are known 
to be highly conserved with an ancient evolutionary origin (Rhodes et al., 2005). They are 
believed to have functions in immune system related processes and are found in negative 
regulators of cytokine activity (Nicholson and Hilton, 1998). Approximately 150 human 
proteins contain SPRY domains, including members of the TRIM family. It has been reported 
that the SPRY domain of the TRIM5α protein, binds to the viral capsid of some retroviruses 
including HIV, targeting HIV-1 restriction (Yap et al., 2005).  This is of interest in the context of 
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otosclerosis given the link between the condition and a number of viral infections including 
measles. In addition, another family member of TRIM17 known as TRIM24 is known to be 
located within the OTSC2 locus and is a transcriptional co-activator that plays a role in bone 
remodelling.  
It is also possible that the premature stop codon in TRIM17 would lead to degradation of the 
entire protein, although this may be unlikely given that the variant is located in the final 
protein coding exon of the gene. TRIM17 is known to initiate neuronal apoptosis and is 
controlled by the PI3K/Akt/GSK3 pathway in cerebellar granule neurons (Lassot et al., 2010). It 
can negatively regulate cell proliferation through interaction with ZW10, a mitotic checkpoint 
protein (Endo et al., 2012). In addition, the variant in family C is predicted to be located within 
a GATA-1 binding site. These are genomic sequences which bind GATA-1 transcription factors 
involved in regulating erythroid development including the switch in production from foetal to 
adult haemoglobin. A mutation in this gene, such as the c.915C>G variant in family C could 
therefore inhibit any of the gene’s functions, many of which could play a role in disease 
pathology. 
Future research into the disease causing variant in family C, could focus either on follow up 
analysis of the segregating variants in EGLN3 or TRIM17, or alternatively could focus on 
identification of additional variants that were not initially prioritised for segregation analysis. 
In this family, the choice of which variants to select for segregation analysis was easier than in 
the other three families as the four variants selected stood out as far better candidates than 
any of those remaining. It was therefore decided that it would be beneficial to prioritise the 
segregating variants for further analysis, rather than to select less desirable candidates. 
Although it was not possible to rule out the variant in EGLN3, since variant c.915C>G in TRIM17 
was such a good candidate, its role in otosclerosis aetiology was further investigated as the top 
priority for this family. Analysis of TRIM17 is discussed in more detail in Chapter 4 Part II.  
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4.10 Genotyping in Family D 
In family D, many good candidate variants emerged from the step-wise prioritisation and 
filtering processes, of which seven were prioritised for segregation analysis (Table 4.16).  
 
G
e
n
e
G
e
n
e
 n
am
e
C
h
ro
m
o
so
m
al
 
Lo
ca
ti
o
n
D
N
A
 C
h
an
ge
A
m
in
o
 A
ci
d
 C
h
an
ge
M
in
o
r 
A
lle
le
 F
re
q
u
e
n
cy
G
ER
P
 s
ta
ti
st
ic
P
o
ly
p
h
e
n
 P
re
d
ic
ti
o
n
C
O
L1
A
2
C
o
ll
a
ge
n
 T
yp
e 
I 
A
lp
h
a
 2
7
q
2
1
.3
EN
ST
0
0
0
0
0
2
9
7
2
6
8
:c
:
8
0
8
G
>A
V
/I
 N
o
n
sy
n
o
n
ym
o
u
s 
co
d
in
g
0
.0
0
1
0
 (
1
0
0
0
 G
en
o
m
es
)
0
.0
0
2
8
 (
N
H
LB
I)
4
.8
6
B
en
ig
n
(0
)
FO
X
K
1
Fo
rk
h
ea
d
 B
o
x 
K
1
7
p
2
2
.1
EN
ST
0
0
0
0
0
3
2
8
9
1
4
:c
:
1
3
8
4
G
>A
E/
K
 N
o
n
sy
n
o
n
ym
o
u
s 
co
d
in
g
P
re
vi
o
su
ly
 u
n
re
p
o
rt
ed
4
.9
4
P
o
ss
ib
ly
 D
a
m
a
gi
n
g(
0
.9
3
2
)
FZ
D
2
Fr
iz
zl
ed
 H
o
m
o
lo
g 
2
 (
D
ro
so
p
h
il
a
)
 1
7
q
2
1
.3
1
 
EN
ST
0
0
0
0
0
3
1
5
3
2
3
:c
:
6
5
5
C
>T
R
/C
 N
o
n
sy
n
o
n
ym
o
u
s 
co
d
in
g
0
.0
0
0
1
 (
N
H
LB
I)
3
.4
4
P
o
ss
ib
ly
 D
a
m
a
gi
n
g(
0
.7
3
2
)
G
N
G
T1
G
u
a
n
in
e 
N
u
cl
eo
ti
d
e 
B
in
d
in
g 
P
ro
te
in
 7
q
2
1
.3
 
EN
ST
0
0
0
0
0
2
4
8
5
7
2
:c
:
8
2
C
>A
L/
M
 N
o
n
sy
n
o
n
ym
o
u
s 
co
d
in
g
P
re
vi
o
su
ly
 u
n
re
p
o
rt
ed
2
.9
5
U
n
kn
o
w
n
(0
)
m
ir
1
8
3
M
ic
ro
R
N
A
 1
8
3
7
q
3
2
.2
EN
ST
0
0
0
0
0
3
8
4
9
5
8
:n
:
8
1
G
>T
P
/L
  N
o
n
sy
n
o
n
ym
o
u
s 
co
d
in
g
0
.0
0
0
2
 (
N
H
LB
I)
5
.8
6
P
o
ss
ib
ly
 D
a
m
a
gi
n
g(
0
.7
9
9
)
SH
A
N
K
2
SH
3
 a
n
d
 M
u
lt
ip
le
 A
n
ky
ri
n
 R
ep
ea
t 
D
o
m
a
in
s 
2
 1
1
q
1
3
.4
 
EN
ST
0
0
0
0
0
2
9
4
0
1
8
:c
:
2
1
7
1
C
>T
P
/L
 N
o
n
sy
n
o
n
ym
o
u
s 
co
d
in
g
0
.0
0
0
2
 (
N
H
LB
I)
4
.8
8
P
o
ss
ib
ly
 D
a
m
a
gi
n
g(
0
.7
9
9
)
ZN
F2
2
5
 Z
in
c 
Fi
n
ge
r 
P
ro
te
in
 2
2
5
 1
9
q
1
3
.3
1
 
EN
ST
0
0
0
0
0
2
6
2
8
9
4
:c
:
1
6
9
8
:A
>T
R
/S
 N
o
n
sy
n
o
n
ym
o
u
s 
co
d
in
g
0
.0
0
0
9
 (
N
H
LB
I)
1
.6
7
P
o
ss
ib
ly
 D
a
m
a
gi
n
g(
0
.9
2
6
)
G
e
n
e
In
 O
TS
C
 L
in
ke
d
 R
e
gi
o
n
M
o
u
se
 m
o
d
e
l
C
O
L1
A
2
n
/a
M
u
ta
n
t 
m
ic
e 
ex
h
ib
it
 b
o
n
e 
d
ef
o
rm
it
ie
s.
 
FO
X
K
1
n
/a
K
O
 m
ic
e 
 a
re
 r
u
n
te
d
 a
n
d
 e
xh
ib
it
 
re
d
u
ce
d
 m
yo
ge
n
ic
 p
ro
ge
n
it
o
r 
ce
ll
s
FZ
D
2
n
/a
M
ic
e 
h
o
m
o
zy
go
u
s 
fo
r 
re
p
o
rt
er
 
a
ll
el
e 
h
a
ve
 a
b
n
o
rm
a
l 
h
a
ir
 c
el
ls
G
N
G
T1
n
/a
H
o
m
o
zy
go
u
s 
n
u
ll
 m
ic
e 
d
is
p
la
y 
im
p
a
ir
ed
 l
ig
h
t 
a
d
a
p
ta
ti
o
n
 
m
ir
1
8
3
n
/a
n
/a
SH
A
N
K
2
n
/a
M
ic
e 
h
o
m
o
zy
go
u
s 
fo
r 
n
u
ll
 
m
u
ta
ti
o
n
s 
d
is
p
la
y 
h
yp
er
a
ct
iv
it
y
ZN
F2
2
5
n
/a
K
O
 m
o
u
se
d
is
p
la
y 
in
cr
ea
se
d
 
o
st
eo
cl
a
st
 c
el
l 
n
u
m
b
er
n
/a
n
/a
A
d
a
p
te
r 
p
ro
te
in
 i
n
 t
h
e 
p
o
st
sy
n
a
p
ti
c 
d
en
si
ty
o
f 
ex
ci
ta
to
ry
 s
yn
a
p
se
s.
 M
u
ta
ti
o
n
s 
ca
u
se
 
D
ea
fn
es
s,
 a
u
to
so
m
a
l 
re
ce
ss
iv
e 
6
3
. S
N
P
 l
o
ca
te
d
 w
it
h
 P
P
A
R
ɣ 
b
in
d
in
g 
si
te
A
ct
iv
a
te
s 
C
O
L1
A
2
 p
ro
m
o
te
r,
 m
ed
ia
te
s 
TG
Fβ
 a
ct
iv
a
ti
o
n
, I
n
vo
lv
ed
 i
n
 w
n
t 
si
gn
a
ll
in
g.
 
B
io
lo
gi
ca
l R
o
le
En
co
d
es
 t
h
e 
p
ro
-a
lp
h
a
2
 c
h
a
in
 o
f 
ty
p
e 
I 
co
ll
a
ge
n
. M
u
ta
ti
o
n
s 
ca
u
se
 E
h
le
rs
 D
a
n
lo
s 
Sy
n
d
ro
m
e 
a
n
d
 O
st
eo
ge
n
es
is
 I
m
p
er
fe
ct
a
. S
N
P
 l
o
ca
te
d
 w
it
h
in
  P
P
A
R
ɣ 
b
in
d
in
g 
si
te
.
R
o
le
 i
n
 m
yo
ge
n
ic
 d
if
fe
re
n
ti
a
ti
o
n
 a
n
d
 i
n
 r
em
o
d
el
in
g 
p
ro
ce
ss
es
 o
f 
a
d
u
lt
 m
u
sc
le
s.
M
ed
ia
te
s 
TG
Fβ
 s
ig
n
a
ll
in
g 
in
 d
ro
so
p
h
il
a
.
In
vo
lv
ed
 i
n
 w
n
t 
si
gn
a
ll
in
g.
In
vo
lv
ed
 i
n
 B
M
P
 s
ig
n
a
ll
in
g.
 M
u
ta
ti
o
n
s 
ca
u
se
s 
O
st
eo
p
o
ro
si
s,
Eh
le
rs
-D
a
n
lo
s 
sy
n
d
ro
m
e,
 t
yp
e 
V
II
B
, O
st
eo
ge
n
es
is
 I
m
p
er
fe
ct
a
 T
yp
e 
II
In
h
ib
it
s 
m
et
a
st
a
si
s 
o
f 
o
st
eo
sa
rc
o
m
a
. m
ir
1
8
3
 f
a
m
il
y 
m
em
b
er
s 
re
gu
la
te
 c
h
lo
ri
d
e 
in
tr
a
ce
ll
u
la
r 
ch
a
n
n
el
 5
 e
xp
re
ss
io
n
 i
n
 i
n
n
er
 h
a
ir
 c
el
ls
R
N
A
 S
e
q
u
e
n
ci
n
g 
St
u
d
y 
D
at
a
n
/a
U
p
re
gu
la
te
d
 i
n
 o
to
sc
le
ro
ti
c 
st
a
p
es
n
/a
n
/a
n
/a
Ta
b
le
 4
.1
6 
Ta
b
le
 il
lu
st
ra
ti
n
g 
th
e 
7 
va
ri
an
ts
 p
ri
o
ri
ti
se
d
 f
or
 s
eg
re
ga
ti
o
n
 a
n
al
ys
is
 in
 f
am
ily
 D
  
Th
e 
D
N
A
 c
h
an
ge
 c
o
lu
m
n
 i
n
cl
ud
es
 t
h
e
 t
ra
n
sc
ri
pt
 I
D
 f
ro
m
 t
he
 E
ns
em
b
l 
d
at
ab
as
e 
(T
h
e 
En
se
m
bl
 I
D
 s
ta
te
d
 is
 i
n
 a
ll 
ca
se
s 
th
e 
m
aj
o
r 
tr
an
sc
ri
pt
 I
D
).
 T
he
 m
in
o
r 
al
le
le
 
fr
eq
ue
n
cy
 d
at
a 
st
at
ed
 i
s 
b
as
ed
 o
n
 d
at
a 
fr
o
m
 t
he
 1
00
0 
G
en
om
es
 p
ro
je
ct
 E
u
ro
p
ea
n
 p
o
p
u
la
ti
o
n
 a
nd
 t
he
 N
H
LB
I 
co
h
o
rt
 E
u
ro
p
ea
n
 A
m
er
ic
an
 p
o
p
u
la
ti
o
n.
 T
h
e 
P
o
ly
p
h
en
 p
re
d
ic
ti
o
n
 s
co
re
 is
 a
 r
at
in
g 
fr
o
m
 0
-1
 w
he
re
 0
 in
d
ic
at
es
 v
ar
ia
n
ts
 p
re
d
ic
te
d
 t
o
 b
e 
b
en
ig
n
 a
nd
 1
 in
d
ic
at
es
 v
ar
ia
n
ts
 t
h
at
 a
re
 v
er
y 
lik
el
y 
to
 b
e 
d
am
ag
in
g.
 
 
 
 
136 
 
In this family, all seven variants were identified in all three affected family members; IV:2, V:1 
and V:III through Sanger sequencing. However, the c.2171C>T variant in SHANK2 was found to 
be homozygous in unaffected family member V:2 and heterozygous in IV:1, so was eliminated 
from further analysis. In addition, variant c.1384G>A in FOXK1 was found to be heterozygous 
in just one unaffected family member V:2.  Although due to variable penetrance, the presence 
of a variant in just one unaffected family member would not usually be sufficient to rule out 
the variant as being disease causing, an exception has been made in this case. This is because 
due to the fact that this family has numerous consanguineous marriages, it can be assumed 
that family members would be more likely to share a greater proportion of their variants than 
families with no consanguinity. This would likely mean that any variants within additional 
modifier genes that may be involved in influencing disease penetrance would be more likely to 
be shared amongst family members than in other families. Therefore incomplete penetrance is 
less likely to be a big concern than in non-consanguineous families. For this reason, the variant 
in FOXK1 was not prioritised for genotyping in the remainder of the cohort, despite its 
presence in just one unaffected family member (Table 4.17). 
Since genomic DNA was only ascertained for five members of family D, segregation analysis 
was less informative than in the other three families.  For this reason and due to time and cost 
limitations, only the two most interesting variants were prioritised in this family for genotyping 
the remainder of the cohort, with a view of returning to this stage if no confirmatory 
mutations emerged from the analysis at a later date.  The choice of variants to follow up is 
discussed in section ‎4.10.1. below. 
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4.10.1 Discussion of which segregating variants in family D to prioritise for 
follow up analysis  
Although it is possible that any of the segregating variants in family D may contribute to 
disease pathogenesis, two variants stood out as being the most likely candidates in this family. 
These are c.81G>T in mir-183 and c.808G>A in COL1A2, which were selected for follow up 
analysis as both are located in particularly good otosclerosis candidate genes.  
COL1A2 is a very large gene, 5411 bases in length and coding for a 1366 amino acid protein 
129kDA in size. SNP c.808G>A in exon 17 of the COL1A2 gene on chromosome 7q21 encodes a 
valine to isoleucine amino acid change at residue 270. It is a fibril-forming collagen that is 
abundant in bone and has been suggested as an otosclerosis candidate gene in the past.  
Association studies have been performed in an attempt to associate SNPs within this gene with 
otosclerosis but none have been identified. 474 unique variants have been reported in this 
gene, 44 of which are located in exon 17 in which the family D SNP was identified. Many of 
these variants have been implicated in various connective tissue disorders including both 
Osteogenesis Imperfecta and Ehlers Danlos syndrome. Since family D appears to exhibit 
symptoms of a systemic connective tissue disorder, COL1A2 is an excellent candidate in this 
family. In addition to the variant in COL1A2, the three affected members of Family D also have 
a nonsynonymous variant in COL21A1, a member of the FACIT (Fibril Associated Collagens with 
Interrupted Triple helices) family of collagens. This SNP c.1748G>C is fairly uncommon, with a 
minor allele frequency (MAF) in the European population (1000 Genomes Project cohort) of 
0.024. However this variant did not quite meet the criteria required to prioritise it for 
segregation analysis as variants with a MAF greater than 0.02 were not prioritised. FACIT 
collagens localise to tissues containing type 1 collagens and are known to be found in 
extracellular matrix component of blood vessel walls (Chou and Li, 2002). There are no 
COL21A1 orthologues in rodents (Fitzgerald and Bateman, 2004), possibly due to its location 
near to evolutionary breakpoints. It is possible that this SNP in combination with SNP c.808G>A 
in family D could result in the otosclerosis phenotype. In addition, SNP c.808G>A is located 
within a PPARγ binding site. Since PPARγ plays a role in the regulation of bone turnover, it is 
possible that a SNP located within a binding site for this gene could interfere with the pathway 
involved in bone growth and maintenance.  This suggests a potential mechanism by which SNP 
c.808G>A could cause aberrant bone growth around the stapes, leading to otosclerosis.   
mir-183 is a non-coding microRNA, a short molecule with a role in transcriptional and post-
transcriptional regulation of gene expression.  mir-183 is a member of a family of microRNAs 
including mir-96 and mir-182 which are known to regulate chloride intracellular channel 5 
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expression in inner ear hair cells (Gu et al., 2013). Overexpression of members of this gene 
family induce duplicated otocysts and extra hair cells. In contrast, knockdown of mir-183 
causes reduced numbers of hair cells in the inner ear and defects in the semi-circular canals (Li 
et al., 2010). Family member mir-96 has been implicated in familial sensorineural deafness 
(Solda et al., 2012) and mutations in this gene in mice are associated with progressive hearing 
loss (Lewis et al., 2009). This suggests a potential link between this family of microRNAs and 
hearing loss which could explain a role for SNP c.81G>T in the disease process. Having said this, 
mir-183 and its family members appear to be involved in sensorineural rather than conductive 
hearing loss when mutated. Although otosclerosis causes conductive hearing loss, 
approximately 10% of clinical cases also have a sensorineural component to their deafness 
(Browning and Gatehouse, 1984), it is therefore possible that the SNP in mir-183 plays a role in 
this.  Since the proband of family D was recruited as a non-surgical participant, access was not 
available to her audiometric data to investigate whether or not she had mixed or solely 
conductive hearing loss. If sensorineural hearing loss is occurring in this family, it is possible 
that SNP c.81G>T in mir-183 may be involved. 
The biological roles of COL1A2 and mir-183 with respect to bone development and hearing loss 
respectively, suggest that variants within these genes are the most promising candidate  
variants identified within this family. These variants were therefore genotyped in a cohort of 
56 additional probands. The variant in mir-183 was genotyped using RFLP genotyping with 
AvaII (see Appendix), however, this variant was not found to be present in any additional 
members of the cohort, resulting in a cohort frequency of 0.008 (Table 4.17). The variant in 
COL1A2 was genotyped using Sanger sequencing, as no appropriate restriction endonuclease 
for RFLP genotyping was available, but again none of the 56 probands possessed this 
nonsynonymous G>A SNP (Figure ‎4.9 and Table 4.17).  
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Figure ‎4.9 Chromatogram of a heterozygote for variant c.808G>A in COL1A2 
Chromatogram of the genotype of the proband in family D showing the heterozygous G>A SNP in exon 17 of the 
COL1A2 gene.  
 
4.10.2 Future work for family D 
In family D, a large number of good candidate genes emerged from the step-wise prioritisation 
and filtering processes, but since the number of family members recruited was small, 
segregation analysis was not particularly informative. The reason that this family was selected 
for WES despite the small number of family members recruited, was because it was thought 
that this family had the potential to yield promising results due to its large size and due to the 
additional connective tissue disorder symptoms experienced by multiple family members. It 
was expected that larger numbers of family members could be recruited in the long term than 
in the other families and it was hoped that by prioritising variants in genes known to be 
involved in other connective tissue disorders, that it would assist in the identification of a 
disease causing variant. However, acquiring these additional DNA samples has proven more 
difficult in reality. In the future, it would be extremely useful to continue to attempt to recruit 
other family members, to help prioritise which of the segregating variants to follow up. This 
could provide further evidence to indicate whether it would be beneficial to continue to 
pursue the segregating variants in mir-183 and COL1A2, or whether to return to the three 
variants in FZD2, GNGT1 and ZNF225 that had also segregated with the disease but were not 
prioritised for genotyping in the remainder of the cohort. Due to previously published 
investigations suggesting that mir-183 is involved in hearing loss and that collagen type I genes 
are associated with otosclerosis, both the c.81G>T SNP in mir-183 and the c.808G>A SNP in 
COL1A2 were further investigated as the top priority candidates for this family. Analysis of mir-
183 and COL1A2 are discussed in more detail in Chapter 4 Part II.  
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Whole Exome Sequencing Part II 
Analysis of prioritised variants that 
segregate with familial otosclerosis 
 
During WES followed by a stepwise variant prioritisation process, four variants within strong 
otosclerosis candidate genes were identified in three of the four families analysed. In family B 
SNP c.601G>A was identified in SERPINF1, in family C variant c.915C>G was found in TRIM17 
and in family D variant c.81G>T was identified in mir-183 as well as SNP c.808G>A in COL1A2. 
In Part II of this chapter, further analyses which was performed on each of these four 
candidate variants will be discussed in turn. 
 
4.11 Evaluation of TRIM17 as an otosclerosis candidate 
gene in family C 
In family C, variant c.915C>G in TRIM17 was found to segregate with otosclerosis. This variant 
results in the introduction of a stop codon at amino acid 305 of TRIM17, suggesting that the 
TRIM17 transcript in affected family members may be truncated upstream of its SPRY domain, 
a protein interaction module which functions in immune system related processes. This is the 
only variant to have survived both candidate gene and non-candidate gene filtering strategies 
following WES. There was therefore a strong rationale for genotyping the whole of exon 6, in 
which the c.915C>G variant was located, in a familial otosclerosis cohort. 
 
4.11.1 Genotyping TRIM17 exon 6 in a familial otosclerosis cohort  
Sanger sequencing was performed on the remainder of exon 6 of TRIM17 in a familial 
otosclerosis cohort of 56 unrelated probands. In addition to variant c.915C>G, which was 
confirmed in the proband of family C using Sanger sequencing (Figure ‎4.10), an additional rare 
variant was identified in one member of the cohort. This c.1233C>T SNP is synonymous, 
encoding amino acid leucine 411 and is present in the European cohort at a very low minor 
allele frequency estimated from the NHLBI cohort (http://www.nhlbi.nih.gov/) to be 
approximately 0.001. Although it is rare, the fact that it does not cause an amino acid change 
and since it is not located at a splice site, suggests that it is unlikely to be a variant that 
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contributes to disease pathogenesis, as it would be expected that a disease causing variant 
would affect the structure and as a result the function of the protein. This SNP was therefore 
considered unlikely to be a disease-causing variant. 
 
 
Figure ‎4.10 Chromatogram of a heterozygote for variant c.915C>G in TRIM17 
 Chromatogram of the genotype of the proband in family C illustrating the heterozygous C>G SNP in exon 6 of the 
TRIM17 gene. 
 
4.11.2 Analysis of RNA-sequencing data to investigate TRIM17 expression in 
stapes 
Analysis of the RNA sequencing data (chapter 5) suggests that TRIM17 is expressed within 
human stapes but at fairly low levels with an average RPKM of 0.017 across all suprastructures. 
This is substantially lower than the average RPKM value of 5.4 across all genes sequenced in all 
stapes. Despite the low RPKM value, a difference in average RPKM was identified between the 
control and affected stapes, suggesting that the expression of TRIM17 is lower in otosclerotic 
stapes compared to controls, although this doesn’t quite reach significance thresholds at 
p=0.06. However, the fold difference in RPKM value between control and affected stapes is 
fairly large, with TRIM17 being 2.9 times down-regulated in otosclerotic stapes compared to 
controls.  
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4.11.3 Discussion of TRIM17 as an otosclerosis candidate gene 
The c.915C>G variant in TRIM17 appears to be the most promising candidate from family C. 
Not only is this a previously unreported variant that introduces a premature stop codon, but it 
was also the only gene across all four families to survive both candidate gene and non-
candidate gene filtering processes following WES. The fact that no other good candidate genes 
emerged from family C also gives further support to suggest that this variant may be involved 
in otosclerosis pathogenesis. Despite this, more evidence would be required to indicate its 
involvement in the pathophysiology of otosclerosis. For this, the identification of additional 
rare nonsynonymous variants in TRIM17 within otosclerotic families would be essential.  
The fact that TRIM17 is expressed at low levels within the human stapes raises questions as to 
its likely involvement in otosclerosis, as it is likely that any gene involved in otosclerosis will be 
expressed in human stapes tissue. Despite this, the level of expression of a gene will depend 
on its role. For example, a structural protein such as collagen would be expected to be highly 
expressed in bone tissue, whilst a transcription factor would be likely to be expressed at a 
lower level. Since the exact function of TRIM17 is unknown, it is not possible to predict 
whether it would be expected that this gene would be highly expressed in stapes or not. 
Therefore the low level of expression of this gene cannot be considered sufficient evidence to 
rule out the c.915C>G SNP as a possible disease causing variant in family C. Furthermore, since 
TRIM17 appears to be 2.9 times down-regulated in affected stapes compared to controls, 
although this does not quite reach statistical significance, a difference in expression in 
otosclerotic stapes could indicate involvement of the gene in disease pathology. 
To further investigate a role for TRIM17 in otosclerosis, the remaining exons of the gene could 
be sequenced in the otosclerosis cohort. Since TRIM17 is an excellent candidate gene and since 
no other promising segregating candidates emerged in family C, it would be recommended to 
focus efforts on this gene rather than to select other lower priority genes for segregation 
analysis. Since TRIM17 contains five additional protein coding exons, Sanger sequencing would 
be fairly costly, but it would be crucial in order to identify if any other rare nonsynonymous 
variants were located within the gene. In the absence of identification of mutations within 
multiple families, there is yet insufficient evidence of a role for this gene in disease 
pathogenesis. 
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4.12 Evaluation of mir-183 and COL1A2 as candidate 
genes in family D 
In family D, variant c.81G>T in mir-183 and SNP c.808G>A in COL1A2 were found to segregate 
with otosclerosis. mir-183 is a small non-coding micro RNA that is a member of a gene family 
thought to play a role in sensorineural hearing loss. COL1A2 encodes a fibril-forming type I 
collagen that has previously been investigated for associations with otosclerosis, although no 
association between this gene and the condition has been confirmed. Mutations in COL1A2 are 
known to be involved in connective tissue disorders, meaning that this variant is an excellent 
candidate in members of family D, who have a range of symptoms suggestive of a connective 
tissue disorder. The biological roles of both these candidate genes provides a strong argument 
for performing further analyses on the variants found within these genes in family D. However, 
due to time and cost limitations, it was not possible to perform Sanger sequencing in the 
otosclerosis cohort for both genes. Due to previous association studies which have implicated 
type I collagen genes in otosclerosis, COL1A2 was prioritised for genotyping over mir-183, 
whilst computational analysis of the secondary RNA structure of mir-183 was also performed. 
 
4.12.1 Genotyping COL1A2 exon 17 in a familial otosclerosis cohort  
The sequencing data from exon 17 of the COL1A2 gene, which was obtained during Sanger 
sequencing in the 56 unrelated familial probands, was analysed for additional variants within 
this exon. An additional coding change was identified in one individual in the cohort. This was a 
previously unreported 9 base pair duplication c.817_825dupGCTGGTCCT in exon 17 of COL1A2, 
(Figure ‎4.11) just 9 bases downstream of the c.808G>A SNP found in family D.  This duplication 
encodes the insertion of three additional amino acids: alanine 273 –glycine 274– proline 275. 
The study participant possessing this duplication was contacted in an attempt to recruit 
additional family members for segregation analysis. Genomic DNA samples were obtained 
from her mother who also had a diagnosis of otosclerosis and her father who had no family 
history of hearing loss. Sanger sequencing showed that her mother was also heterozygous for 
this duplication and that her father was wild type.  
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Figure ‎4.11 Chromatogram of a heterozygote for variant c.817_825dupGCTGGTCCT  in COL1A2 
Chromatogram of the genotype of the additional cohort member who is heterozygous for a nine base GCTGGTCCT 
duplication in exon 17 of the COL1A2 gene (Reverse complement of original sequence with reverse primer shown 
for clarity). 
 
 
4.12.2 Predicting the effect of SNP c.81G>T on the secondary structure of mir-
183 
Variant c.81G>T in mir-183 in family D is located at nucleotide 81 of the 150 bases that code 
for the pre-microRNA hairpin (mir-183). The functional portion of this non-coding RNA is the 
highly conserved mature-microRNA sequence (miR-183), which is encoded by nucleotides 27-
48 of the hairpin structure and includes the seed sequence, the short region at its 5’ end, 
which is thought to play a role in target specificity. Variant c.81G>T is not located within this 
mature RNA sequence but is located within the conserved miRNA* region, which is the 
complementary region on the opposite arm of the hairpin that binds to the mature RNA 
sequence during hair pin folding. It is thought that in some miRNAs, the mature sequence can 
be derived from either arm of the hairpin. If this were the case in mir-183 and the mature RNA 
was derived from the miRNA* region, it is possible that variant c.81G>T could affect the 
structure of the mature RNA produced, which in turn could have an impact on the regulation 
of mir-183 target genes.  
Alternatively, due to the precise secondary structure of microRNAs, it is possible that this 
variant could result in changes to the hairpin structure which could affect normal processing of 
the mature RNA. RNAfold software (http://bibiserv.techfak.uni-bielefeld.de/rnafold/) was 
therefore used to predict the effect of the c.81G>T variant on folding of mir-183 hairpin 
according to two models; the conventionally used Minimum Free Energy (MFE) model which 
predicts the structure of the RNA molecule using an algorithm based on the assumption that 
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the molecule will fold into the least energy state, and the more recently developed Centroid 
model, which is thought to more accurately predict secondary structure by taking into account 
known reference structures (Hajiaghayi et al., 2012). The figure below shows the predicted 
secondary structure of the pre-microRNA mir-183 both with and without variant c.81G>T, 
according to the MFE and Centroid models (Figure ‎4.12).  
 
Figure ‎4.12 Secondary structure predictions for pre-microRNA mir-183 
Images of the predicted secondary structure of the pre-microRNA mir-183 both with and without variant c.81G>T 
according to the MFE and Centroid models using RNAfold software (http://bibiserv.techfak.uni-
bielefeld.de/rnafold/). 
 
4.12.3 Discussion of mir-183 and COL1A2 as candidate genes in family D 
Both mir-183 and in COL1A2 are good candidate genes in family D. Computational predictions 
that suggest that variant c.81G>T in mir-183 may affect the secondary structure of the pre-
microRNA, indicates that this variant could have an impact on the processing of this pre-
microRNA into the mature micro-RNA. Given that mutations within mature micro-RNAs in this 
gene family are known to play a role in hearing loss, it is possible that abnormal processing of 
the mature micro-RNA could result in a similar effect on target genes, leading to deafness. 
Whilst SNP c.81G>T  in mir-183 appears to be a promising candidate variant in family D, more 
evidence would be required to suggest its involvement in the pathogenesis of otosclerosis 
including identification of additional variants throughout the gene within otosclerotic families.  
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In COL1A2, an additional rare variant was identified in exon 17, the same exon in which the 
family D c.808G>A SNP was identified. This c.817_825dupGCTGGTCCT insertion, which was 
identified in an additional cohort member and her mother, is a novel duplication that has not 
been previously reported in the literature. However a rare variant, c.821G>A/T, has been 
reported within this 9 base pair region resulting in a p.glycine>aspartic acid/valine change at 
residue 274 in individuals with Osteogenesis Imperfecta (Ward et al., 2001, Shaheen et al., 
2012, Marini et al., 2007). In addition, another rare 9 base pair duplication 
c.825_833dupGCTGGTCCC has been reported immediately downstream of 
c.817_825dupGCTGGTCCT, resulting in the 3 amino acid insertion alanine- glycine – proline in a 
further patient with Osteogenesis Imperfecta (Gentile et al., 2012). Due to the repetitive 
nature of the COL1A2 gene, this nine base duplication c.825_833dupGCTGGTCCC results in the 
exact same amino acid sequence for COL1A2 as the duplication c.817_825dupGCTGGTCCT 
found within the member of the otosclerosis cohort. 
The proband possessing duplication c.817_825dupGCTGGTCCT is a 30 year old female with 
bilateral hearing loss which begun in the second decade of life. She does not have a diagnosis 
of Osteogenesis Imperfecta or any other connective tissue disorder besides otosclerosis, but 
has reported to have broken three bones in her life time; her collar bone at age three and a 
finger and toe in her late twenties. This may suggest that the duplication in COL1A2 may be 
having an effect on her bones, causing her to be more susceptible to bone damage and 
breakages. Her 60 year old mother also has bilateral hearing loss that begun in the second 
decade. She has never broken a bone but has reported chronic neutropenia, an autoimmune 
condition associated with various collagen vascular disorders. Given that 
c.817_825dupGCTGGTCCT and c.825_833dupGCTGGTCCC result in the same amino acid 
sequence in the encoded protein, it is surprising that the family with otosclerosis possessing 
the c.817_825dupGCTGGTCCT duplication do not have Osteogenesis Imperfecta, whereas the 
individual with duplication c.825_833dupGCTGGTCCC does.  One explanation for this is that 
perhaps the individual with the c.825_833dupGCTGGTCCC duplication identified by Gentile et 
al. also possesses an additional Osteogenesis Imperfecta causing variant within the COL1A2 
gene or within another Osteogenesis Imperfecta gene that was not identified. Another 
explanation could be that the otosclerosis family with the c.817_825dupGCTGGTCCT 
duplication have a mild form of Osteogenesis Imperfecta with associated stapes fixation which 
is undiagnosed. If this is the case, it is suggestive that there is a shared genetic aetiology 
between otosclerosis and Osteogenesis Imperfecta. To investigate the link between these two 
conditions further, the Italian research group reporting duplication c.825_833dupGCTGGTCCC 
was contacted in an attempt to gather phenotypic information in regards to hearing loss from 
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the individual with this duplication; however, the research group were not able to provide us 
with this information. If this individual did have conductive hearing loss, it could support the 
theory that otosclerosis is a localised manifestation of Osteogenesis Imperfecta, as has 
previously been suggested in the literature (Weber, 1930). Although the subsequent 
identification of an additional variant within COL1A2 in an unrelated otosclerosis family, is 
consistent with a role for COL1A2 in the disease process, there is still insufficient evidence to 
implicate this gene as causative in family D. Recruitment of additional members of family D 
would be required to provide more convincing data from segregation analysis. 
Analysis of the RNA-sequencing data (chapter 5) suggests that COL1A2 may be a more 
promising candidate gene in family D than mir-183. Analysis of this data showed that that mir-
183 was not expressed in human stapes, whilst COL1A2 was found to be highly expressed with 
an average RPKM of 6.65 across all stapes suprastructures. Since it is likely that any gene 
involved in otosclerosis will be expressed in human stapes tissue, this calls into question the 
role that mir-183 could play in the disease process. However, given that microRNAs tend to be 
expressed at very low levels, it is possible that this gene is expressed in the stapes but at such 
low levels that it was not detected during RNA-sequencing. In contrast, since COL1A2 encodes 
a structural protein, it would be expected to be highly expressed in bone tissue whether or not 
it was involved in the disease process. In addition, no significant difference in expression was 
found in COL1A2 between otosclerotic and control samples, which might be expected of a 
gene involved in the disease process. Since no stapes were available from members of family D 
for gene expression analysis, it was not possible to investigate changes in expression of mir-
183 or COL1A2 within the stapes of individuals who possessed these variants. This would have 
been useful in order to determine if these variants had an impact on expression levels of these 
genes, which could help to prioritise one of the candidates in this family. 
For further investigations into causative variants in family D, Sanger sequencing could be 
performed in the remainder of the otosclerosis cohort of 56 probands on mir-183. Since this is 
a short gene, just 150 bases in length, this would be relatively inexpensive. This would be 
crucial in order to identify if any other rare nonsynonymous variants were located within the 
gene, as in the absence of identification of additional mutations within this gene in other 
families, it is difficult to support a role for mir-183 in disease pathogenesis at this stage. For 
further analysis of COL1A2, it would not be possible to perform Sanger sequencing in the 
remainder of the gene in the otosclerosis cohort as it is an extremely large gene consisting of 
52 exons so would not be financially viable. Targeted re-sequencing of specific regions of 
COL1A2 may be a better option, however, with a lack of knowledge regarding disease 
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pathogenesis, it would be difficult to identify the regions of the gene that are most likely to 
contain mutations involved in otosclerosis. For this reason, it may be most beneficial to wait 
until a larger number of probands with familial otosclerosis have been recruited in order to 
perform sequencing on exon 17 in these individuals. If no additional mutations within this exon 
in other families are identified, it is difficult to provide enough evidence that strongly supports 
a role for COL1A2 in disease pathogenesis.  
 
4.13 Evaluation of SERPINF1 as a family B candidate gene  
In family B, SNP c.601G>A in SERPINF1 was found to segregate with otosclerosis. This SNP 
results in an aspartic acid to asparagine amino acid change in exon 5 of the SERPINF1 gene, a 
gene involved in the connective tissue disorder Osteogenesis Imperfecta type VI which is 
known to occasionally occur concomitantly with otosclerosis. The biological role of the gene, 
which is highly expressed in bone and cartilage, provides a strong justification to prioritise 
SERPINF1 for follow up analysis in a cohort of 56 familial otosclerosis probands. 
 
4.13.1 Genotyping SERPINF1 exon 5 in a familial otosclerosis cohort  
When the sequencing data from exon 5 of the SERPINF1 gene, which was obtained during 
Sanger sequencing in the 56 unrelated familial probands, was analysed for additional variants 
within the exon, an additional SNP c.441G>C was identified at the second base of exon 5 in 
two unrelated probands in the cohort (Figure ‎4.13).  
 
Figure ‎4.13 Chromatogram of a heterozygote for variant c.441G>C in SERPINF1 
Chromatogram of the genotype of one of the two additional cohort members with the heterozygous G>C SNP at the 
second base of exon 5 in the SERPINF1 gene. 
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Both probands possessing this rare variant were 57 year old British females with a strong 
family history of otosclerosis. Neither proband had any living relatives with otosclerosis so 
segregation analysis was not possible in either of these families. However, gDNA from an 
unaffected elderly maternal aunt was secured from one of these probands who had a strong 
history of otosclerosis in her maternal line. The variant was not found in this unaffected aunt 
who had a mother, sister and niece all with early onset hearing loss characteristic of 
otosclerosis. It was not possible to secure genomic DNA from any family members of the other 
proband with this variant. However this participant was recruited via the surgical recruitment 
path and has received stapedotomy surgery on both ears within the last three years at the 
Royal National Throat Nose and Ear Hospital in London. As a result, access was available to 
both her stapes bones for gene expression analysis (‎4.13.6).  
SNP c.441G>C causes an amino acid change from lysine 147 to asparagine and is present in the 
general population at a very low frequency, estimated from data from the NHLBI cohort of 
4,300 European American individuals (http://www.nhlbi.nih.gov/) to be approximately 0.0003, 
which is much lower than the frequency in the familial otosclerosis cohort of 0.0175. This 
variant is therefore 58 times more common in the otosclerosis cohort than in the general 
population. In addition, this variant was not identified when a cohort of 190 controls were 
genotyped by restriction endonuclease digest using TseI, confirming that this SNP is rare in the 
general population. 
 
4.13.2 Genotyping the remainder of SERPINF1 in a familial otosclerosis 
cohort  
Following the identification of additional rare SNP c.441G>C in SERPINF1 in two unrelated 
probands in the cohort, the remainder of the coding region (exons 2-8) of the SERPINF1 gene 
was sequenced in 56 familial otosclerosis probands. In total 8 additional variants were 
identified in the cohort. A nonsynonymous SNP c.167C>G was identified in SERPINF1 exon 3 
within one of the 56 probands (Figure ‎4.15 A). This SNP causes an alanine to glycine change at 
amino acid 56 and is very rare in the general population with an allele frequency of just 0.0001 
based on the European American data from the NHLBI cohort. Two other nonsynonymous 
SNPs were also identified in exon 3. These were c.202G>C and c.215C>T, both of which 
occurred in the otosclerosis cohort at a frequency similar to that of the general population 
based on data from the NHLBI cohort (http://www.nhlbi.nih.gov/). In addition, four variants 
were identified in exon 4 of SERPINF1. One of these was a previously unreported c.331G>A 
variant (Figure ‎4.15 B) which causes an amino acid change from aspartic acid 111 to 
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asparagine. The other three SNPs within exon 4 are located within a highly polymorphic region 
spanning nine bases that contains six known SNPs. One of these is a synonymous SNP c.389T>C 
which is very common in the general population according to data from the NHLBI cohort. 
Another is a nonsynonymous SNP c.392C>A (Figure ‎4.15 C) which causes an amino acid change 
from alanine 131 to aspartic acid and which is has an allele frequency of just 0.0008 in the 
NHLBI cohort. The third is a common nonsynonymous SNP c.395C>G which occurred in the 
otosclerosis cohort at a frequency similar to that of the general population as predicted by 
NHLBI. The final SNP was a common synonymous SNP c.963T>C within exon 7 which again 
occurred in the otosclerosis cohort at a frequency similar to general population frequencies. 
The location and frequency information on each of these SNPs in addition to the c.601G>A SNP 
in family B and the c.441G>C SNP also identified in the cohort are summarised in Figure ‎4.14 
and Table ‎4.18. 
 
 
Figure ‎4.14 Illustration of variant locations in SERPINF1 
Image illustrating the location of the 10 SNPs identified in the familial otosclerosis cohort in the SERPINF1 gene. 
Rare SNPs in the general population are highlighted in bold. 
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SNP Exon 
Frequency of allele 
in otosclerosis 
cohort 
Frequency of 
allele in NHLBI 
cohort  
Amino Acid 
change 
Variant 
Prediction 
software 
c.167C>G 3 0.0088 0.0001 56 A/G 
Possibly 
damaging(0.428) 
c.202G>C 3 0.0088 0.0036 68 V/L Benign (0) 
c.215C>T 3 0.6404 0.6519 72 T/M Benign (0) 
c.331G>A 4 0.0088 
Previously 
unreported 
111 D/N 
Probably 
damaging(0.915) 
c.389T>C 4 0.2807 0.2942 Synonymous Synonymous 
c.392C>A 4 0.0088 0.0008 131 A/D 
Probably 
damaging(0.993) 
c.395C>G 4 0.0526 0.0327 132 P/H 
Probably 
damaging(0.929) 
c.441G>C 5 0.0175 0.0003 147 K/N Benign(0.129) 
c.601G>A 5 0.0088 
Previously 
unreported 
201 D/N Benign(0) 
c.963T>C 7 0.2895 0.2921 Synonymous Synonymous 
 
Table ‎4.18 Table showing the 10 variants identified in SERPINF1in the otosclerosis cohort 
Table shows all variants identified in SERPINF1 ENST00000254722 in a cohort of 57 unrelated probands with familial 
otosclerosis. Rare SNPs in the general population are highlighted in bold. The minor allele frequency of the variant is 
based on data from the European American population in the NHLBI cohort. The Polyphen prediction score is a 
rating from 0-1 where 0 indicates variants predicted to be benign and 1 indicates variants that are very likely to be 
damaging. 
Please note that although the original SERPINF1 SNP c.601G>A was identified in family B of Caribbean origin; here 
the frequencies of a European cohort are stated as this best represents the ethnicity of the otosclerosis cohort 
recruited. 
 
 
 
 
 
153 
 
A. 
 
Chromatogram of a heterozygote for variant c.167C>G in SERPINF1 
B. 
 
Chromatogram of a heterozygote for variant c.331G>A in SERPINF1 
C. 
 
Chromatogram of a heterozygote for variant c.392C>A in SERPINF1 
Figure ‎4.15 Chromatograms showing variants in SERPINF1 
(A) Chromatogram of the genotype of the additional cohort member who has the heterozygous c.167C>G SNP in 
exon 3 of the SERPINF1 gene. (B) Chromatogram of the genotype of the additional cohort member who has the 
heterozygous c.331G>A SNP in exon 4 of the SERPINF1 gene. (C) Chromatogram of the genotype of the additional 
cohort member who has the heterozygous c.392C>A SNP in exon 4 of the SERPINF1 gene. This individual also has 
common synonymous c.389T>C SNP in this region. 
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Of the eight additional SNPs identified, two were synonymous and six nonsynonymous.  Since 
synonymous SNPs do not cause an amino acid change, it was decided that these were unlikely 
to be disease causing, so were eliminated from further analysis. Of the remaining six variants, 
three occurred at a frequency in the cohort similar to the frequency that would be expected in 
the general population based on data from the NHLBI cohort.  It was therefore decided that 
these were also unlikely to be involved in the disease process as it would be expected that a 
disease causing variant would be over-represented in the otosclerosis cohort. Therefore three 
additional variants of interest were identified in the cohort; c.167C>G in exon 3, c.331G>A in 
exon 4 and c.392C>A also in exon 4. These variants were also predicted to be damaging 
according to Polyphen prediction software. It was not possible to recruit family members from 
any of the probands possessing these three SNPs for segregation analysis. However, two of 
these individuals, one with SNP c.167C>G in exon 3 in the other with SNP c.331G>A in exon 4 
were recruited via the surgical recruitment path. As a result, access was available to their 
stapes bones for gene expression analysis (‎4.13.6).  In total, including the two previously 
identified SNPs, five rare nonsynonymous variants of interest were identified within the coding 
region of SERPINF1.  
 
4.13.3 Analysis of SERPINF1 isoforms 
SERPINF1 has 5 known protein coding, 3 putative protein coding and 4 non-protein coding 
transcripts (Figure ‎4.16). The nonsynonymous c.441G>C variant, which was identified in two 
unrelated otosclerosis probands, is located at the second nucleotide of exon 5 of the major 
protein-coding transcript SERPINF1-001. The location of this SNP suggests that it may play a 
role in altered expression of specific SERPINF1 transcripts, as the 5’ end of an internal exon 
typically acts as splice acceptor site, indicating that this SNP may be involved in splicing. The 
locations of the additional SERPINF1 variants were also investigated, to identify if any were 
located at a splice sites within any of the 12 SERPINF1 transcripts. Whilst three were not found 
to be located at a splice site, the Family B SNP c.601G>A was located at the final base of 
truncated exon 5 in non-protein coding transcript SERPINF1-008 (Figure ‎4.16). This suggests 
that both exon 5 SNPs (c.441G>C and c.601G>A) could have an effect on splicing, and could 
thus impact the expression of certain isoforms. Furthermore, whilst the family B SNP c.601G>A 
is the final base in the terminal exon of non-protein coding transcript SERPINF1-008, SNP 
c.441G>C is located 160 bases upstream at the second base of this same exon. This suggests 
that the sites of variants c.441G>C and c.601G>A are likely to be significant for splicing of 
SERPINF1. 
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Figure ‎4.16 Image illustrating all 12 SERPINF1 transcripts.   
Transcripts 1, 3, 4, 10 and 11 are known to be protein coding, transcripts 9, 12 and 13 are putative, transcripts 5, 6, 
7 and 8 are predicted to be non-protein coding.  Exon numbers are labeled on SERPINF1 transcript 001. Location of 
family B SNP c.601G>A is shown (Image from www.ensembl.org) 
 
There is also evidence that suggests that Family B variant c.601G>A could affect translation of 
putative transcript SERPINF1-012. This transcript is 729 bases in length and codes for a 138 
amino acid protein spanning from exon 5 to exon 8. It encodes an untranslated region (UTR) at 
the 5’ end of exon 5 where SNP c.601G>A is the final base of the 5’UTR, meaning that the SNP 
is located at the -1 position (one base upstream of the AUG start codon) in SERPINF1-012. It 
therefore lies within the Kozak sequence, a highly conserved element at the 5’ end of a 
messenger RNA transcript which spans the translational initiation site. This sequence is 
essential for binding of the 43s ribosome complex at the initiation of translation. There are no 
other initiation signals within this exon, suggesting that if the variant in family B resulted in 
inhibition of ribosomal binding at this site, translation of the entire transcript could be 
compromised.  
 
 
 
 
156 
 
4.13.4 Analysis of RNA-sequencing data to investigate SERPINF1 expression 
in human stapes 
To investigate whether there were any differences in the expression of specific SERPINF1 
isoforms in the stapes tissue of the proband in family B who possessed SNP c.601G>A, RNA-
sequencing data (chapter 5) was analysed in this individual. During RNA-sequencing, reads 
were mapped against a specialist reference transcriptome known as the spliceome, a sequence 
database consisting of sequences of all known splice isoforms, which enabled detection and 
relative quantification of specific isoforms within the samples. Since this tool generates a read 
count for each exon within each sample analysed, it is useful for comparing differential 
expression of specific isoforms between affected and control tissue. It was found that the read 
count in SERPINF1 was greater for exons downstream of exon 5 than for those upstream. The 
average read count for exons 1 to 4 was just 18.67 compared to 78.58 for exons 5 to 8 in this 
individual. This finding was unexpected as it would be expected that if SNP c.601G>A did 
impair ribosome binding in the Kozak sequence of transcript SERPINF1-012, that it would result 
in reduced expression of this transcript and thus a lower read count for exons downstream of 
exon 5. However, when the read count for each exon of this gene was analysed in all 8 
otosclerotic and 4 control samples sequenced, it was found that this pattern was consistent 
throughout all samples. On average the read count was greater for exons downstream of exon 
5 than for upstream exons (Table ‎4.19).  
Exon 
Average read count Read Count in Stapes 
from Family B Proband 
p value 
Control stapes Otosclerotic stapes 
exon 1 7.90 12.75 12.17 0.52 
exon 2 11.65 17.33 14.17 0.55 
exon 3 40.89 40.77 23.17 1.00 
exon 4 39.66 40.28 25.16 0.98 
exon 5 134.84 52.78 49.16 0.02 
exon 6 135.33 42.16 45.16 0.02 
exon 7 228.17 74.02 107.99 0.03 
exon 8 293.77 64.75 112.00 0.01 
 
Table ‎4.19 Table showing read count data for SERPINF1 exons 
Table shows the average read count of SERPINF1 exons in the 8 otosclerotic and 4 control stapes and from the 
stapes in the proband of family B. p-values calculated using a Student’s two-tailed paired-end t-test illustrate a 
significant difference in expression between affected and control stapes of exons 5-8 but not 1-4.   
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Although the read count for exons 1-4 was fairly consistent across all control and otosclerotic 
stapes, there was a marked reduction in the read count of downstream exons in otosclerotic 
stapes compared to controls. Moreover, when the expression levels both up and downstream 
of exon 5 in the cohort of the 8 otosclerotic and 4 control stapes samples were compared, it 
was found that there was a significant difference (p<0.05) in expression of SERPINF1 exons 5 to 
8, but this was not the case for exons 1 to 4 (Table ‎4.19).  
Further analysis of the RNA-sequencing data found that the 5’UTRs unique to downstream 
transcripts SERPINF1-012 and SERPINF1-013 were detected in both otosclerotic and control 
human stapes. However, the level of expression of these UTRs was lower than for the coding 
region of exon 5. (Figure 4.17). In the stapes suprastructure of the proband of family B who 
possessed SNP c.601G>A, the difference in read count between the UTR and the coding region 
of exon 5 is larger than in the three control suprastructures (Figure 4.17), particularly when 
compared to control stapes 1 and 2.  
 
4.13.5 Investigating alternative splicing in SERPINF1 
Due to the evidence suggesting that a mechanism of alternative splicing in SERPINF1 may be 
involved in otosclerosis, an in silico splicing assay was carried out on all rare nonsynonymous 
variants identified within SERPINF1. Spliceport (www.spliceport.cs.umd.edu) analysis was 
performed on both wild-type and mutant sequences surrounding each variant to calculate the 
probability of a splice donor or acceptor site within the sequence. Splice donor and acceptor 
sites are highly conserved sequences at which the spliceosome, a complex of ribosomal RNA 
and associated proteins, assembles during splicing. The 5’ donor splice site is located at the 
upstream region of the intron being excised, whilst the 3’ acceptor splice site is located at the 
downstream region of the intron (Figure ‎4.18). Using a feature generation algorithm (FGA) 
framework, the Spiceport software classifies all AG dinucleotides into acceptor and non-
acceptor sites and all GT dinucleotides into donor and non-donor sites. When applied to the 
five variants identified in SERPINF1, four were not found to be located in the immediate region 
surrounding an AG or GT dinucleotide, so were not assigned a Spliceport computational score. 
However SNP c.441G>C results in a G to C change at the G of an AG dinucleotide immediately 
downstream of the donor site. A computational score of -1.05 was assigned to the wild-type G 
allele, which is greater than the threshold score of -10 implemented, above which any score is 
considered significant (sensitivity value=100%, AG false positive rate = 85.21%). However, 
when the analysis was run to include the C allele, no computational score was generated. This 
suggests that c.441G>C may affect the splice acceptor site at the 5’ end of exon 5.  
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Figure ‎4.18 Image illustrating the process of splicing  
Image shows binding of the U1 and U2 snRNPs to the 5’ splice site and branch site respectively, assembly of the 
mature spliceosome, nucleophilic attack and lariat excision. (Adapted from Kornblihtt et al., 2013) 
 
ESE finder (www.rulai.cshl.edu/tools/ESE) is a second splice prediction software that was used 
to predict whether the variants were located within an additional consensus sequence known 
as the branch site. This sequence is less strongly conserved than the donor and acceptor sites 
but contains an invariant adenosine residue approximately 18 nucleotides upstream of the 
acceptor site, followed by a polypyrimidine tract (Figure ‎4.18). This adenosine residue is 
recognised by a specialist component of the splicesome complex called the U2 snRNP (small 
nuclear ribonuclear protein) which plays a crucial role in lariat excision during the splicing 
together of adjacent exons (Kornblihtt et al., 2013).  
This software predicted that the c.392C>A SNP in exon 4 would result in the introduction of a 
branch point adenosine residue within the conserved branch point sequence (Table ‎4.20). ESE 
finder also predicted that variant c.331G>A in exon 4, which had not been reported in previous 
literature and SNP c.601G>A in Family B may reduce efficiency of binding of the U2 snRNP to 
the branch point consensus sequence. However, there was a smaller difference in the branch 
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site threshold score generated by ESE finder between the wild type sequence and sequence 
containing the variant for both of these variants, than was the case for the 392 C>A SNP 
(Table ‎4.20). Neither SNP c.167C>G in exon 3 nor the c.441G>C SNP at the second base of exon 
5 were predicted to be located within a branch point consensus sequence. 
 
SNP Exon 
ESE Finder 
Branch site score 
Wild-type sequence Sequence containing variant 
c.167 C>G 3 0 0 
c.331 G>A 4 3.20 2.79 
c.392 C>A 4 1.19 7.49 
c.441G>C 5 0 0 
c.601G>A 5 3.71 3.31 
 
Table ‎4.20 Table showing predicted impact on splicing of SERPINF1 variants 
Table shows the 5 variants identified in SERPINF1 and the predicted impact of each variant on splicing according to 
ESE finder software. Scores reflect the extent of matching to a degenerate consensus and are adjusted for 
background nucleotide composition. The default threshold setting used was 0. The scoring system for ESEfinder 
ranges from the default threshold signifying no effect, to positive values which predict an increasing probability that 
a variant is damaging to a branch site. 
 
4.13.6 Investigating the relative expression of alternative SERPINF1 isoforms 
Since the RNA-sequencing data, as well as the results of genotyping followed by an in silico 
splicing assay, suggested that alternative splicing of SERPINF1 may be occurring in otosclerotic 
stapes, quantitative PCR was performed in a large number of stapes in order to analyse 
relative expression levels of specific SERPINF1 isoforms. Two Taqman® gene expression assays 
were performed to analyse relative expression levels of specific SERPINF1 transcripts. One of 
these assays only amplified transcripts containing exons upstream of exon 5, whilst the other 
only amplified transcripts containing exons downstream of exon 5.  The probe of the upstream 
assay (Hs011006934-Applied Biosystems ®) binds to the exon-exon junction between exons 3 
and 4, so would be predicted to amplify SERPINF1 transcripts 1, 3, 4, 5, 9 and 10. The probe of 
the downstream assay (Hs011006937-Applied Biosystems ®) binds to the exon-exon junction 
between exons 6 and 7 so would be predicted to amplify SERPINF1 transcripts 1, 9, 12 and 13 
(Figure ‎4.19).  
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Figure ‎4.19 Image illustrating the location of the upstream and downstream Taqman assay probes for all  
SERPINF1 transcripts.  
The upstream probe Hs011006934 binds at the junction between exons 3 and 4.  It can therefore detect transcripts 
1, 3, 4, 5, 9 and 10. The downstream probe Hs011006937 binds at the junction between exons 6 and 7. It can 
therefore detect transcripts 1, 9, 12 and 13 (Image from www.ensembl.org) 
 
Both upstream and downstream assays were performed on cDNA extracted from 81 
otosclerotic and 5 control stapes suprastructures. Of the 81 otosclerotic stapes, three were 
from individuals known to possess variants within the SERPINF1 gene that had been predicted 
to have an effect on alternative splicing. Of these individuals, one had the c.167C>G SNP in 
exon 3, one had the c.331G>A SNP in exon 4 and the other had the c.441G>C SNP in exon 5. 
The Taqman® assays were carried out in triplicate in each of the five controls and six replicates 
were performed for the three samples with known mutations in SERPINF1, to provide a better 
estimate of the true expression levels in these stapes, whilst the remaining 78 otosclerotic 
samples were performed once and analysed as one sample. SERPINF1 expression levels were 
compared between otosclerotic and control stapes and in those individual patients with 
known variants. The design of the assays also allowed a comparison between levels of 
downstream and upstream exons in the same group to indicate whether there were 
differences in the transcripts expressed. 
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The results from the Taqman® assays are shown in Figure ‎4.20. These results show that 
SERPINF1 expression is reduced in otosclerotic samples compared to controls, for both 
upstream and downstream exons. The degree of this reduction is significantly greater for the 
downstream assay (RQ=0.52) than for the upstream the upstream assay (RQ=0.75). The 
downstream assay indicates expression of SERPINF1 in otosclerotic stapes is only half that of 
control stapes, whereas the upstream assay suggests expression in otosclerotic stapes at three 
quarters that of control stapes.  
In the stapes of the individual with variant c.167C>G in exon 3, SERPINF1 appeared to be 
expressed at higher levels than in the control stapes for both assays, although this only 
reached significance for the upstream assay. In the stapes of the individual with SNP c.331G>A 
in exon 4, SERPINF1 appeared to be expressed at slightly lower levels than in the control 
stapes, although this did not reach significance for either assay. The stapes from individuals 
with both these variants appeared to have reduced expression of downstream compared to 
upstream exons relative to controls, however again this did not reach significance. 
In the individual with SNP c.441G>C in exon 5, the SNP which was found in two cohort 
members and is known to be located near a splice acceptor site, SERPINF1 was expressed at 
significantly lower levels than in the control stapes for both assays and was expressed at even 
lower levels than the otosclerotic stapes cohort as a whole. In addition, the downstream exons 
were expressed at lower levels than the upstream exons when compared to controls. This 
indicates that this variant may be affecting splicing of SERPINF1 in this individual, causing a 
reduction in expression of SERPINF1 and particularly of exons downstream of exon 5.  
Since relative quantification rather than absolute quantification assays were performed, it was 
considered unsuitable to make a direct comparison between expression levels of the upstream 
and downstream assays within a sample category due to  possible differences in assay 
efficiencies. 
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A
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Figure ‎4.20 Graphs showing the relative expression of SERPINF1 transcripts in otosclerotic and control stapes 
suprastructures  
Assays were located at two targets within the gene, one at the exon 3-4 boundary (A) and one at the exon 6-7 
boundary (B). 18s ribosomal RNA served as endogenous control. Error bars represent 95% confidence intervals. 
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4.13.7 A possible mechanism of alternative splicing in SERPINF1 in 
otosclerosis pathophysiology 
The data obtained from both RNA-sequencing assays indicate that there is increased 
expression of downstream compared to upstream exons in all human stapes. This suggests 
that alternatively spliced SERPINF1 transcripts SERPINF1-012 and/or SERPINF1-013, which 
encode the downstream region of the protein, are expressed in human stapes in addition to 
the major full length transcript SERPINF1-001. Further evidence to support this is the detection 
of the 5’UTR of transcripts SERPINF1-012 and SERPINF1-013 in both otosclerotic and control 
stapes during RNA-sequencing. Since this UTR sequence is unique to these transcripts, it is 
suggestive that transcripts SERPINF1-012 and SERPINF1-013 are expressed in the human 
stapes. In addition, since the level of expression of this 5’UTR region is reduced compared to 
that of the remainder of exon 5 in the human stapes, it indicates that other transcripts 
containing exon 5 that do not possess the UTR, such as major full length transcript SERPINF1-
001 are also expressed in the stapes. Due to the overlapping nature of transcripts SERPINF1- 
012 and SERPINF1-013, it has not been possible to confirm which of these are expressed in 
human stapes, but the data indicates that it is extremely likely that either one or both of these 
transcripts are expressed.  
RNA-sequencing and quantitative real time PCR assays also suggests that expression of 
SERPINF1 is reduced in otosclerotic stapes compared to controls, in particular for exons 
downstream of exon 5. The most plausible explanation for this is that in individuals with 
otosclerosis, there is a reduction in expression of downstream transcripts SERPINF1-012 
and/or SERPINF1-013 compared to controls. There are other possible theories, for example 
that there is an increase in expression of transcripts encoding upstream exons in otosclerotic 
stapes, which would support the relative reduction in expression of downstream exons within 
these stapes, but would not account for the difference in expression between control and 
affected stapes. Therefore a reduction in expression of transcripts encoding downstream 
exons seems to be the most likely explanation.  
This theory is corroborated by the results of the gene expression assays in the individuals in 
whom rare nonsynonymous variants in SERPINF1 were identified, as well as the results of the 
in silico splicing assay. In the stapes of the family B proband possessing the c.601G>A SNP, 
there is a reduction in expression of downstream exons compared to controls based on the 
results from the RNA-sequencing data. There is also a greater difference in read count 
between the 5’UTR of SERPINF1-012 and SERPINF1-013 and the coding region of exon 5 in the 
stapes of the family B proband than there is in control stapes, indicating a reduction in 
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expression of downstream transcripts. These observations could be explained by the fact that 
this SNP is located at the -1 position of the Kozak sequence of transcript SERPINF1-012, a 
sequence that is required for translation initiation. The Kozak consensus sequence of 
SERPINF1-012 is weak, as it possesses a pyrimidine base at the -3 position. The presence of a 
pyrimidine rather than a purine at this position causes translation to become more sensitive to 
mutations located at the -1 position (Kozak, 1986). Therefore the G>A variant at -1 of 
SERPINF1-012, resulting in a change from a well conserved G base to a less well conserved A 
base, could lead to reduced binding affinity of the translational machinery and thus a 
reduction in expression of this transcript. Alternatively, based upon the results of the in silico 
splicing assay, it is possible that this SNP in family B could have a weak effect on binding of the 
U2 snRNP to the branch point consensus sequence, which would be predicted to inhibit 
recruitment of the splicesome at this site. Since the SNP is located at that start of SERPINF1-
012 and only 40 bases downstream of the SERPINF1-013 start site, it is possible that it could 
reduce splicing at this site and thus lead to a reduction expression of downstream transcripts. 
This could therefore provide an alternative explanation as to how the G>A SNP in family B 
could result in the reduction in expression of downstream exons observed. 
In the stapes from the individual with the c.167C>G variant in exon 3, the quantitative PCR 
assays found that expression of SERPINF1 is greater than in control stapes for both up and 
downstream exons and that there is no significant difference in expression of downstream 
than upstream exons. This is consistent with the results of the in silico splicing assay which do 
not predict this SNP to be located within a splice acceptor, donor or branch point consensus 
site and is therefore not predicted to affect splicesome recruitment. Since this variant is 
located in exon 3, it would not be expected to affect splicing between exons 4 and 5 and is 
therefore unlikely to affect expression of SERPINF1- 012 and SERPINF1-013. It is possible that 
this variant may have another effect on SERPINF1 that is involved in the otosclerosis disease 
process, or may be non-casual. However, it must also be considered that there was greater 
variability in the expression of SERPINF1 between replicates in this stapes compared to the 
other samples analysed, resulting in larger error bars than for other samples. More repeats of 
the assay could be performed to find out if there is any true difference in expression levels of 
this gene between this individual and control stapes.  
In the stapes of the individual with variant c.331G>A in exon 4, there was reduced expression 
of downstream compared to upstream exons when compared to controls, based on findings 
from the quantitative PCR assays, although this was not significant. This trend is consistent 
with the results of the in silico splicing assay suggesting that like the variant found in family B, 
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variant c.331G>A may have a weak effect on binding of the U2 snRNP to the branch point 
consensus sequence, which could impact on expression of downstream exons. Since this effect 
is predicted to be weak, it is consistent with the lack of significance in the expression data. It 
would have been interesting to have had access to the stapes from the individual with variant 
c.392C>A in exon 4, as the in silico splicing assay predicted this variant to have a larger effect 
on splicing. However, since this individual was recruited through the non-surgical arm of the 
study, this was not possible. 
Of greatest interest, are the results from the individual with variant c.441G>C in exon 5, a 
variant which was also found in a non-surgical study participant and which is predicted to be 
located near a splice acceptor site. The results from the quantitative PCR assay show that the 
reduction in expression of downstream exons is greater in this stapes than in both control 
stapes and in other otosclerotic stapes. There is therefore convincing evidence that the 
presence of this SNP directly affects splicing of SERPINF1 and thus causes a reduction in 
expression of downstream exons. 
It is surprising that the reduction in expression of downstream relative to upstream exons is 
not only seen in individuals with known variants in SERPINF1, but also in the larger cohort of 
78 otosclerotic stapes when compared to controls. Whilst 46% of these otosclerotic stapes had 
reduced expression of upstream exons compared to controls, 88% had reduced expression of 
downstream exons compared to controls. Although it is possible that some of these 78 
individuals possess rare nonsynonymous variants in SERPINF1, Sanger sequencing was 
performed on the genomic DNA of eight of these individuals, in whom no variants were 
identified. This therefore suggests that a reduction in expression of downstream exons also 
occurs in individuals who do not possess variants in SERPINF1. There is no obvious explanation 
for this finding, but it may be due to an interacting pathway of molecular factors that result in 
a pathogenic shift in expression away from the downstream isoforms. A hypothetical model of 
SERPINF1 isoform expression in normal human stapes and otosclerotic human stapes both in 
the presence and absence of known SERPINF1 variants is illustrated in Figure ‎4.21. 
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Figure ‎4.21 Hypothetical model of expression of SERPINF1 in normal and otosclerotic human stapes in the 
presence and absence of known variants in SERPINF1.  
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4.13.8 Discussion of SERPINF1 as an otosclerosis candidate gene 
In SERPINF1, five rare nonsynonymous variants were identified in six unrelated probands from 
a cohort of 57 individuals with a history of familial otosclerosis. Therefore in total, 10.5% of the 
otosclerosis cohort recruited possessed a rare nonsynonymous variant within exons 3-5 of this 
gene, which together is a far greater percentage than would be expected in the general 
population. Several lines of evidence provide support for mutations in SERPINF1 resulting in 
differential expression of various PEDF isoforms. In silico splicing assays suggest that variants 
within the gene may influence efficiency of alternative splicing of SERPINF1, and the location 
of SNP c.601G>A in family B indicates that it may affect efficiency of translation of certain 
SERPINF1 transcripts. This together with data collected from analysis of the RNA sequencing 
study and quantitative PCR analysis, suggests that there may be differential expression of 
specific SERPINF1 transcripts within otosclerotic stapes.  
Mutations within this gene have been linked to the connective tissue disorder Osteogenesis 
Imperfecta, a condition in which conductive hearing loss similar to that of otosclerosis is often 
experienced. To date 16 unique sequence variants in SERPINF1 have been identified in 
Osteogenesis Imperfecta VI. These include nonsense and frameshift mutations within all exons 
with the exception of exon 5, each of which causes nonsense mediated decay of mRNA 
transcripts, leading to loss of PEDF expression (Becker et al., 2011). Since none of the 
mutations identified in the otosclerosis cohort are nonsense or frameshift mutations, it is 
unlikely that they would lead to nonsense mediated decay. However, it is possible that the 
variants identified have a less extreme impact on the protein they encode and thus result in a 
less extreme phenotype. This would support previously published theories that otosclerosis is 
a localised manifestation of Osteogenesis Imperfecta (Weber, 1930). Although it is expected 
that a loss of PEDF results in production of undermineralised bone, the mechanism by which 
this occurs is unknown. In bone, since PEDF binds to collagen with high affinity and is actively 
expressed in osteoblastic regions of active bone formation, it is possible that PEDF plays an 
important functional role in bone matrix remodelling (Tombran-Tink and Barnstable, 2004). 
SERPINF1 therefore represents an extremely promising otosclerosis candidate gene both for 
family B and for other otosclerosis families.  
Furthermore, an investigation of known and predicted functional domains located with PEDF 
reveals that variants identified within the otosclerosis cohort could have an effect on protein 
structure and function. The c.441G>C SNP near the splice acceptor site of exon 5 encoding a 
lysine to asparagine amino acid change at residue 147 is located within a highly conserved 
region spanning residues 141-151 which has been proposed as a putative nuclear localisation 
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signal (Tombran-Tink et al., 2005). It is therefore possible that this SNP could affect nuclear 
localisation of the PEDF protein. In addition, PEDF contains a reactive centre loop (RCL), a 
proteinase recognition site that is thought to be a critical component of serpin function 
located at the C terminus of the protein. Although the role of the RCL in PEDF is unknown, it 
has been suggested to be involved in secretion of PEDF (Shao et al., 2003). It is thus a 
possibility that a reduction in expression of downstream exons encoding the RCL as a result of 
aberrant splicing in otosclerotic stapes, could have an impact on secretion of PEDF.  
To further investigate alternative splicing of SERPINF1 in human otosclerotic stapes, an in vitro 
translation assay could be performed to identify whether the family B SNP c.601G>A has an 
effect on translation of transcript SERPINF1-012.  If this SNP was found to affect the resulting 
gene product, it may indicate that the variant in family B is affecting the translation of specific 
SERPINF1 transcripts in human stapes. This would suggest that these transcripts are essential 
in the human stapes and would lead towards a better understanding of the otosclerosis 
disease process.  
An alternative option for future work would be the construction of a minigene system to 
characterise alternative splicing elements. This could be used to identify cis-acting elements 
that define the usage of splice sites and to identify trans-activating factors that regulate 
alternative splicing. Through the amplification of the gene region containing the known 
variant(s), insertion of this region into an appropriate plasmid, followed by transfection into a 
cell line, it may be possible to identify if these variants are having an effect on the transcripts 
being transcribed. This could indicate which SERPINF1 transcripts are affected by the variant 
and thus also indicate which transcripts are essential for stapes function. As a result, this 
technique could also bring investigators closer to elucidating the otosclerosis disease 
mechanism. 
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4.14 Discussion of WES 
 
4.14.1 WES was successful in identification of segregating variants in four 
otosclerosis families 
The results from this study indicate that WES is a useful tool for investigating disease causing 
genes in families exhibiting autosomal dominant inheritance of otosclerosis. The high 
sequencing depth and read quality obtained during WES has resulted in the identification of 
large numbers of variants with high confidence. The step-wise variant prioritisation process 
has been effective at narrowing down the large number of potential disease causing variants 
from an average of 89,656 variants per family to a small pool of those that are most likely to be 
involved in the disease process. Although the variant selection process may be considered 
somewhat stringent, it was essential in order to reduce the long lists of variants to manageable 
levels. To minimise the risk of eliminating the true disease causing variant at each stage in the 
prioritisation process, the benefits of using the filter versus the limitations of omitting it were 
weighed up and appropriate decisions were made.  Each family was considered in turn at every 
stage to ensure that the most appropriate prioritisation steps were implemented.  
Following the step-wise prioritisation process, a further filtering strategy was implemented to 
select those variants of greatest interest for segregation analysis within the otosclerosis 
families. This involved annotation of the genes in which variants were located, with respect to 
their biological role. From these annotations, along with various other factors, variants were 
ranked by those perceived to be of greatest interest, and top ranking variants were selected 
for segregation analysis. This variant selection process is therefore unavoidably subjective, but 
was crucial, in order to hone in on the most interesting candidates. The greatest limitation 
associated with this filtering strategy is that there is a limit to human knowledge as to the 
function and role of genes, so it is possible that good candidates were missed if the role of the 
genes in which they are located is currently unknown. Despite this, 23 variants within good 
candidate genes were prioritised for segregation analysis in the four families. 
Segregation analysis has proven particularly useful in families B and C where large numbers of 
family members were recruited. This resulted in the elimination of a substantial proportion of 
variants in each family, enabling the remaining variants to be prioritised further for the next 
stages of analysis. However, segregation analysis proved less informative in families A and D, 
where it had not been possible to secure genomic DNA samples from as many relatives as had 
initially been anticipated when the families were selected for WES. This meant that it was not 
 
 
171 
 
possible to definitively eliminate variants in these families. In family A, since only four genes 
had been prioritised for segregation analysis, it was possible to follow up all four in the 
subsequent genotyping stage; however in family D, due to time and cost constraints, it was 
necessary to select just the two highest priority candidates for follow up. In hindsight, families 
A and D may not have been the optimal choice for WES out of the sixteen otosclerosis families 
recruited. However, at the end of year one of this research project at which time the families 
for WES were selected, they appeared to be amongst those most likely to yield promising 
results. 
 
4.14.2 Genotyping segregating variants in a familial otosclerosis cohort 
enabled prioritisation of variants of interest 
Genotyping 56 additional probands for each of the variants surviving segregation analysis was 
successful in the identification of one of these variants in unrelated cases of familial 
otosclerosis. The c.1224_1226dupCAT duplication in SMAP1 in family A was identified in a 
heterozygous state in two of the 56 unrelated probands and in a homozygous state in one of 
the 56 probands. Despite this, its relatively high frequency in the general population calls into 
question the likelihood of its involvement in disease pathogenesis. Although at least one 
strong otosclerosis candidate variant emerged from each of the other three otosclerosis 
families for further analysis; the c.601G>A variant in SERPINF1 in family B, c.915C>G variant in 
TRIM17 in family C and  the  c.81G>T variant in mir-183 and c.808G>A variant in COL1A2 in 
family D, none were identified in unrelated cohort members. However, this neither confirms 
nor refutes a role for these variants in disease pathogenesis. Due to the heterogeneous nature 
of otosclerosis, it would be expected that any disease causing variant found within an 
otosclerosis family would be very rare. As a result it is possible that although a variant may be 
disease causing, it may not be found in any additional cohort members. On-going recruitment 
could help to tackle this, as the more individuals that are recruited with a strong family history 
of otosclerosis, the greater the likelihood of identifying an unrelated family who shares the 
variant. Since recruitment for this study is on-going, it may be possible to perform these 
genotyping assays on newly recruited participants reporting a strong family history of 
otosclerosis at a later date.  
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4.14.3 Further analysis was performed on four variants of interest 
Of the four prioritised variants, those in SERPINF1 and COL1A2 stand out as the most 
promising candidates identified in this study, due to the identification of additional rare 
variants within the otosclerosis cohort. Although the c.915C>G variant in TRIM17 and the 
c.81G>T variant in mir-183 remain good candidates in their respective families, without the 
identification of any additional variants in the remainder of the cohort, their role as disease 
causing variants cannot be confirmed. Although there is greater evidence to support a role for 
COL1A2 in the disease process, due to the small number of genomic DNA samples secured 
from family D, this is insufficient to confirm a role for this gene in otosclerosis. Additional 
research is required in order to suggest possible mechanisms by which these genes may be 
involved in the disease process. 
However, for SERPINF1 there is greater evidence for a role in disease pathophysiology. Rare 
nonsynonymous variants were identified in 10.5% of the familial otosclerosis cohort, and since 
familial otosclerosis is highly heterogeneous, it would be expected that any disease causing 
variant identified within an otosclerosis family would be rare.  Since the otosclerosis cohort 
have a substantially greater than expected frequency of mutations within this gene, there is 
convincing evidence that SERPINF1 may be involved in the disease process. Moreover, the 
location of the variants identified in the cohort, within sites predicted to be involved in 
alternative splicing or aberrant expression of specific transcripts, further supports a role for 
SERPINF1 in otosclerosis. This combined with the gene expression data obtained from both 
RNA-sequencing and quantitative PCR assays, which suggest that transcripts coding for the 
downstream exons of SERPINF1 are less highly expressed in otosclerotic than control stapes, 
implicates abnormal expression of specific SERPINF1 transcripts in the disease process. There is 
therefore highly persuasive evidence that mutations in SERPINF1 result in the production of 
alternatively spliced SERPINF1 transcripts in the stapes of individuals affected by otosclerosis.  
In future research, it would be necessary to elucidate the exact role that SERPINF1 transcripts 
play in bone formation in the stapes in order to determine if variants within this gene are 
causing monogenic inheritance of otosclerosis. 
It is necessary to evaluate the choice of the four variants for follow up analysis, as by focussing 
on these variants, other possible disease causing variants may have been overlooked. For this 
reason, it must be taken into consideration that of the four prioritised variants; the c.601G>A 
variant in SERPINF1 and the c.808G>A variant in COL1A2, were initially genotyped in the 
remainder of the otosclerosis cohort using Sanger sequencing rather than restriction 
endonuclease digests, as was the case for the majority of other variants identified. This was 
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because no suitable restriction endonuclease cut at the site of these variants. Since the Sanger 
sequencing revealed additional variants of interest in each of these genes, which would not 
have been possible if restriction endonuclease digests had been performed, it is possible that 
an element of bias was introduced into the study, as following identification of additional 
variants, these genes were prioritised over others for further analysis. Had appropriate 
restriction enzymes been available, no additional variants would have been identified and 
therefore it is possible that these two good candidates would not have been prioritised for 
follow up. Having said this, given the biological role of these two genes, both of which are 
known to be involved in systemic connective tissue disorders, they would have been excellent 
candidates for follow up even if no additional variants had been identified within these genes. 
 
 
In summary, through WES followed by a step-wise prioritisation process, a number of good 
candidate variants have been identified which may be involved in disease pathology. At least 
one strong candidate gene has emerged from three of the four otosclerosis families: SERPINF1 
in family B, TRIM17 in family C and mir-183 and COL1A2 in family D. In family A, it would be 
necessary to return to an earlier stage of the filtering process to identify additional good 
candidate variants for segregation analysis. For the four prioritised variants identified within 
the other three families, analysis of RNA sequencing data as well as further genotyping on 
these genes revealed that all are good candidates for involvement in disease pathology. In 
particular, strong evidence suggests that alternative splicing of SERPINF1 in the human stapes 
may be involved in the disease process leading to otosclerosis. It is hoped that this research 
will contribute to the current literature to help improve understanding of the pathways 
involved in pathogenesis of otosclerosis, with the hope of improving treatment options for 
otosclerosis patients in the future. 
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5 Whole transcriptome expression 
analysis identifies dysregulated genes 
in otosclerotic stapes 
 
5.1 Introduction 
Whole transcriptome expression analysis by Next Generation Sequencing (NGS) is acquiring 
increasing importance in investigating molecular mechanisms involved in complex human 
disease. RNA-sequencing (RNA-seq) is one such NGS technique, which provides a high 
throughput transcriptome–wide approach to gene expression analysis, allowing 
comprehensive evaluation of all RNA molecules expressed within a tissue type (Ozsolak and 
Milos, 2011). Since its initial application, RNA-seq has made significant progress in 
quantification and characterisation of transcriptomes, particularly in the fields of cancer 
research and neurodegenerative disease (Costa et al., 2013). It is now increasingly acquiring an 
important role in elucidating molecular pathways involved in the development of other 
complex human diseases and traits.  
To date, RNA-seq has not been used to analyse the gene expression profiles of otosclerotic 
tissue, however previous attempts have been made to characterise gene expression in the 
stapes. Most of these gene expression studies have focused on a small number of candidate 
genes, with only one employing a transcriptome-wide approach. In this study, a whole genome 
hybridisation array was used to investigate gene expression in nine otosclerotic and seven 
control stapes (Ealy et al., 2008). This provided a comprehensive stapes gene expression 
dataset, enabling the identification of 110 dysregulated genes. However, of seven 
dysregulated genes prioritised for validation using quantitative reverse transcription PCR (qRT-
PCR) in the same stapes samples, dysregulation of only two of these genes was confirmed. This 
may have been due to the small number of stapes analysed during this study. As a whole 
transcriptome approach, RNA-seq has great promise for identifying novel genetic pathways 
involved in otosclerosis, through the provision of a comprehensive stapes gene expression 
dataset and has the benefit over more traditional techniques of being able to detect and 
quantify previously uncharacterised transcripts, as well as transcripts expressed at low levels 
(Ozsolak and Milos, 2011).  
During RNA-seq, millions of short RNA fragments are generated from a messenger RNA 
sample. These are converted into a library of cDNA fragments by a fragmentation process 
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followed by the addition of sequencing adaptors to each cDNA fragment. High throughput 
sequencing generates a series of sequence reads which are aligned to a reference 
transcriptome. Reads that align to exons, genes and splice junctions within the transcriptome 
are counted, which enables a read count for each transcript to be generated. From this read 
count, transcript-level expression is calculated. This data is then subject to statistical analysis 
as well as visualisation on an appropriate data analysis platform. Following this, pathway 
analysis along with various other analyses such as functional annotation may be performed to 
identify trends in the data (Wang et al., 2009) (Figure ‎5.1). 
 
Figure ‎5.1 Flow chart showing the four stages involved in RNA-seq 
Stage include acquisition of the sequence, read counting, data interpretation and data analysis 
 
Although this next generation sequencing technique has many benefits over traditional 
analyses, there are some obstacles which have been encountered in previous otosclerosis 
gene expression studies that are likely to remain issues when employing an RNA-seq approach. 
These include difficulties in gaining access to appropriate human tissue. This is particularly 
problematic in regards to acquisition of large numbers of control stapes, as there are few 
clinical scenarios during which healthy stapes are removed. It is also likely to be true of 
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ascertainment of otosclerotic stapes footplates, as the stapedotomy procedure where the 
footplate is not routinely removed is standard practice in the UK. 
Furthermore, the RNA-seq technique also has a number of additional limitations. The 
fragmentation process performed during library construction may introduce experimental bias 
by leading to an under-representation of RNAs with a stable secondary structure, including 
non-coding RNAs and those with a high GC content (Risso et al., 2011). In addition, during RNA-
seq, since more reads will map to long than short transcripts of similar expression levels, short 
transcripts are at an inherent statistical disadvantage over longer transcripts (Oshlack and 
Wakefield, 2009). A similar issue is true of genes expressed at low levels such as transcription 
factors, when comparing expression of genes between experimental groups, as when absolute 
differences in expression levels of a specific transcript are compared, those expressed at low 
levels will be less likely to be significantly different between groups than more highly 
expressed transcripts. To overcome this obstacle, it is essential to consider relative expression 
levels of transcripts between experimental groups in addition to absolute expression levels. 
Furthermore, false positive results may occur during RNA-seq due to misalignment of reads, 
and are particularly common in gene families with paralogous members or genes with highly 
repetitive regions. RNA-seq also leads to issues with downstream computational analysis as a 
result of the large volumes of data generated which must be analysed, validated and 
interpreted. Despite attempts to streamline analysis of such data between research groups, 
there is currently no consensus as to the best method of data analysis. This introduces an 
element of variability in analysis techniques between research groups and subjectivity in 
interpretation of findings (Ozsolak and Milos, 2011). Moreover, this technique is more 
expensive than traditional microarray based techniques, costing roughly $1,000 U.S. to 
perform per sample. Despite these limitations, the great potential benefits associated with 
whole transcriptome profiling combined with a steady reduction in cost, has meant that RNA-
seq has emerged as a popular technique of choice for researchers performing gene expression 
analysis (Qi et al., 2011). 
Here, a small number of otosclerotic and unaffected stapes samples were subjected to RNA-
seq in order to provide a transcriptome-wide gene expression dataset. Differentially expressed 
genes of interest within the otosclerotic stapes identified within this small discovery group, 
were further investigated using qRT-PCR in a larger cohort of stapes. In this chapter, the choice 
of stapes selected for RNA-seq will be discussed, along with statistical analysis of the data 
obtained, in order to provide a stapes gene expression dataset and to identify genes 
significantly dysregulated in otosclerotic stapes compared to unaffected stapes. Functional 
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annotation and pathway analysis performed on datasets of these dysregulated genes will then 
be outlined and trends identified using this technique will be summarised. Following this, the 
choice of which dysregulated candidate genes to select for follow up single gene expression 
studies using qRT-PCR will be discussed, as well as the results from these single gene assays. 
The results and discussion sections will be combined in this chapter, as it is essential to 
interpret the findings following RNA-seq in order to select the best possible candidates for 
follow up analysis. An overall general discussion will summarise the findings at the end of the 
chapter in section ‎5.3. 
 
5.2 Results and Discussion 
5.2.1 Selection of stapes for RNA-seq 
Throughout the course of this research project, 110 otosclerosis patients were recruited to the 
surgical arm of the study. Of these study participants, 109 received stapedotomy surgery, 
during which their stapes suprastructure was collected, whilst one participant received a 
stapedectomy surgery, where their whole stapes was acquired. A further 11 stapes 
suprastructures and two footplates were collected from unaffected individuals receiving 
middle-ear surgery.  
Of these samples, twelve were selected for RNA-seq including four unaffected and eight 
affected stapes samples (Table ‎5.1). Within the unaffected group, which is referred to hereon 
as the control group, two whole stapes, one from each ear from the same individual 
(ConStap1L and ConStap1R) were dissected into footplate and suprastructure components and 
pooled. In addition, the whole otosclerotic stapes (OtoStap1) which had been collected during 
stapedectomy surgery, was also dissected into footplate and suprastructure components, 
which were analysed separately.  
 
5.2.1.1 Rationale for choice of stapes for RNA-seq 
During selection of stapes for RNA-seq, four control stapes samples were chosen in addition to 
eight otosclerotic samples. This enabled a comparison to be made between gene expression 
datasets in diseased and healthy tissue. The lack of control samples available was a major 
limitation when selecting stapes for sequencing. For this reason, RNA from all control stapes 
that had been collected at the time of sequencing were included in the RNA-seq study, and all 
that were subsequently collected were used in follow up analysis.  
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Sample ID 
Footplate/ 
Suprastructure 
Unaffected/ 
Confirmed 
otosclerosis 
Age at 
recruitment 
Gender Disease and Hearing status 
ConStap1L&RFP Footplate Unaffected 11 m 
Child with meningitis, whole 
stapes removed 
ConStap1L&RSS Suprastructure Unaffected 11 m 
ConStap2SS Suprastructure Unaffected 51 m 
Stapes removed following 
head trauma 
ConStap3SS Suprastructure Unaffected 34 f 
Exploratory surgery 
following injury to ear 
OtoStap1FP Footplate 
Confirmed 
otosclerosis 
50 m 
Peripheral 
fixation 
Conductive 
Hearing 
Loss OtoStap1SS Suprastructure 
Confirmed 
otosclerosis 
50 m 
OtoStap2SS Suprastructure 
Confirmed 
otosclerosis 
75 m 
Peripheral 
fixation 
Mixed 
Hearing 
Loss 
OtoStap3SS* Suprastructure 
Confirmed 
otosclerosis 
63 f 
Peripheral 
fixation 
Conductive 
Hearing 
Loss 
OtoStap4SS Suprastructure 
Confirmed 
otosclerosis 
36 f 
Peripheral 
fixation 
Conductive 
Hearing 
Loss 
OtoStap5SS Suprastructure 
Confirmed 
otosclerosis 
47 f 
Peripheral 
fixation 
Conductive 
Hearing 
Loss 
OtoStap6SS Suprastructure 
Confirmed 
otosclerosis 
56 f 
Peripheral 
Fixation 
Conductive 
Hearing 
Loss 
OtoStap7SS Suprastructure 
Confirmed 
otosclerosis 
37 m 
Peripheral 
fixation 
Conductive 
Hearing 
Loss 
 
Table ‎5.1 A table illustrating the twelve stapes selected for RNA sequencing 
* OtoStap3SS collected from individual III:3 in family B (Chapter 4) for whom WES was performed 
 
Since the stapes footplate is the predominant location of histologic changes during 
otosclerosis, it is important that a comparison can be made between expression patterns in 
the stapes footplate and suprastructure. Therefore all three stapes footplates collected, two of 
which were from the same unaffected individual and one of which was from an otosclerosis 
patient, were selected from the cohort for analysis. This will help to clarify any doubts 
concerning differences in gene expression between footplates and suprastructures.  
Stapes suprastructure OtoStap3SS was selected for sequencing because this stapes came from 
an individual who had a very strong family history of otosclerosis and was a member of one of 
the families selected for Whole Exome Sequencing (WES) (see chapter 4). It was hoped that 
the results from the RNA-seq on this particular stapes would assist in the candidate gene 
identification process following WES in this family.  
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The remaining otosclerotic stapes were selected from individuals of age range from 36-75, 
with peripheral fixation of the stapes which is indicative of early or mid-stage disease, who had 
either conductive or mixed hearing loss. By selecting stapes with early or mid-stage stage 
disease, the samples were standardised as much as possible, in order to increase the likelihood 
of finding any differentially expressed genes, as it would be expected that individuals with 
similar disease characteristics would also share similar gene expression profiles in their stapes. 
Approximately equal numbers of individuals of each gender were selected (3 male and 4 
female stapes suprastructures) to account for any gender-specific changes in gene expression. 
It is important to account for this due to the reported variation in incidence of otosclerosis 
between the genders. 
Due to the high cost of RNA-seq, only small numbers of stapes were included in the analysis. 
This small cohort of stapes was therefore considered a discovery group. A larger cohort of 
stapes was later used to further investigate the results obtained. 
 
5.2.2 Overview of RNA-seq data 
RNA-seq was performed on twelve individual stapes samples by the U.S.A based sequencing 
company Otogenetics Corp (Norcross, GA). Before the samples were sent to Otogenetics, a 
quality control procedure was performed on the cDNA isolated from each of the stapes 
samples using the Agilent Bioanalyzer 2100. The results obtained were sent to Otogenetics 
which confirmed that the sample integrity and quantities of cDNA were sufficient for RNA-seq. 
The samples were then sent to Otogenetics which performed cDNA fragmentation on the 
samples and constructed cDNA libraries before carrying out high-throughput paired-end RNA 
sequencing using Illumina HiSeq 2000. Paired-end 100 nucleotide reads were aligned to human 
genomic assembly hg19, which generated a read count for every transcript. An average of 2.3 
billion bases and 23 million reads were generated per sample (Table ‎5.2). This data was 
analysed using the platform provided by DNAnexus Inc (Mountainview, CA), a cloud-based 
data analysis platform for sequencing data.  
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Sample ID Total bases Total reads 
ConStap1L&RFP 2,788,077,000 27,880,770 
ConStap1L&RSS 2,899,915,000 28,999,150 
ConStap2SS 3,036,257,600 30,362,576 
ConStap3SS 2,903,808,400 29,038,084 
OtoStap1FP 3,307,667,000 33,076,670 
OtoStap1SS 2,436,615,000 24,366,150 
OtoStap2SS 843,953,600 8,439,536 
OtoStap3SS* 2,782,302,200 27,823,022 
OtoStap4SS 3,272,769,800 32,727,698 
OtoStap5SS 2,167,111,800 21,671,118 
OtoStap6SS 903,777,800 9,037,778 
OtoStap7SS 2,269,353,400 22,693,534 
 
Table ‎5.2 Table showing a summary of RNA-seq statistics for each sample  
* Stapes from individual III:3 in family B (Chapter 4) for whom WES was performed 
 
Through DNAnexus the expression level of each transcript was quantified through two tools 
for expression profiling of annotated transcripts; RNA-Seq and 3SEQ/transcriptome.  Using 
these tools, the expression levels of specific transcripts were quantified by mapping reads 
against a reference transcriptome, generating a measure of RNA relative abundance for 21,563 
annotated genes. This data was represented in two formats; RPKM (reads per kilobase of 
transcript per million mapped reads) values and z scores. The statistical analysis performed on 
the RPKM values and z scores generated for each gene are discussed in sections ‎5.2.3.1 
and ‎5.2.3.2 respectively.  
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5.2.3 Identification of a gene expression profile in human stapes 
suprastructures 
To compare gene expression datasets for affected and control stapes, two statistical analyses 
were performed in parallel, using the RPKM data and z score data independently. This analysis 
was performed using only the data from stapes suprastructures, in order to avoid introducing 
inconsistency and bias through use of the footplate data.  
 
5.2.3.1 RPKM analysis 
The RPKM value  is a measure of the level of expression of a transcript which is calculated by 
normalising the read count for the transcript against the transcript length across samples of 
varying coverage. This enables expression levels of transcripts to be compared without bias of 
transcript length. To identify differential expression in control and affected human stapes 
suprastructures from the RPKM data, a two tailed paired Student’s t-test was conducted on all 
21,563 annotated genes, to identify those genes with a significant difference in expression 
between the control and affected groups. The fold difference in expression between the mean 
RPKM for the control and affected groups was also calculated because t-tests frequently result 
in arbitrarily small fold-changes in expression being considered statistically significant. It is 
generally considered that genes are differentially expressed if they show a fold-change of at 
least 1.5 and also satisfy p value threshold of 0.05 (Raouf et al., 2008). In total 2,220 genes met 
both these criteria with 1,673 genes found to be significantly down-regulated in human stapes 
suprastructures compared to controls and 547 found to be significantly up-regulated 
(Table ‎5.3).  
During statistical analysis of large gene expression datasets such as these, where multiple 
comparisons have been performed, the probability of incorrectly assigning significance to a 
gene is in excess of 0.05. Therefore corrections for multiple testing were performed on the 
RPKM dataset. A Bonferroni correction was carried out in order to control for the probability of 
incorrectly assigning significance; however none of the differentially expressed genes in stapes 
suprastructures reached significance after Bonferroni correction. Therefore the False Discovery 
Rate (FDR) was also calculated. This exerts less stringent controls over false discovery than the 
Bonferroni correction, however again, none of the transcripts reached significance (Benjamini 
et al., 2001). Although this raises concerns regarding false positive results in the data, it has 
been postulated that Bonferroni and FDR corrections are too stringent for transcriptome-wide 
expression data and are not routinely applied to whole transcriptome analysis.  
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5.2.3.2 z score analysis 
The z score is a measure of the level of expression of a transcript, a statistic which is generated 
from just one read per transcript, calculated from the read count. It is normalised by the total 
number of reads in the sample, thus allowing a comparison of data between samples. From 
the z score data, z ratios were calculated by dividing the difference in mean z score between 
the affected and control stapes by the standard deviation of difference in mean z score across 
all 21,563 annotated genes. This normalises the dataset in order to reduce bias across the 
samples.  A z ratio that is greater than ±1.96 is considered to be significant at 95% confidence 
intervals (Cheadle et al., 2003). A positive z ratio represents genes that are up-regulated in 
otosclerotic stapes compared to controls whilst negative z ratios represent down-regulated 
genes. In total of the 21,563 annotated genes, 176 were found to be dysregulated; 97 were 
found to be up- regulated and 79 down-regulated in otosclerotic stapes (Table ‎5.3). 
 
5.2.3.3 A comparison of RPKM and z score gene expression datasets 
Genes identified as significantly differentially expressed through analyses of RPKM values, 
were compared with those identified through the z score analysis, and only those that reached 
significance in both analyses were prioritised for further analysis. In total, 101 genes were 
dysregulated in both datasets; 51 genes that were down-regulated and 50 that were up-
regulated (Table ‎5.3). The full list of 101 dysregulated genes can be found in the Appendix. 
 
 
RPKM 
[p value threshold = 0.05 & 
Fold difference threshold = 1.5] 
z ratio 
[Threshold = +/- 1.96] 
Overlap 
Up-regulated 547 97 50 
Down-regulated 1673 79 51 
Total 2220 176 101 
 
Table ‎5.3 Table showing the number of up and down-regulated genes identified during RNA-seq 
Table shows numbers of genes that met statistical analysis thresholds for the RPKM analysis, z ratio analysis and the 
total number of genes that met threshold criteria in both analyses 
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5.2.4 Identification of a gene expression profile in human stapes footplates 
Statistical analysis was also performed on the stapes footplate data in order to identify if there 
was any overlap in genes found to be dysregulated in otosclerotic suprastructures and 
footplates. Since only one control and one affected stapes footplate had undergone RNA-seq, 
a Student’s t-test was not possible as this statistical test relies on there being multiple data 
points within a single group. For this reason, RPKM data was not analysed for the footplate 
samples. z ratios were calculated by dividing the difference in z score between the affected 
and control footplate by the standard deviation of difference in z score across all 21,563 
annotated genes. In total, of the 21,563 annotated genes, 97 were found to be dysregulated in 
the footplate samples; 6 were found to be up-regulated and 91 down-regulated. These 97 
genes were then compared with those found to be dysregulated in the suprastructure samples 
based on z score analysis. In total, 63 genes were dysregulated in both tissue types; 4 genes 
that were up-regulated and 59 that were down-regulated (Figure ‎5.2). 
 
Figure ‎5.2 Venn diagram illustrating overlapping dysregulated genes from stapes suprastructure and footplate 
analyses  
Number of genes identified is based on z score data analysis 
 
The predominant focus of this chapter is on the genes found to be dysregulated in stapes 
suprastructures rather than footplates. This is because since only one control and one affected 
footplate sample was available for analysis; confidence in the results from the footplate 
analysis is not as strong as for the suprastructure analysis. Having said this, genes that were 
found to be dysregulated in stapes footplates in addition to suprastructures were considered 
as good potential candidates for follow up gene expression analysis in the remainder of the 
cohort (see section ‎5.2.6). 
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5.2.5 Identifying molecular pathways in the stapes gene expression 
transcriptome 
The stapes gene expression dataset identified during z score analysis was analysed using two 
tools; Ingenuity Pathway analysis (IPA) (http://www.ingenuity.com), and the DAVID functional 
classification tool (http://david.abcc.ncifcrf.gov). Each of these tools will be discussed in turn 
before pathways identified from use of both tools are summarised. 
 
5.2.5.1 Ingenuity Pathway Analysis 
Gene network analysis was performed using Ingenuity Pathway Analysis (IPA) on all 176 
significantly dsyregulated genes identified in stapes suprastructures based on the z score 
analysis. This was chosen, as opposed to the gene list identified through RPKM analysis, 
because z score data is normalised by the total number of reads in each sample, meaning that 
greater confidence can be had in genes identified through this technique than RPKM analysis. 
A network score was generated by IPA for each network of genes identified. This score takes 
into account the likelihood of a group of genes being identified in a single gene network purely 
by chance. (Letwin et al., 2006). The figure below illustrates the five highest scoring networks 
identified using IPA (Figure ‎5.3). 
 
Figure ‎5.3 Bar graph showing five highest scoring networks from IPA analysis and their respective network scores.  
Networks with a score greater than 2 are considered to be statistically significant with confidence of 99% (Letwin et 
al., 2006) 
70 
44 
42 
33 
24 
0 10 20 30 40 50 60 70 80
Cancer
Hematological Disease
Protein Synthesis
Cancer
Tumor Morphology
Hair and Skin Development
Cancer
Gastrointestinal Disease
Hepatic System Disease
Cardiovascular Disease
Cellular Development
Connective Tissue Development
Developmental Disorder
Hereditary Disorder
Neurological Disease
IPA Network score 
G
en
e
 N
e
tw
o
rk
 
 
 
185 
 
IPA was also used to identify trends in biological functions amongst the dysregulated genes. 
This analysis considers the number of genes in the dataset that are involved in three biological 
function categories; diseases and disorders, molecular and cellular functions, and physiological 
system development and function. The graph below shows the five top biological functions for 
each of these three criteria including the number of genes dysregulated within each category 
(Figure ‎5.4).  
 
Figure ‎5.4 Bar graphs showing top biological functions identified during IPA analysis  
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5.2.5.2 DAVID Functional classification analysis 
The 176 significantly dsyregulated genes identified in stapes suprastructures based on the z 
score analysis were also analysed using the gene functional classification tool DAVID 
Bioinformatics resource v6.7, in order to identify functionally related gene groups within the 
list of dysregulated genes (http://david.abcc.ncifcrf.gov). This was performed by analysing the 
Gene Ontology (GO) terms attributed to each gene. These are standardised terms that 
represent gene and gene product attributes across species and databases 
(http://www.geneontology.org/), thus allowing cross-comparisons to be made between gene 
functions in order to group together those genes with shared or similar functions. Genes that 
were both significantly up and down-regulated were analysed using the DAVID functional 
classification tool. During analysis, clusters of genes were assigned an enrichment score based 
on agreement between GO terms, with a higher score representing greater similarity between 
terms. The three highest scoring clusters for up-regulated genes are genes encoding zinc finger 
proteins, transcription factors and purine nucleotide binding proteins, whilst the three highest 
scoring clusters for down-regulated genes are ribosomal genes, genes encoding leucine-rich 
repeat proteins and myosin proteins (Table ‎5.4).  
Gene Cluster 
Up or 
Down-regulated 
No. 
genes 
Top 3 scoring 
genes in cluster 
Enrichment score 
Zinc Finger Proteins Up-regulated 8 
ZBTB8A 
ZNF793 
ZNF461 
1.17 
Transcription Factors Up-regulated 4 
SIX4 
FOXK1 
TAF8 
0.39 
Purine Nucleotide Binding 
Proteins 
Up-regulated 6 
HSP90AB2P 
CAM1KD 
PTK6 
0.35 
Ribosomal Genes Down-regulated 36 
RPL23A 
RPL15 
RPS25 
40.87 
Leucine-rich Repeat 
Proteins 
Down-regulated 6 
LUM 
OMD 
ASPN 
1.32 
Myosin Proteins Down-regulated 3 
MYL6 
MYL12A 
MYL12B 
2.70 
 
Table ‎5.4 Table of the three top scoring gene clusters for both up and down-regulated genes from the RNA-seq 
dataset 
Clusters identified from functional gene classification using DAVID (http://david.abcc.ncifcrf.gov).  
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5.2.5.3 Discussion of pathway and functional classification analysis 
Both the IPA gene network and biological function analysis suggest that the dataset is highly 
enriched for genes involved in cancer. Cancer-related gene networks constitute the three top 
scoring networks, and 71 out of the 176 dysregulated genes are known to be involved in 
cancer, based on biological function analysis. Since both cancer and otosclerosis are 
characterised by cellular hyperproliferation, it is of interest that these conditions share 
molecular pathways. It is therefore more likely that dysregulated genes involved in cell 
proliferation are markers of disease tissue rather than genes involved in disease pathogenesis. 
However, caution must be taken when interpreting this as due to an overwhelming body of 
research on the genetics of cancer, an extremely large number of genes have been implicated 
in the various forms of this disease through numerous different genetic studies. This makes it 
more likely that genes with a known involvement in cancer will be present in any randomly 
selected group of genes in comparison to other disorders which have not been investigated in 
so much depth.  
The IPA gene network analysis and biological function analysis also suggest that the dataset is 
highly enriched for genes involved in connective tissue disorders with 33 out of the 176 
dysregulated genes known to be involved in connective tissue disorder pathways. In addition, 
the DAVID functional classification analysis suggests that the dataset is over-represented for 
genes containing leucine- rich repeats, a motif which is frequently found in connective tissue 
proteins (Bengtsson et al., 1995). Since it has been suggested that otosclerosis occurs 
concomitantly with other connective tissue disorders, it is possible that genes involved in such 
disorders may also be involved in the otosclerosis disease process. These 33 dysregulated 
genes are known to be involved in numerous connective tissue disorders, three of which have 
been linked to at least three of the dysregulated genes in the otosclerosis dataset. 29 
dysregulated genes are involved in arthritis, and three in each of osteosarcoma and pigmented 
villonodular synovitis, a disease characterised by inflammation and overgrowth of the joint 
lining (Figure ‎5.5). One of these genes, SPP1 (Osteopontin), which is involved in the 
attachment of osteoclasts to the mineralised bone matrix, is involved in all three of these 
disorders. Genes involved in these disorders are therefore excellent candidates for 
involvement in disease pathogenesis. Having said this, it must also be taken into consideration 
that since RNA-seq was performed on RNA extracted from bone tissue, genes encoding 
connective tissue proteins that form key constituents of bone are likely to be dysregulated in 
otosclerotic stapes. It is therefore possible that these genes could be markers for disease 
tissue rather than being involved in disease pathogenesis.   
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Figure ‎5.5 Venn diagram showing the dysregulated genes known to be involved in arthritis, osteosarcoma and  
pigmented villonodular synovitis 
 
The IPA biological function analysis of molecular and cellular functions also suggests that the 
dysregulated gene list is enriched for genes involved in functions involved in translational 
processes including protein synthesis, gene expression and RNA post-transcriptional 
modification. This coincides with the outcome from the DAVID analysis where 36 dysregulated 
ribosomal genes were identified in the dataset, with an extremely high enrichment score of 
40.87. Since ribosomes are involved in the translational process, dysregulation of large 
numbers of these genes are likely to have an impact on protein synthesis and gene expression. 
It is therefore possible that local dysregulation of ribosomal genes is common in this type of 
gene expression analysis where disease tissue is being compared with healthy tissue. These 
findings may therefore suggest that aberrant expression of ribosomal genes is a result of the 
disease process rather than a causative factor.  
The IPA biological function analysis of physiological system development and function suggests 
that genes involved in immune cell trafficking and endocrine system development and 
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function are enriched in the list of dysregulated genes. This coincides with suggestions in the 
literature that viral infection and hormones may be involved in otosclerosis. It is likely that if 
these factors are involved in otosclerosis pathogenesis, that genes encoding proteins involved 
in these functions would be dysregulated in the diseased stapes. Since the evidence for viral 
infection and a hormonal role in disease pathology from previous research studies is 
somewhat conflicting, the outcome of this analysis could provide some supporting evidence 
for the previous studies that made a positive link between these factors and otosclerosis. 
The DAVID functional classification analysis also suggests that both zinc finger proteins and 
transcription factors are over-represented in the list of dysregulated genes. Since both these 
groups encode proteins involved in regulating gene expression, it is possible that dysregulation 
of these genes could be involved in regulation of a large numbers of other genes and gene 
pathways.  Given that both zinc finger proteins and transcription factors have previously been 
suggested by various research groups as possible contributors to otosclerosis pathophysiology 
and that both have been implicated in numerous other genetic diseases, it is possible that 
dysregulation of these could contribute to development of otosclerosis.  
Pathway and functional classification analysis can be useful in the identification of interacting 
genes and those with shared biological functions. However, since genes interact with one 
another as well as environmental factors in numerous interacting pathways, of which few have 
been well characterised, the identification of a dysregulated gene or group of related genes 
may indicate involvement in a disease process but cannot be used to identify a causative gene. 
It is also possible that these dysregulated genes are markers for the disease rather than being 
involved in the pathologic switch that leads to otosclerosis in the stapes. For this reason, any 
findings obtained during pathway or functional classification analysis must be considered in 
the relevant context and their impact should not be over-stated. Having said this, such tools 
are extremely useful for helping to prioritise genes for follow up analysis after RNA-seq, as is 
discussed in the following section.  
 
5.2.6 Selection of candidate genes for follow up gene expression studies 
A small number of genes dysregulated in the discovery group were selected as interesting 
candidates for follow up gene expression analysis in the remainder of the cohort. All were 
selected from the list of 101 genes that were found to be significantly dysregulated through 
both z score and RPKM analysis. By prioritising overlapping genes from both analyses, greater 
confidence can be had that the each gene is significantly dysregulated in the otosclerotic 
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stapes than by using the results of just one analysis alone. In order to ensure that the genes 
most likely to be involved in the disease process were selected for follow up, all 101 genes 
were annotated by gathering further information from online databases. These annotations 
combined with the pathway analysis and functional annotation analysis, revealed that eight of 
the 101 genes had roles in bone growth and maintenance and two were involved in hearing 
loss, according to data from the Gene Cards website (Table ‎5.5). Mutations within four of 
these genes led to bone and growth defects when mutated in mice whilst mutations in one of 
these genes caused a hearing loss phenotype in mice, based on information from the JAX lab 
website. One of these genes has been implicated in the connective tissue disorder Ehlers 
Danlos Syndrome, according to the OMIM website. These annotations prioritised genes most 
likely to have an impact on bone regulation or conductive hearing loss, or to be involved in 
another connective tissue disorder, as genes involved in these processes are good otosclerosis 
candidates. 
Website Bone abnormalities Hearing anomalies Connective Tissue 
Disorders 
 
Gene Cards 
 
8 2  
JAX lab  
(Jackson Lab - Mouse 
Genome Informatics) 
4 1  
OMIM 
(Online Mendelian 
Inheritance in Man) 
  1 
 
Table ‎5.5 Table showing the number of genes known to be involved in bone abnormalities, hearing anomalies 
and connective tissue disorders  
Number of genes identified from data obtained from three online databases. 
 
In addition to these annotations, when selecting the most promising dysregulated genes for 
further investigation studies in larger numbers of stapes, it was also taken into account if 
genes were located within one of the eight otosclerotic loci identified during linkage analysis, 
found to be dysregulated in the 2008 gene expression analysis of otosclerotic stapes (Ealy et 
al., 2008), or contained variants that had been associated with otosclerosis during the 2009 
Genome Wide Association Study (Schrauwen et al., 2009a). However, none of these genes 
were found to be dysregulated in the Ealy et al. study, nor were any associated SNPs identified 
within these genes in the otosclerosis Genome Wide Association Study. Although four of the 
genes were located in linked regions, all of these were located in the two largest linked 
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regions, OTSC3 and OTSC10, which contain 423 and 148 protein coding genes respectively. 
Since these genes were located within linked regions containing such a large number of 
possible genes, it was decided that these genes would not be prioritised solely on this basis. 
Genes were also given greater priority for follow up analysis if they were found to be 
differentially expressed in stapes footplates as well as stapes suprastructures, since the stapes 
footplate is the predominant location of histologic changes during disease.  
 
5.2.6.1 Six candidate genes of interest were selected for further investigation 
Six genes of interest were selected for follow up studies using qRT-PCR, including three that 
were up-regulated and three that were down-regulated in otosclerotic tissue. Based on the 
annotations derived from the three online databases, as well as taking into account gene 
expression in footplate samples, the following six genes illustrated in Table ‎5.6 were selected. 
 
Gene 
Up or down 
regulated 
z ratio 
RPKM 
Dysregulated in 
footplates p value 
Fold 
difference 
ASPN  
(Asporin) 
Down -3.02 0.0004 5.3 No 
FBLIM1 
(Filamin binding LIM 
protein 1) 
Up 2.6 0.0009 2.0 No 
FKBP14 
(FK506 binding 
protein 14) 
Up 4.0 0.03 1.5 No 
LAIR1 
(leukocyte-associated 
immunoglobulin-like 
receptor 1) 
Up 2.6 0.01 1.7 No 
LUM 
(Lumican) 
Down -16.3 0.006 2.7 Yes (z=-13.9) 
SPARCL1 
(SPARC-like 1) 
Down -3.9 0.002 3.4 Yes (z= -3.0) 
 
Table ‎5.6 Table illustrating the 6 genes prioritised for follow up analysis in the remainder of the cohort 
The table highlights the 6 genes selected for follow up analysis. The table identifies the gene name, whether it was 
found to be up or down-regulated during the RNA-seq study, the z ratio, p value and fold difference calculated 
during statistical analysis for each gene, the role of the gene according to annotations and whether or not the gene 
was also found to dysregulated in stapes footplates 
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5.2.6.2 Justification for selection of six candidate genes for further analysis 
The gene which was found to be the most significantly down-regulated in otosclerotic stapes 
compared to controls based upon RPKM values is Asporin (ASPN). ASPN is one of the six 
leucine-rich repeat proteins identified during the DAVID functional classification analysis and is 
known to be highly expressed within cartilage. It is thought to regulate chondrogenesis by 
inhibiting TGFβ-1 induced gene expression. Since members of the TGFβ superfamily have been 
associated with otosclerosis during association studies, ASPN is an excellent otosclerosis 
candidate. It is also known to bind both collagen and calcium and is thought to induce collagen 
mineralisation. Polymorphisms within this gene have been associated with osteoarthritis, 
suggesting that this gene may be involved in disorders characterised by bone defects.  
ASPN is located in a cluster of four linked genes on chromosome 9q22. The other genes within 
this cluster are Osteomodulin (OMD), Osteoglycin (OGN) and Extracellular matrix protein 2 
(ECM2). All four of these genes are extracellular matrix proteins that are members of the small 
leucine-rich proteoglycan family and are all bone or cartilage extracellular matrix proteins. Like 
ASPN, ECM2 is significantly downregulated in the otosclerotic suprastructures based on RPKM 
calculations, although this is not the case for z score calculations (Figure ‎5.6). In contrast, OMD 
is significantly downregulated based on z score calculations but not RPKM values. OGN does 
not reach significance in either statistical analysis but regulation appears to be in the same 
downward direction in otosclerotic stapes. Given that these genes are linked, share similar 
functions and show a general trend of down-regulation in the otosclerotic stapes, it raises the 
possibility that they may be involved in the development of disease. In addition, since these 
four genes are also linked in the mouse, it suggests that this cluster is evolutionarily conserved, 
indicating that these genes may share various crucial gene functions. For this reason, ASPN, 
the most significantly dysregulated of these four genes and the only one significantly down- 
regulated based in both RPKM and z score analysis, is an excellent candidate for follow up gene 
expression studies. 
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Figure ‎5.6  Bar graph showing the RPKM fold difference and p values as well as the z ratios calculated for each of 
the four linked genes located within the cluster on chromosome 9q22 
 
In addition to ASPN, two other leucine-rich repeat extracellular matrix proteins identified 
during DAVID functional classification analysis, Lumican (LUM) and SPARC-like 1 (SPARCL1) 
were selected for follow up. LUM is a gene known to regulate collagen fibril organisation and 
to be secreted by osteoblasts. It is therefore possible that reduced expression of LUM in 
otosclerotic tissue could be caused by abnormal osteoblast function. LUM also has many 
similarities to another small leucine-rich proteoglycan called Decorin (DCN), a component of 
connective tissue which binds to type I collagen fibrils and plays a role in bone matrix 
assembly, which was also found to be downregulated in otosclerotic suprastructures based on 
z score analysis. SPARCL1 is a non-collagenous bone constituent known to function in 
morphogenesis of the inner ear, thus making it an excellent otosclerosis candidate gene. Both 
LUM and SPARCL1 were also found to be dysregulated in otosclerotic footplates, giving further 
evidence to suggest that these genes may be involved in the otosclerosis disease process.  
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Among the up-regulated genes, FK506 binding protein 14 (FKBP14) was identified as a 
promising candidate gene for follow up qRT-PCR. This gene is known to be involved in 
accelerated protein folding and has been identified as a causative gene in a specific form of the 
connective tissue disorder Ehlers Danlos syndrome that is associated with sensorineural 
hearing loss (Baumann et al., 2012). This is therefore an excellent otosclerosis candidate gene 
and so was selected for follow up analysis.  
Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) was also prioritised for follow 
up. This encodes a receptor found on the surface of mononuclear cells, a type of cell that 
differentiates into osteoclasts during bone remodelling. This receptor is known to interact with 
extracellular matrix collagens in regulation of the immune system. Given that it has been 
suggested that otosclerosis may be an autoimmune condition and that otosclerosis is 
characterised by abnormal bone remodelling within the otic capsule, LAIR1 is also a promising 
candidate for follow up studies. 
Filamin binding LIM protein 1 (FBLIM1) was also selected. This gene is involved in actin 
filament assembly and stabilisation in the cell. Although it doesn’t have a role that suggests 
obvious involvement in otosclerosis pathology, it was selected for follow up due to the 
extremely low p value calculated during RPKM analysis. Unlike the down-regulated gene list 
where there were numerous good candidate genes to select from, there were fewer good 
candidates in the set of up-regulated genes. For this reason FBLIM1 was selected for follow up.  
 
5.2.7 qRT-PCR assays on the six genes selected for follow up analysis 
The expression levels of the three genes, ASPN, LUM and SPARCL1, that were found to be 
down-regulated through RNA-seq in 7 otosclerotic and 3 control stapes suprastructures, were 
analysed in a larger cohort of 81 additional otosclerotic and 5 additional control stapes using 
qRT-PCR Taqman® assays (Figure ‎5.7). The results of these assays showed that ASPN was 
expressed at significantly lower levels in the otosclerotic stapes relative to control samples 
with the relative quantification (RQ) value for ASPN being 0.35, representing an approximately 
three fold reduction in expression. However, the results showed that LUM and SPARCL1 were 
expressed at significantly higher levels in otosclerotic compared to control samples in the 
larger stapes cohort. This finding was unexpected as it showed an opposite trend in expression 
of LUM and SPARCL1 to that shown in the RNA-seq study.  
It was noticed that the cycle threshold (CT) values of all three replicates for one of the control 
assays for LUM were substantially higher than for the other controls, with an average ∆CT 
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value of 17.98 compared to 12.30 for the remainder of the control replicates. This represents a 
fold difference of 25.68 which is equivalent to a 51.27 fold difference in expression for this 
sample. Therefore, this outlier was excluded from the analysis (Figure ‎5.7). This is discussed in 
more detail in section ‎5.2.7.1. 
 
 
Figure ‎5.7 Graph showing relative expression of 3 down-regulated genes in control and otosclerotic stapes 
ASPN, LUM, LUM with outlier removed and SPARCL1 relative expression in 5 control stapes (grey) compared to 81 
otosclerotic stapes (white). 18s ribosomal RNA served as an endogenous control. Error bars represent 95% 
confidence intervals. 
 
The expression levels of the three genes, FBLIM1, FKBP14 and LAIR1, that were found to be up-
regulated through RNA-seq of 7 otosclerotic and 3 control stapes suprastructures, were also 
analysed in the larger cohort of 81 additional otosclerotic and 5 additional control stapes using 
qRT-PCR Taqman® assays. However, the FBLIM1 assay was unable to detect the presence of 
FBLIM1 mRNA in the majority of stapes samples (data not presented). This is discussed in 
detail in section ‎5.2.7.1. The results of the Taqman® assays for the additional two up-regulated 
genes showed that FKBP14 and LAIR1 were both expressed at significantly lower levels in the 
otosclerotic stapes relative to control samples (Figure ‎5.8). This trend is in the opposite 
direction to the trend shown in the data from the RNA-seq study.  
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Figure ‎5.8 Graph showing relative expression of 2 up-regulated genes in control and otosclerotic stapes  
FKBP14 and LAIR1 relative expression in 5 control stapes (grey) compared to 81 otosclerotic stapes (white). 18s 
ribosomal RNA served as an endogenous control. Error bars represent 95% confidence intervals. 
 
5.2.7.1 Discussion of discrepancies between RNA-seq and qRT-PCR data 
A likely explanation for the discrepancy in findings between the RNA-seq study and the qRT-
PCR analysis is the small number of otosclerotic and control stapes analysed in the RNA-seq 
study, in addition to the small number of control stapes available for follow up qRT-PCR assays. 
These small sample sizes reduce the reliability of the findings, particularly in the case of 
transcripts with variable expression between samples. Since otosclerosis is thought to be a 
multigenic complex disease, caused by mutations in a variety of different genes as well as a 
number of environmental contributors, it is possible that different genetic factors are 
responsible for the condition in different individuals, which could lead to varying patterns of 
gene expression between stapes. Therefore selecting just a small subset of the stapes for 
whole transcriptome analysis, may be misleading if these samples are not representative of 
diseased stapes in general. However, due to cost constraints, it was not possible to analyse 
large numbers of samples, a common problem encountered when using NGS techniques. This 
concern was raised at an early stage in the project, for which reason the otosclerotic stapes 
selected for sequencing were intentionally chosen to be representative of the cohort as a 
whole. However variability between samples is still likely to be an issue in such a small cohort. 
Due to the small size of the discovery group, particularly in regards to the control stapes, 
variability between samples is the most likely explanation for the differences in findings 
between the two gene expression assays.  
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This explanation is particularly convincing when explaining the difference in findings between 
RNA-seq and qRT-PCR assays for LUM, as this gene is extremely highly expressed in bone 
tissue. LUM has a mean RPKM value across all stapes suprastructures of 508.5 (Table ‎5.7) and 
therefore falls within the top 20 most highly expressed of all 21,563 genes annotated in the 
RNA-seq study. There is likely to be greater variability in absolute expression levels of more 
highly expressed genes between samples than lowly expressed genes, it is possible that 
dramatically different expression of a highly expressed gene in just one sample could skew the 
data. This was not a concern when performing the qRT-PCR assay on the otosclerotic stapes, as 
since a large number of samples were analysed, any anomalies would likely be averaged out. 
However, since only five control stapes were available for analysis, just one control sample 
could skew the data if it had a different level of expression to the majority of other controls. 
This theory is supported by the identification of the one control stapes with an exceptionally 
high CT value for LUM, which demonstrates that expression of this gene is variable between 
samples.  
An alternative possible explanation for the discrepancy in results between the RNA-seq study 
and Taqman® assays in regards to SPARCL1 is that this gene has numerous splice isoforms. The 
major transcript SPARCL1-001 (ENST00000282470) consists of 11 exons, of which the target for 
the Taqman® assay is located between exons 10 and 11. This means that this major isoform 
will be detected by the Taqman® assay. However, a number of other known SPARCL1 isoforms 
contain an additional exon located between exons 10 and 11. If these isoforms are expressed 
in stapes tissue, they will therefore not be detected using the Taqman® assay, although would 
have been using RNA-seq. This could provide a potential alternative explanation for the 
difference in outcome of the two studies.  
An explanation for the lack of detection of FBLIM1 in the Taqman® assays despite detection 
during RNA-seq, is that RNA-seq is a more sensitive technique and can therefore detect 
transcripts expressed at lower levels. This explanation is supported by the fact that FBLIM1 
was detected in just two of the five control and six of the 81 otosclerotic stapes (Table ‎5.7) 
during qRT-PCR, suggesting that this gene is expressed at low levels in the human stapes. 
Furthermore, in the two control samples in which FBLIM1 was detected, expression was not 
consistent across all replicates, as it was detected in just one of the three replicates in each 
case. This indicates that there may not have been sufficient cDNA for accurate detection of this 
transcript. Furthermore, the average CT value was 38.2 for affected stapes and 38.1 for control 
stapes further indicating low level expression of this transcript in the human stapes. In 
addition, FBLIM1 had the lowest normalised read count of all six genes prioritised for follow up 
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gene expression assays at just 0.11 across all suprastructures, when the normalised read count 
data from the RNA-seq study was analysed (Table ‎5.7). The low level of expression of this gene 
had been overlooked at earlier stages of analysis during the candidate gene selection process, 
as the focus had been on the RPKM and z score data rather than the normalised read count 
data. Since RPKM normalises the read count against the length of the transcript and z score 
normalises by the total number of reads, these statistics are useful when considering relative 
expression levels, but not as effective as normalised read count data when considering 
absolute levels of expression.  
 
Gene 
Up or 
down 
regulated 
Mean 
normalised 
read count 
across all 
suprastructures 
Mean RPKM 
value across all 
suprastructures 
No. (%) control 
suprastructures 
No. (%) 
otosclerotic 
suprastructures 
ASPN Down 1.65 50.8 5 (100%) 78 (96%) 
FBLIM1 Up 0.11 14.8 2 (40%) 6 (7%) 
FKBP14 Up 0.18 19.4 5 (100%) 64 (79%) 
LAIR1 Up 0.12 10.1 5 (100%) 70 (86%) 
LUM Down 14.29 508.5 5 (100%) 81 (100%) 
SPARCL1 Down 2.97 88.2 5 (100%) 79 (98%) 
 
Table ‎5.7 Table showing the normalised read count data from RNA-seq analysis for each of the three up and 
down-regulated genes selected for qRT-PCR analysis and number and percentage of control and affected stapes 
samples in which each transcript was detected. 
 
By observing the normalised read count data for all six genes selected for follow up analysis, it 
can be seen that the other two up-regulated genes FKBP14 and LAIR1 also have low mean read 
counts, especially compared to the three down-regulated genes. In addition, they were also 
found to be detected in fewer stapes during Taqman® assays than the three down-regulated 
genes. Whilst ASPN, LUM and SPARCL1 were detected in almost all of the 81 affected stapes, 
with the exception of two otosclerotic stapes for ASPN and one for SPARCL1, FKBP14 was 
detected in only 64 otosclerotic samples and LAIR1 in just 70 (Table ‎5.7). There is an issue 
associated with non-detection of transcripts during qRT-PCR, as the 7500 System SDS software 
used to analyse the results of the Taqman® assays assigns a CT value of 0 to samples that do 
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not meet threshold detection levels. These samples are therefore excluded from the analysis, 
meaning that only the small number of samples in which the mRNA is detected are analysed. 
This means that only those samples in which the gene is most highly expressed are included in 
the analysis, compromising the reliability of the results obtained. In order to tackle this issue, 
both FKBP14 and LAIR1 were re-analysed by assigning a maximum CT value of 46 to all samples 
in which the transcript was not detected, and the relative quantification values were 
calculated manually. This ensured that the lowly expressed transcripts, which may have 
required more rounds of cycling before the florescence signal crossed the detection threshold, 
were not omitted from the analysis. For this reason, all non-detected transcripts were assigned 
a CT value of 46, making the assumption that these transcripts may have been detected, had 
more than 45 rounds of cycling been performed. This enabled the findings to be re-assessed in 
order to increase the reliability of the results by ensuring inclusion of a greater number of 
samples. However, the re-analysis of the data did not cause any substantial changes to the RQ 
value with a decrease from 0.15 to 0.11 for FKBP14 and an increase from 0.06 to 0.07 for 
LAIR1.  
Since it is likely that any gene involved in the otosclerosis disease process, will be expressed in 
human stapes, genes that are not expressed or are expressed at very low levels in this tissue 
are not likely to be good pathologic candidates. In hindsight, it therefore seems that the three 
up-regulated genes selected for follow up assays were perhaps not the best choice, and that 
normalised read count data and absolute difference in expression levels between otosclerotic 
and control samples, in addition to fold difference, should have been considered when making 
the candidate gene selection.  
 
5.3 Discussion of RNA-seq  
In this study, the entire transcriptomes of 8 otosclerotic and 4 control stapes samples were 
sequenced using Illumina HiSeq 2000 paired end RNA-seq. Statistical analysis was performed 
to distinguish significant changes in gene expression between the diseased and control stapes 
suprastructures, providing stapes gene expression datasets for both otosclerotic and healthy 
stapes. This is the first study to perform transcriptome-wide NGS on human stapes and thus 
provides a unique dataset upon which to base future studies. The number of otosclerotic 
stapes analysed during this RNA-seq study are comparable to the most comprehensive 
published otosclerosis gene expression study conducted to date (Ealy et al., 2008) which 
employed a whole genome hybridisation array technique, and has the additional benefit over 
this previous study of  being able to detect and quantify previously uncharacterised transcripts 
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and those expressed at low levels. Furthermore, the follow up qRT-PCR analysis performed in 
81 additional otosclerotic stapes following this RNA-seq study was much larger than the nine 
otosclerotic stapes used for validation of the array-based study. 
Pathway and functional analysis using IPA and DAVID showed that the dataset was enriched 
for genes involved in pathways including immune cell trafficking and endocrine system 
development. These findings support the somewhat contradictory evidence in the published 
literature which suggests that viral infection and hormones such as oestrogen may be involved 
in otosclerosis pathogenesis. The analysis also showed that the dataset was enriched for genes 
encoding connective tissue proteins. Since otosclerosis is a connective tissue disorder and such 
disorders often occur concomitantly with other connective tissue disorders, these genes 
represent good pathologic candidates in otosclerosis. The dataset was also enriched for genes 
encoding regulatory proteins such as transcription factors and zinc fingers. Since regulatory 
proteins are known to be involved numerous genetic disorders, these findings could indicate a 
role for regulatory proteins in the disease process. However, the results from pathway analysis 
and functional annotation should not be over-stated due to limited knowledge on the complex 
nature of interacting gene networks. Despite this, the results of the pathway and functional 
annotation analysis were taken into consideration during the selection of candidate genes of 
interest for follow up analysis.   
A difficulty encountered during the candidate gene selection process was distinguishing 
between dysregulated genes that were likely to be involved in disease pathology, and genes 
that were dysregulated as a result of the disease process. It is likely that in disease tissue, there 
will be local dysregulation of genes that act as a pathogenic switch in initiating the change that 
leads to onset of symptoms, as well as genes whose expression is altered as a result of 
pathogenicity. The gene annotation stage for dysregulated genes was designed in an attempt 
to overcome this obstacle with the aim of prioritising those genes most likely to be involved in 
otosclerosis pathophysiology. However, it is possible that due to this, genes that are disease 
markers rather than causative factors were among those selected for follow up studies. 
A further limitation of the candidate gene selection process was the strategy involved in the 
selection of these genes for follow up analysis. Following annotation of the 51 down-regulated 
genes, a large number of good candidates emerged based on the biological role of the gene 
combined with statistical analysis of both suprastructure and footplate samples, enabling 
selection of three promising otosclerosis candidates for follow up. However, when the 50 up-
regulated genes were annotated, there were fewer good candidates to select for follow up. As 
a result, the three best possible choices were selected, however following analysis, when it 
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emerged that these genes selected were all expressed at very low levels, it became apparent 
that these had probably not been the best choice. In hindsight, it may have been more 
beneficial to have selected the six top candidates from the dysregulated gene set as a whole, 
not taking into consideration if genes were up or down-regulated. Alternatively, perhaps genes 
should have been selected based solely on statistical analysis findings and the gene functions 
should not have been considered. This would have resulted in a less biased approach to gene 
selection. In addition, it would have been beneficial to take into account the normalised read 
count data in addition to the RPKM data to identify genes that were expressed at high enough 
levels to be efficiently detected using qRT-PCR. Absolute difference in expression in addition to 
fold difference could also have been considered during the selection process. Whilst absolute 
difference was initially dismissed as a useful parameter due to concerns that it could 
discriminate against lowly expressed genes that may have been of interest such as 
transcription factors, in hindsight, it may have been useful to consider, as excluding it from the 
prioritisation process meant that three very lowly expressed genes were selected for follow 
up. If further genes were to be selected from the RNA-seq dataset for follow up in the future, it 
would be useful to take all factors into account to ensure that a balance is obtained between 
absolute and fold difference in expression. 
The relative expression levels of the three up and three down-regulated genes selected from 
the dysregulated gene set were analysed using qRT-PCR in a follow up cohort of 81 otosclerotic 
and 5 control stapes suprastructures collected at the Royal National Throat Nose and Ear 
Hospital in London. The relative expression levels of one of the three down-regulated genes, 
ASPN, was reduced in the otosclerotic stapes compared to controls in the larger stapes cohort, 
supporting the results from the RNA-seq study and suggesting a possible role for this gene in 
disease pathogenesis. However, the results from the RNA-seq study were not replicated in any 
of the other five genes selected for follow up analysis. The most likely explanation for this is 
the small size of the discovery group used for RNA-seq and the lack of available control stapes 
for analysis. This is a problem that was also encountered in the whole genome hybridisation 
array study which analysed gene expression in nine otosclerotic and seven control stapes (Ealy 
et al., 2008). During follow up analysis for this study, only two of seven dysregulated genes 
prioritised for validation were found to be dysregulated. The issue of non-validation during 
follow up analysis is therefore not unique to this RNA-seq study and has been encountered by 
other research groups investigating gene expression in otosclerotic stapes. It is likely that this 
is due to the small cohort sizes of the discovery groups used in both these studies, meaning 
that a number of possible dysregulated genes of interest may not have reached statistical 
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significance. Genes of interest may therefore have been overlooked in the datasets, leading to 
the selection of less desirable candidates for follow up analysis.  
Variability in expression levels of genes between samples is another crucial contributing factor 
to the lack of consistency between the results of the RNA-seq study and the qRT-PCR assays. It 
would have been desirable to perform Taqman® assays on the same stapes samples that had 
undergone RNA-seq to ensure that results from both assays were consistent. However, this 
was not possible because the cDNA samples sent for RNA-seq had been reverse transcribed 
using the highly sensitive SMARTer™ kit (Clontech) rather than using the Qiagen Omniscript 
Reverse Transcription kit, which was used for the samples analysed using Taqman® assays. 
cDNA processed using the Clontech kit is not suitable for Taqman® assays because 18s 
ribosomal RNA is not polyadenylated so is not reverse transcribed during the Clontech reverse 
transcription process. It is therefore not suitable for use as an endogenous control during the 
Taqman® assay. If it were possible to perform Taqman® assays on the same samples as the 
RNA-seq, it would be possible to evaluate whether or not the discrepancy in findings was due 
to differing patterns of expression between stapes.  
One of the greatest advantages of the data obtained during the RNA-seq study for this 
research project as a whole has been its value in regards to the WES study (chapter 4). The 
identification of dysregulated genes in the otosclerotic relative to control stapes during RNA-
seq has provided an invaluable tool to assist with prioritisation of candidate variants following 
WES. After WES, rare nonsynonymous variants identified in families exhibiting monogenic 
inheritance of otosclerosis were prioritised for segregation analysis if located within a gene 
found to be dysregulated in otosclerotic stapes during the RNA-seq study. This was extremely 
useful in highlighting good pathologic candidates in these families, in particular in family B, in 
which the stapes of the proband was one of those sequenced.  
In summary, this study has shown that RNA-seq can be used to facilitate the identification of 
genetic factors involved in complex disorders such as otosclerosis. However, this technique is 
limited by the high costs involved, which limits the number of samples that can be analysed 
and thus reduces the reliability of findings. Care must therefore be taken when selecting 
appropriate genes for follow up analysis, particularly in the case of lowly expressed genes and 
any findings must be followed up in a larger cohort of stapes using more cost-effective 
approaches. Despite the limitations associated with this technique, RNA-seq is an effective tool 
that can provide valuable information to elucidate the disease pathways involved in 
otosclerosis and in particular to help prioritise genes of interest for future research. 
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6 Investigating reelin (RELN) expression 
in otosclerotic stapes 
 
6.1 Introduction 
Reelin (RELN) is a an extracellular matrix protein involved in neuronal positioning during brain 
development (Quattrocchi et al., 2002), which was found to be associated with otosclerosis 
during a genome wide association study (Schrauwen et al., 2009a). Analysis of variants within 
694 Belgian-Dutch cases and controls, as well as a replication cohort of 455 French cases and 
480 controls, revealed a significant association signal that reached genome wide significance in 
the reelin (RELN) gene, spanning 180kb from intron 1 to 4 of this 65 exon gene. The association 
of this gene with otosclerosis was confirmed in a study of four additional European 
populations (Schrauwen et al., 2010a) as well as a study in a Tunisian population, which also 
suggested an interaction with sex (Khalfallah et al., 2010). However, the association was not 
replicated in an Indian population (Priyadarshi et al., 2010). The association with RELN was 
unexpected as there is no obvious role for the reelin protein, a large 388kDa protein 3,460 
amino acids in length, in the pathogenesis of otosclerosis.  
Subsequent expression studies have produced conflicting evidence regarding presence of the 
RELN transcript in human stapes tissue. Schrauwen et al.,  in their genome wide association 
study, successfully detected RELN transcripts in 1 of 2 human stapes footplate samples 
through semi-quantitative RT-PCR assays (Schrauwen et al., 2009a). However, a study 
published in 2011 by Csomor et al. did not detect RELN mRNA in 47 stapedial footplates using 
the same technique (Csomor et al., 2011). Despite absence of RELN mRNA, Csomor et al. did 
detect the reelin protein in stapes footplates using immunohistochemistry (Csomor et al., 
2011). Together with the fact that RELN is an unlikely candidate for an otosclerosis gene, 
evidence of a lack of expression in disease tissue raised concerns that the genetic link to RELN 
may be spurious.  
In this chapter, gene expression of RELN within human and mouse stapes bones has been 
investigated using a combination of Quantitative real-time PCR (qRT-PCR), Semi-quantitative 
Reverse Transcription PCR and RNA-seq, in order to clarify this discrepancy in the literature. 
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6.2 Results 
6.2.1 Selection of stapes for gene expression analysis 
The expression of RELN transcripts was investigated in stapes suprastructures from 78 
otosclerosis patients and 8 unaffected individuals, in order to clarify the conflicting reports on 
its expression in the published literature, and to investigate whether there was any difference 
in the expression of RELN in the stapes between individuals with otosclerosis and unaffecteds. 
The stapes cDNA used in this study included 71 otosclerotic and 5 unaffected control 
suprastructure samples for PCR assays and a further 7 otosclerotic and 3 control 
suprastructure samples as well as 1 otosclerotic and 1 control footplate sample for RNA-seq. 
Expression was investigated in both suprastructure and footplate samples to investigate 
whether there was any difference in expression of RELN between these two distinct parts of 
the stapes bone, which are believed to have different embryonic origins. See Table ‎6.1 for a 
summary of stapes analysed in this study. 
Species Stapes Samples 
Total no. 
Samples 
Gene Expression 
Assay 
No. Samples 
Used in Assay 
Human 
Control 
Suprastructures 
8 
PCR assays 5 
RNA-seq 3 
Control 
Footplates 
1 
PCR assays 0 
RNA-seq 1 
Otosclerotic 
Suprastructures 
78 
PCR assays 71 
RNA-seq 7 
Otosclerotic 
footplates 
1 
PCR assays 0 
RNA-seq 1 
 
Table ‎6.1 Table showing the total number of human stapes suprastructure and footplate samples used for PCR 
assays and RNA-seq 
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6.2.2 An alternatively spliced variant of RELN is detected in human stapes   
RELN is a large gene located on chromosome 7q21 which is composed of 65 exons. Two known 
protein coding isoforms exist in humans including the major full length RELN transcript 
ENST00000428762 (RELN-001) and an alternatively spliced RELN transcript ENST00000343529 
(RELN-002), which lacks the penultimate 6 nucleotide micro exon, exon 64. In addition, it has 
been proposed that a prematurely truncated RELN transcript exists in human tissue (Lambert 
de Rouvroit et al., 1999). In order to identify which of these isoforms were expressed in human 
stapes suprastructures, sequence-specific primers were designed to amplify each of two 
confirmed human RELN isoforms independently of one another using Semi-quantitative 
Reverse Transcription PCR. To amplify the major RELN transcript (RELN-001), the forward 
primer (A) was designed to span exons 63 and 64 with the 3’ end binding to exon 64 which is 
unique to the full-length transcript, whilst the reverse primer (B) was designed to bind to exon 
65 (Figure ‎6.1). To amplify the alternatively spliced RELN transcript (RELN-002), the forward 
primer (C) was designed to bind to exon 62 while the 5’ end of the reverse primer (D) was 
designed to bind to exon 65 with the 3’ end binding to exon 63, thus skipping the excised exon 
64 (Figure ‎6.1). Primers were also designed to amplify the prematurely truncated RELN 
transcript. Primer C was used as the forward primer, while the reverse primer (E) was designed 
to bind only to alternative exon 63a, which exists only in this isoform (Figure ‎6.1). GAPDH 
primers were also designed to confirm integrity of the cDNA samples. The primer sequences 
can be found in Chapter 2 Materials and Methods table 2.2.  
Subsequently, qRT-PCR was performed on the human stapes suprastructures in order to 
identify if there was any difference in the level of gene expression between the affected and 
control stapes. A Taqman® gene expression assay (Hs01022646-Applied Biosystems®) which 
bound to the exon-exon junction between exons 62 and 63 was performed, as the location of 
the target ensured that all three RELN isoforms would be detected if present (Figure ‎6.1). The 
Taqman® assay was carried out in triplicate for each otosclerotic sample, whilst six replicates 
were performed on cDNA from the five control samples.  
All PCR assays were performed on cDNA extracted from 71 otosclerotic and 5 control stapes 
suprastructures as well as on cDNA extracted from MG-63 cells, a human osteosarcoma cell 
line which served as a positive control for each PCR assay to demonstrate successful 
amplification of the desired DNA fragment. 
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Figure ‎6.1 Structure of the C-terminal region of the RELN gene and its three mRNA isoforms illustrating the 
positions of the Taqman® gene expression assay amplicon and isoform-specific primers  
A) Genomic exon structure of the C-terminus of the RELN gene (not to scale). Isoform-specific exons 63a and 64 are 
indicated by grey and hatched shading respectively. Exon 65 which is absent from the truncated isoform is indicated 
by black shading. 
B)  Structure of the three RELN mRNA isoforms; the major isoform RELN-001, an alternatively spliced isoform RELN-
002 from which exon 64 is absent, and a prematurely truncated transcript containing an isoform specific terminal 
exon 63a. Location of the Taqman® assay amplicons are illustrated in grey below the transcript. Arrows indicate 
forward and reverse isoform-specific RT-PCR primers. A and B indicate the forward and reverse primers which can 
only amplify RELN-001, C and D indicate the forward and reverse primers which amplify RELN-002, E indicates the 
reverse primer which along with forward primer C can amplify only the truncated variant. 
 
Through semi-quantitative RT-PCR assays, the alternatively spliced RELN isoform, lacking the 6 
nucleotide micro exon (RELN-002) was detected in 43 of the 71 otosclerosis and 4 of the 5 
control samples (see Figure ‎6.2 for a representative sample). Of the otosclerosis samples, 
RELN-002 was detected in 32 out of 52 female samples and 11 out of 19 male samples. 
Although both RELN isoforms were detected in the MG-63 cells, the major full length RELN 
transcript (RELN-001) was not detected in any of the 71 otosclerosis or 5 control human stapes 
suprastructures. This indicates that whilst both transcripts are expressed in the osteosarcoma 
cell line, only the alternatively spliced transcript, RELN-002, is expressed in human stapes. 
There does not appear to be any difference in expression of this isoform between the genders. 
In addition, the prematurely truncated RELN transcript was not detected in any of the human 
stapes samples or MG-63 cells, indicating that this predicted transcript may not be expressed 
in bone tissue. Human GAPDH cDNA was detected in all human stapes suprastructures and 
MG-63 cells, confirming successful RNA purification and reverse transcription in all samples.  
61 62 63 64 6563a
61 62 63 64 65
61 62 65
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Figure ‎6.2 A 2% agarose gel showing RELN transcript variant 2 RT-PCR amplicons in human stapes cDNA.  
RELN-002 was detected in MG-63 cells and 5 out of 10 human stapes suprastructures (a representative cohort 
sample), illustrated by a 209 bp fragment.   
 
Although the RELN-002 PCR product was detected in a large number of the stapes 
suprastructures, the faint bands visible on the gel relative to the brighter band detected in the 
MG-63 sample suggests that this transcript is expressed at low levels in human stapes. This 
indicates that the semi-quantitative PCR assay may lack the sensitivity to detect this transcript 
efficiently. The results from the qRT-PCR assay confirm that RELN is expressed at significantly 
lower levels in the stapes relative to MG-63 cells (Figure ‎6.3) and also suggests that expression 
of RELN is significantly reduced in otosclerotic stapes compared to controls with detection of 
RELN in 39 out of the 71 otosclerotic stapes compared to 4 out of the 5 controls (Figure ‎6.3). 
The CT values in human stapes were high in comparison to those in MG-63 cells, with an 
average CT of 31.2 for MG-63 cDNA, 36.6 for otosclerotic stapes cDNA and 36.7 for control 
stapes cDNA.  Overall, the proportion of stapes in which RELN was detected in qRT-PCR assays 
is comparable to the proportion of stapes in which RELN-002 was detected through the semi-
quantitative PCR assays. This suggests that it is likely that the qRT-PCR assay is detecting solely 
RELN-002. The outcome of all PCR assays is summarised in Table ‎6.2. 
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Figure ‎6.3 RELN relative quantification graph.  
Relative expression of RELN in MG-63 cells (red), 5 control stapes (blue) and 71 otosclerotic stapes (green) shows 
that RELN is more highly expressed in MG-63 cells compared to stapes and is more highly expressed in control  than 
otosclerotic stapes. 18s ribosomal RNA served as an endogenous control. Error bars represent 95% confidence 
intervals. 
 
 No. (%) of samples in which transcript is detected 
 Semi-quantitative RT-PCR 
Quantitative 
Real Time PCR 
Sample GAPDH RELN-001 RELN-002 
Truncated 
RELN 
MG-63 cells (1) 1 (100%) 1 (100%) 1 (100%) 0 (0%) 1 (100%) 
Female stapes suprastructures (52) 52 (100%) 0 (0%) 32 (62%) 0 (0%) 29 (56%) 
Male stapes suprastructures (19) 19 (100%) 0 (0%) 11 (58%) 0 (0%) 10 (53%) 
Control suprastructures (5) 5 (100%) 0 (0%) 4 (80%) 0 (0%) 4 (80%) 
Total stapes suprastructures (76) 76 (100%) 0 (0%) 47 (62%) 0 (0%) 43 (57%) 
 
Table ‎6.2 Table showing RELN transcript detection in human stapes 
Table showing the number of stapes suprastructure samples and MG-63 cells in which each of the three RELN 
isoforms was detected using semi-quantitative and qRT-PCR assays and the results from a GAPDH assay confirming 
cDNA integrity. 
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Detection of RELN was not consistent across the three replicates performed for each stapes 
sample. Whereas RELN was detected in all replicates in MG-63 cells, it was detected in all 
replicates in only 8 of the 43 suprastructures that were positive for RELN expression in qRT-
PCR assays (Table ‎6.3).  
 
Samples in which RELN was 
detected in qRT-PCR assays 
No. replicates in which RELN was detected 
1 replicate 2 replicates All replicates 
MG-63 cells (1) 0 0 1 
Female stapes suprastructures (29) 8 14 7 
Male stapes suprastructures (10) 8 2 0 
Control suprastructures (4) 1 2 1 
Total stapes suprastructures (43) 17 18 8 
 
Table ‎6.3 Table showing the number of replicates in which RELN was detected in qRT-PCR assays in human stapes 
suprastructures as well as MG-63 cells 
 
6.2.3 Expression of RELN in human stapes is confirmed by RNA-seq 
RELN mRNA was detected in all 12 human stapes samples through RNA-seq (chapter 5), 
confirming the expression of this gene in human stapes.  However, the expression of RELN 
transcripts was very low, with a mean RPKM (reads per kilobase of transcript per million 
mapped reads) value of just 0.058 for control stapes and 0.060 for otosclerotic stapes 
(Table ‎6.4). This is approximately 100 times fewer reads than the mean RPKM value of 5.421 
across all 21,563 annotated genes.  RNA-seq was unable to detect the presence of the major 
RELN-001 isoform in human stapes tissue, as exon 64 which is unique to this transcript was not 
detected in any of the stapes samples. Although it was difficult to detect the presence of 
specific isoforms due to the low read count for RELN in the RNA-seq data, both exons 63 and 
65 were detected in the control stapes footplate with reasonably high read counts of 1.999 
and 0.999 respectively. 
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Control human stapes 
Stapes 
ID 
ConStap1L&R 
FP 
ConStap1L&R 
SS 
ConStap2 
SS 
ConStap3 
SS 
RPKM 0.04032 0.07157 0.05982 0.05957 
Mean 
RPKM 
0.058 
Otosclerotic human stapes 
Stapes 
ID 
OtoStap1 
FP 
OtoStap1 
SS 
OtoStap2 
SS 
OtoStap3 
SS 
OtoStap4 
SS 
OtoStap5 
SS 
OtoStap6 
SS 
OtoStap7 
SS 
RPKM 0.04968 0.06389 0.05276 0.04973 0.09777 0.05587 0.05327 0.04573 
Mean 
RPKM  
0.060 
 
Table ‎6.4 Table showing RPKM values from RNA-seq for RELN in four control and eight otosclerotic stapes  
 
6.3 Discussion of expression of RELN in human stapes 
6.3.1 Resolving controversies in RELN expression in otosclerosis 
Reelin is a large extracellular matrix protein that plays an important role in brain development 
and function.  Despite no obvious role for this protein in the development of conductive 
hearing loss due to otosclerosis, strong evidence for an association between variants in RELN 
and otosclerosis have been reported (Schrauwen et al., 2009a). The RELN gene reportedly 
exists in three alternative isoforms which are conserved across species, which suggests 
functional importance (Lambert de Rouvroit et al., 1999). In this study, the expression of RELN 
isoforms in human stapes were analysed to investigate a discrepancy reported regarding 
detection of RELN transcripts in stapes tissue. Whilst Schrauwen et al., reported successful 
detection of RELN transcripts in 1 of 2 human stapes footplates in their 2009 research 
(Schrauwen et al., 2009a), a 2011 study by Csomor et al.  failed to detect the RELN transcript in 
a much larger study (Csomor et al., 2011). In designing transcript specific primers for this 
study, it was observed that PCR primers designed by Schrauwen et al and Csomor et al. would 
be predicted to have different transcript specificities.  Primers used by Csomor et al. would 
exclusively amplify the major RELN transcript (RELN-001), as the 3’ end of the oligonucleotide 
binds to exon 64 which is unique to this isoform. In contrast, the primers used by Schrauwen et 
al. would detect all RELN transcripts if present in the tissue (Figure ‎6.4).   
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Figure ‎6.4 Structure of the three RELN mRNA isoforms, illustrating the positions of primers designed by 
Schrauwen et al. and Csomor et al. 
Structure of the three RELN mRNA isoforms; the major isoform RELN-001, an alternatively spliced isoform RELN-002 
from which exon 64 is absent, and a prematurely truncated transcript containing an isoform specific terminal exon 
63a. Isoform-specific exons 63a and 64 are indicated by grey and hatched shading respectively. Exon 65 which is 
absent from the truncated isoform is indicated by black shading. Black arrows indicate the forward and reverse 
primers designed by Schrauwen et al. that can amplify all three RELN isoforms.  Grey arrows indicate the forward 
and reverse primers designed by Csomor et al. which can only amplify the major transcript RELN-001. 
 
Therefore a possible explanation for the discrepancy in findings between the two research 
groups is that only the alternatively spliced RELN-002 transcript or the truncated RELN 
transcript is present in human stapes samples.  Given the primer positions selected by each 
group, only the assay used by Schrauwen et al. would be able to detect RELN-002 and the 
truncated RELN isoform in their RT-PCR assays. This would also explain why Csomor et al. were 
able to detect the reelin protein in human stapes in the absence of RELN mRNA detection. The 
results presented here from much larger numbers of human stapes suprastructures support 
the theory that only the alternatively spliced RELN-002 isoform is expressed in human stapes.  
Transcript specific RT-PCR assays and RNA-seq failed to detect the presence of the major RELN-
001 isoform and the truncated isoform in human stapes but were successful in the detection 
of the alternatively spliced isoform RELN-002 lacking the penultimate 6 nucleotide micro exon 
64 encoding the amino acids Val-Ser.  Whilst little is known about the impact of this two amino 
acid sequence on protein function, it is though that the C-terminal splicing events in RELN may 
affect downstream signalling (Nakano et al., 2007). Hence, it can be concluded that isoform 
specificity is the most likely explanation for the discrepancy between previous studies. 
However, it must also be taken into account that Csomor et al. used stapes footplates from 
otosclerosis patients while Schrauwen et al. used control stapes footplates from individuals 
undergoing translabyrinthine surgery for vestibular schwannoma, which could result in 
differences in gene expression due to the differing disease status of the tissue.  Alternatively, it 
61 62 63 64 65
61 62 65
61 62 63a
62 63
62 63
RELN-001
RELN-002
Truncated 
RELN
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is possible that the discrepancy is due to the variability in expression of RELN between 
individual stapes, an explanation which has been previously proposed by other research 
groups and which is supported by the results of this study. 
It must also be considered that whilst the RT-PCR assays conducted by Schrauwen et al. and 
Csomor et al. used human stapes footplates, in this study the stapes analysed by RT-PCR 
originated from suprastructure tissue. Laser-assisted stapedotomy is the preferred surgical 
technique in the UK for treatment of conductive otosclerosis, which results in removal of only 
the suprastructure and not footplate, meaning that in the UK it is difficult to gain access to 
stapes footplate samples for analysis. Since the primary origin of otosclerotic lesions is 
postulated to be the stapes footplate rather than suprastructure, differences in gene 
expression could exist between the suprastructure and footplate. For this reason, analysis of 
RNA-seq data from the one otosclerotic and one control footplate collected was performed. 
RELN was detected in both footplate samples, and although expression levels in the 
otosclerotic sample were too low to definitively detect the presence of specific isoforms, in the 
control footplate, the alternatively spliced transcript was detected, whilst the full-length 
transcript was not. This indicates that the alternatively spliced transcript is expressed in human 
stapes footplates as well as suprastructures. Whilst the absence of the full length major 
transcript in just one control footplate is not sufficient to rule out the possibility that this 
transcript may be expressed in stapes footplates, it indicates that there is some concordance 
of expression of RELN between footplate and suprastructures, although more footplates would 
need to be collected to confirm this. For this reason, a recent collaboration has been 
established between the research groups of Dr Sally Dawson at UCL Ear Institute in London and 
Dr Athanasios Bibas at the National and Kapodistrian University of Athens to initiate 
recruitment of Greek otosclerosis patients, as in Greece, the stapedectomy is the preferred 
surgical procedure for treatment of otosclerosis, where the entire stapes, including the 
footplate is removed. By gaining access to larger numbers of stapes footplates, the expression 
patterns between footplates and suprastructures can be analysed and the suitability of using 
suprastructures for this type of analysis can be determined. 
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6.3.2 A critical analysis of RELN expression data 
Through the use of three different gene expression assays; Quantitative real-time PCR, Semi-
quantitative Reverse Transcription PCR and RNA-seq, RELN mRNA was successfully detected in 
human stapes suprastructures. In both types of PCR assay, there appeared to a reduction in 
expression of RELN in otosclerotic stapes compared to controls. However, since only 5 control 
stapes were available for analysis, larger number of control stapes would need to be collected 
in order to support this. The results from all three methods also suggested that this gene is 
expressed at very low levels within human stapes and that there is considerable variation 
between stapes samples and between replicates for a single stapes sample. The high CT values 
in the human stapes, which are at the limit of detection, may account for the inconsistency 
between replicates, since transcripts expressed at low levels are less likely to meet the 
threshold for detection. However, it is also possible that it may be due to contamination of 
samples with RELN cDNA, or due to pipetting error which may have led to variability in the 
amount of cDNA pipetted into each well and thus a difference in detection of RELN between 
the replicates. Whilst these are both plausible explanations, the lack of variability between 
replicates in the MG-63 assay, which had a lower CT value than human stapes, suggests that 
this is not the case. Evidence suggesting that the variability is due to low level expression can 
be seen when the results from the semi-quantitative and quantitative PCR assays are 
compared. This is because there is consistency between the two assays as to which stapes 
samples RELN was detected in, indicating that the results from both assays support one 
another. In total, RELN was detected in the qRT-PCR assay, as well as in the semi-quantitative 
PCR assay, in 34 out of 76 suprastructures. RELN was detected solely in the qRT-PCR assay in 9 
stapes samples and only in the semi-quantitative PCR assay in 12 samples. RELN was not 
detected in 21 of the stapes samples in either of the assays. Therefore, the results of both 
assays concur in 55 out of the 76 samples, representing consistency between the assays of 
72% (Table ‎6.5).  
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Assay in which RELN was 
detected 
Female stapes 
suprastructures 
(52) 
Male stapes 
suprastructures 
(19) 
Control 
suprastructures 
(5) 
Total stapes 
suprastructures 
(76) 
RELN detected in qRT-PCR and  
semi-quantitative PCR assay 
22 8 4 34 
RELN detected in only  
qRT-PCR assay 
7 2 0 9 
RELN detected in only semi- 
quantitative PCR assay 
9 3 0 12 
RELN detected in neither qRT-
PCR or semi- quantitative PCR 
assay 
14 6 1 21 
Expression of RELN consistent 
between qRT-PCR and semi-
quantitative PCR assay 
36 (69%) 14 (74%) 5 (100%) 55 (72%) 
 
Table ‎6.5 Table showing the number of samples in which detection of RELN was consistent in both qRT-PCR 
assays and semi-quantitative PCR assays in human stapes suprastructures 
The argument that low expression of RELN is causing the inconsistency between replicates is 
further supported by the fact that there is a strong correlation between the samples in which 
RELN is detected using qRT-PCR and the quantity of cDNA present in each stapes sample as 
measured by the 18s endogenous control assay. The average 18s cycle threshold (CT) value for 
the samples in which RELN was detected in one or more replicates was 21.87, whereas for 
samples in which it was not detected in any replicates, the CT value was 23.01. This difference 
is highly significant (p=0.00005), suggesting that the reason for the inconsistency in replicates 
is due to the lack of sensitivity of the assay as a result of the low expression of the RELN 
transcript in human stapes. If it is considered that due to low levels of expression, detection of 
RELN in at least one of the PCR assays is sufficient evidence to suggest that it is expressed in 
the stapes, it can be determined that RELN is expressed in 73% of female otosclerotic stapes, 
68% of male otosclerotic stapes and 80% of control stapes.  This suggests that RELN is 
expressed in the majority of stapes but that expression is variable between both affected and 
control individuals. This is consistent with the findings from previous research groups, where 
conflicting reports have been published as to whether or not RELN is expressed in human 
stapes, and where detection of RELN mRNA varies between stapes samples. 
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6.3.3 Investigating a link between RELN expression and gender 
Variation in isoform specific expression of RELN between males and females was also 
investigated, as there is a reported interaction with gender in the prevalence of otosclerosis 
and in the genetic effect of RELN (Khalfallah et al., 2010). In addition, variation in the RELN 
gene has also been linked to risk of schizophrenia and a recent study suggested that women of 
specific risk genotype (SNP rs7341475 GG), experience a higher proportion of micro exon 
skipping in brain tissue than those with alternative genotypes, while men showed the opposite 
trend (Ovadia and Shifman, 2011). SNP rs7341475 is located within intron 4 of RELN and is in 
strong linkage disequilibrium with a number of SNPs which showed significant association with 
otosclerosis in the genome wide association study (Schrauwen et al., 2009a)(Figure ‎6.5). 
However, no evidence was found in this study to support a difference in expression of this 
alternatively spliced isoform between the genders.  
 
Figure ‎6.5 Haploview plot depicting linkage disequilibrium between the rs7341475 SNP associated with 
microexon skipping and 15 SNPs associated with otosclerosis 
The strength of LD (D’ value) is shown in shades of grey. SNP rs7341475 which was associated with micro exon 
skipping in the Ovadia et al. study is highlighted in black (Ovadia and Shifman, 2011). All other SNPs were found to 
be associated with otosclerosis in the discovery and/or one of the replication groups in the otosclerosis GWAS 
(Schrauwen et al., 2009a).  The nine SNPs highlighted in grey were associated with otosclerosis in either the 
discovery group or a replication cohort. The three SNPs highlighted by dotted lines were associated with 
otosclerosis in the discovery group and a replication cohort. The three SNPs highlighted by dashed lines were 
associated with otosclerosis in the discovery group and two replication cohorts. (HapMap release 21, phase III). 
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In summary, RELN-specific mRNA is present in human stapes footplates and suprastructures in 
both individuals affected by otosclerosis and controls, although at low levels. However, only 
the RELN-002 isoform which undergoes alternative splicing was detected in the human stapes.  
This provides an explanation for the discrepancy in results published by Schrauwen et al. who 
were able to detect the RELN-002 isoform in their PCR assay and Csomor et al. who were not. 
This study therefore resolves the controversies regarding RELN expression in the stapes. 
Further studies are required to determine the exact role of the RELN isoforms and their 
possible functions in the pathogenesis of otosclerosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
217 
 
7 General Discussion 
Throughout the course of this research project, two next generation sequencing technologies; 
RNA-seq and WES, have been used in combination with one another to identify new 
otosclerosis candidate genes, in an attempt to shed light on the disease process involved in 
otosclerosis. WES has proven to be an extremely useful tool in identifying a number of 
promising pathologic candidate variants within genes of interest in families exhibiting 
monogenic inheritance of otosclerosis. This technique has great value for genetic analysis of 
otosclerosis families to identify segregating candidate variants for follow up analysis in a larger 
cohort of otosclerosis individuals. RNA-seq also has been useful in the provision of an 
otosclerosis stapes transcriptome, although the reliability of this data is limited as a result of 
the small cohort size of the discovery group and lack of available control stapes for follow up 
analyses. Despite these limitations, by using the results of the RNA-seq study to inform variant 
prioritisation following WES and by making use of the alternative splicing data produced during 
RNA-seq, one very promising novel otosclerosis candidate gene, SERPINF1, has emerged during 
this study. Thus, by combining genotyping data with gene expression data, progress has been 
made in beginning to understand the disease process involved in otosclerosis. A cross-
comparison of the results obtained across the studies conducted during this research project 
have indicated a number of possible themes which could explain how SERPINF1, as well as 
other genes of interest identified during this project, could be potential triggers for 
otosclerosis pathogenesis. These common themes and possible otosclerosis disease 
mechanisms are discussed below followed by a summary of the conclusions drawn from this 
PhD thesis. 
 
7.1 Could a shift in isoform expression of otosclerosis 
candidate genes be involved in disease pathogenesis? 
The identification of possible splice site variants in the SERPINF1 gene provides evidence to 
suggest a possible alternative splicing disease mechanism for otosclerosis. Alternative splicing 
is the process by which multiple messenger RNA products are produced from a single gene. It 
plays a crucial role in the regulation of eukaryotic gene expression and increases the coding 
capacity of the human genome. Approximately 95% of all mammalian genes undergo 
alternative splicing (Pan et al., 2008). An increasing number of examples are emerging that 
show that alternative splicing can lead to human disease (Tazi et al., 2009). Various hereditary 
diseases of the skeletal system are known to be caused by splice site mutations, including 195 
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known splice site mutations within the COL1A1 gene that lead to the brittle bone disease 
Osteogenesis Imperfecta (Fan and Tang, 2013).   
Through WES followed by Sanger sequencing, five rare nonsynonymous mutations were 
identified in six unrelated otosclerosis families within the SERPINF1 gene. The location of these 
variants, within sites predicted to be involved in either alternative splicing or reduced 
expression of specific SERPINF1 transcripts based on an in silico splicing assay, suggest that an 
alternative splicing mechanism of this gene may be involved in otosclerosis. This, combined 
with gene expression data obtained from both RNA-seq and qRT-PCR assays, suggests that 
downstream SERPINF1 transcripts may be less highly expressed in otosclerotic than control 
stapes in both familial and non-familial cases, implicating a role for alternative splicing of 
SERPINF1 in the development of otosclerosis. A more detailed description of this possible 
disease mechanism can be found in Chapter 4 section 4.13.7 including figure 4.21. 
Furthermore, the results from the RELN expression study in human stapes also indicate 
involvement of a potential alternative splicing mechanism in otosclerosis. Semi-quantitative 
RT-PCR assays along with data from the RNA-seq study indicate that the major RELN transcript 
is not expressed in human stapes but that an alternatively spliced variant, lacking the 
penultimate six nucleotide microexon is expressed. This, combined with qRT-PCR assays which 
indicate that expression of RELN may be reduced in otosclerotic compared to control stapes, 
suggests that there may be a reduction in expression of this alternatively spliced RELN 
transcript in otosclerotic stapes. Having said this, due to the small number of control stapes on 
which the quantitative real time PCR assays were performed, these results should be treated 
with caution, as a greater number of control stapes would need to be collected and analysed 
to confirm these findings. 
Further research into the characterisation of splice site mutations within otosclerosis 
candidate genes could help improve understanding of the disease mechanism, which could 
potentially provide a basis for diagnosis as well as the foundation for development of new 
effective therapies and treatments for otosclerosis. 
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7.2 A possible link between heparan sulphate 
modulation of TGFβ signalling and the otosclerosis 
disease process? 
PEDF, the protein encoded by SERPINF1, is known to bind to heparan sulphate, a 
glycosaminoglycan which regulates transforming growth factor beta (TGFβ) signalling by 
modulating the assembly of latent TGFβ1 (Chen et al., 2007a). The TGFβ super-family is a 
group of genes involved in growth, development, homeostasis and regulation of the immune 
system. TGFβ1 is a polypeptide abundant in the bone matrix that is known to be a potent 
stimulator of osteoblastogenesis and inhibitor of osteoclastogensis, for which reason it has 
been repeatedly proposed as an otosclerosis candidate gene. Various members of this family 
including TGFβ1 and bone morphogenetic proteins BMP2 and BMP4 have been associated 
with otosclerosis during association studies, however a precise role for this gene family in 
development of otosclerosis has not been defined. In this study, a possible link between 
heparan sulphate and modulation of TGFβ signalling in otosclerosis has emerged as a common 
theme across multiple lines of research.  
Based on homology modelling, there is a putative binding site for heparan sulphate on PEDF 
located between residues 134 and 214 of the protein. This region is densely populated with 
lysine residues that are able to interact with glycosaminoglycans such as heparan sulphate 
(Alberdi et al., 1998). This putative binding site corresponds to a region spanning SERPINF1 
exons 4 and 5, including the region in which both exon 5 variants identified in the otosclerosis 
cohort are located. Since the c.441G>C variant identified in two unrelated members of the 
otosclerosis cohort causes a lysine to asparagine change at residue 147, it is possible that this 
variant could disrupt a heparan sulphate binding site. This would lead to a reduction in binding 
of heparan sulphate to PEDF, which would result in accumulation of heparan sulphate and thus 
have an effect on TGFβ signalling (Figure ‎7.1). Alternatively, it is possible that the presence of 
variants that lead to alternative splicing or reduced expression of downstream SERPINF1 
transcripts that cause a reduction in expression of exon 5, could reduce the number of 
heparan binding sites available, thus also leading to heparan sulphate accumulation and 
altered TGFβ signalling. 
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Figure ‎7.1 Schematic showing the possible effect of SERPINF1 variants on TGFβ signaling via heparan sulphate 
mediated modulation of latent TGFβ. 
 
In addition, PEDF is known to compete with heparan sulphate for binding sites located within 
collagen genes. Both PEDF and heparan sulphate bind to similar recognition sites located 
within the triple helix region of collagen genes (Sekiya et al., 2011). The triple helix region of 
COL1A2 is the region in which the two variants identified within this gene in the otosclerotic 
cohort are located, although it doesn’t appear that either of these variants are located directly 
within the PEDF or heparan sulphate binding sites themselves. Reduced expression of 
downstream SERPINF1 transcripts as a result of alternative splicing could therefore reduce 
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competition for binding by heparan sulphate, which could have an impact on both TGFβ 
signalling and the collagen matrix within bone tissue. 
Further evidence from this study to support a possible role for heparan sulphate modulation of 
TGFβ signalling in otosclerosis can be found in the pathway and functional analyses performed 
following RNA-seq. These studies revealed that genes dysregulated in otosclerotic stapes were 
enriched for those encoding a number of small leucine-rich proteoglycans (SLRPs). Following 
quantitative real-time PCR to validate these findings, the SLRP ASPN (Asporin) was confirmed 
to be significantly downregulated in otosclerotic compared to control stapes. Asporin regulates 
chondrogenesis by modulating the TGFβ1 signalling pathway. It does this through inhibition of 
the interaction between TGFβ1 and its type II receptor in the presence of heparan sulphate 
(Kou et al., 2010). This could implicate a potential role for heparan sulphate in combination 
with ASPN in the regulation of the TGFβ signalling pathway in the stapes. 
Further indications that heparan sulphate may play a role in otosclerosis disease pathology, 
stems from the observation of otosclerosis in children with Hunter’s syndrome (Zechner and 
Moser, 1987). This rare X-linked lysosomal storage disorder is caused by deficiency or absence 
of the enzyme iduronate-2-sulphatase which results in accumulation of heparan sulphate. Due 
to the rarity of childhood otosclerosis, it has been proposed there is a causal connection 
between Hunter’s syndrome and otosclerosis.  
This possible link between heparan sulphate and otosclerosis also provides a plausible 
explanation for the persistent reports of a role for viral infection in the disease. Heparan 
sulphate proteoglycans possess large polysaccharide chains which serve as receptors for 
viruses. Binding of a viral protein to heparan sulphate is frequently the first step in a cascade of 
interactions leading to viral entry into a cell and the initiation of infection (Shukla and Spear, 
2001). It is therefore possible that otosclerosis is a xenogenetic disease where genetic and 
environmental factors are interlinked in predisposing an individual to otosclerosis. 
Furthermore, it has also been proposed that reelin, the large extracellular matrix protein found 
to be associated with otosclerosis during the genome wide association study, may serve a 
similar function to proteoglycan molecules such as heparan sulphate. During quantitative real-
time PCR assays conducted during this study, RELN was found to be expressed in otosclerotic 
stapes at less than a fifth of the level at which it is expressed in control stapes, indicating that 
this gene, like various members of the SLRP family may be downregulated in otosclerotic 
stapes. Although Reelin is itself not a proteoglycan, its size and structure indicates that it may 
have a similar role to proteoglycans, such as by providing binding sites and concentrating 
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growth factors (Tissir and Goffinet, 2003). This is supported by a recent study where reelin was 
found to be an essential negative regulator of TGFβ1-induced cell migration in an oesophageal 
carcinoma cell line (Yuan et al., 2012). This publication represents the first time that reelin has 
been postulated to be involved in a genetic pathway involving other otosclerosis candidate 
genes and offers a plausible link between this gene and a possible disease mechanism 
involving TGFβ.  
Through analysis of data collected from a combination of next generation sequencing and 
single gene assays, a trend has emerged implicating proteoglycans and in particular heparan 
sulphate modulated TGFβ signalling in otosclerosis pathogenesis. A number of proteoglycans 
including the SLRPs found to be dysregulated in otosclerotic stapes through RNA-seq, as well 
as heparan sulphate, not only interact directly with members of the TGFβ superfamily to 
modulate signalling, but also interact via genes in which variants were identified during 
sequencing in otosclerosis families. Further experimentation would be required to investigate 
this theory. 
 
7.3 Osteogenesis Imperfecta and Otosclerosis: A shared 
genetic aetiology? 
The identification of multiple variants within two genes, COL1A2 and SERRPINF1 during this 
research project, both of which are known to be involved in the systemic connective tissue 
disorder Osteogenesis Imperfecta (OI), suggests a possible shared genetic aetiology for this 
condition and otosclerosis. There are numerous similarities between the clinical features of 
otosclerosis and the hearing loss associated with OI. These similarities have previously led 
researchers to postulate that otosclerosis may be a localised manifestation of OI (Weber, 
1930). Like in otosclerosis, the temporal bones of OI patients frequently exhibit delayed 
ossification of the auditory ossicles, and OI-associated conductive hearing loss, which usually 
develops in early adulthood shows similarities to that of otosclerosis patients. This, in 
combination with an association found between variants in the OI-causing gene COL1A1 and 
otosclerosis, suggests that some cases of clinical otosclerosis may be caused by mutations 
similar to those found in mild forms of OI (McKenna et al., 1998).  
The results from the WES study conducted during this research project support the concept of 
a shared genetic aetiology between otosclerosis and OI. Within two of the four families 
sequenced, rare nonsynonymous segregating variants were identified within two of the six 
known OI genes; SERPINF1 and COL1A2. Although these variants were not identified in any 
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other cohort members from a population of 53 additional probands reporting a strong family 
history of otosclerosis, four further rare nonsynonymous variants within SERPINF1 were found 
in five unrelated probands through Sanger sequencing of the remainder of the gene. In 
addition, an unknown 9 base insertion was identified within the COL1A2 gene in one further 
proband and her affected mother. Due to the large size of COL1A2, which consists of 52 exons, 
only the exon in which the familial mutation had been found was sequenced in the remainder 
of the cohort. It is therefore possible that additional COL1A2 mutations could reside within 
other exons in additional members of the cohort. Therefore in total, rare nonsynonymous 
variants were identified within known OI genes in eight of the 57 otosclerosis probands, 
constituting approximately 14% of the cohort. In reality, this percentage could be far higher 
since only 6% of the exons present within the six known OI genes were sequenced during this 
study. This provides strong evidence to suggest that genes known to be involved in OI may also 
contribute to otosclerosis pathogenesis. 
Furthermore, the Ingenuity Pathway Analysis performed on the dysregulated gene set 
identified during RNA-seq of otosclerotic and control stapes suggested that 33 of the 176 
dysregulated genes were involved in connective tissue disorders. In addition, the functional 
classification analysis performed on the same dysregulated gene set using DAVID suggested 
that the dataset is over-represented for genes that encode leucine- rich repeat motifs, which 
are common in connective tissue proteins (Bengtsson et al., 1995). This evidence is consistent 
with the concept of a shared genetic aetiology for otosclerosis and other connective tissue 
disorders. 
In individuals with OI VI, 16 unique sequence variants have been identified within SERPINF1. 
These variants include both nonsense and frameshift mutations which lead to nonsense 
mediated decay of SERPINF1 mRNA, and thus loss of expression of PEDF (Becker et al., 2011). 
Since it appears that the SERPINF1 variants identified in the otosclerosis cohort do not cause 
nonsense mediated decay but rather are more likely to affect alternative splicing of this gene, 
it is possible that these variants lead to loss of expression of specific SERPINF1 isoforms in the 
stapes rather than complete loss of expression of this gene in all tissues of the body. This could 
explain the phenotypic differences seen between OI VI and otosclerosis and would support the 
theory that otosclerosis is a localised manifestation of OI. 
The findings of this research have important implications for the treatment of both 
otosclerosis and the otopathology associated with OI. An improved understanding of the genes 
involved in the development of conductive hearing loss in these conditions may help in the 
elucidation of the disease processes. This in turn could assist the development of specific 
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targeted therapies tailored to an individual’s needs based on their genetic composition. Since 
personalised medicine is becoming a realistic option for treatment of disease through 
improvements in pharmacogenomics, tailored drug therapy for these otopathologies could be 
an alternative to surgical options in the not too distant future. 
 
 
7.4 Conclusions 
Throughout the course of this PhD research project, a UK-wide recruitment strategy has been 
successfully implemented to establish large collections of both genomic DNA and cDNA from 
the stapes of otosclerosis patients. This valuable resource has enabled the implementation of a 
range of genetic analyses including both traditional approaches and NGS techniques to 
investigate the genetics of otosclerosis, and has opened up a range of opportunities for future 
research.  
Single gene PCR assays conducted during this research project have helped to resolve a 
discrepancy in the published literature regarding the expression of the otosclerosis candidate 
gene RELN in human stapes. 
WES followed by segregation analysis in otosclerosis families has enabled the identification of 
a number of good otosclerosis pathologic candidate variants within SERPINF1, TRIM17, mir-
183 and COL1A2 genes. Subsequent genotyping assays in a larger cohort of familial 
otosclerosis probands identified additional variants within two of these candidate genes, 
SERPINF1 and COL1A2. Both these genes are excellent otosclerosis candidates due to their 
known role in the systemic connective tissue disorder Osteogenesis Imperfecta, in which 
patients frequently display an otopathology with a similar phenotype to that seen in 
otosclerosis. 
RNA-seq has enabled the provision of an otosclerosis stapes transcriptome which has assisted 
the variant prioritisation process following WES and will provide a useful gene expression 
dataset for future genetic research into otosclerosis. It has also been valuable in evaluating 
expression of the candidate genes prioritised during WES, suggesting a possible shift in 
expression of specific SERPINF1 isoforms in the stapes, a theory which was supported by 
subsequent in silico splicing assays and qRT-PCR in a larger stapes cohort. Thus, the two NGS 
technologies employed during the project; WES and RNA-seq, have enabled the identification 
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of a promising new otosclerosis candidate gene; SERPINF1, for which there is strong evidence 
for a possible role in disease aetiology.  
It is hoped that this new knowledge will help to unravel the molecular mechanisms involved in 
disease pathology. Improved knowledge of the genetic pathways involved in otosclerosis will 
pave the way for future research in order to help pinpoint genes and gene families in which to 
search for both rare variants that contribute to the familial form of the condition, and the 
multiple common variants which are expected to be involved in the complex form of the 
disease. It will be crucial to maintain strong links between genetic research into otosclerosis 
and the clinical treatment for otosclerosis patients, as not only will such relationships enable 
the provision of otosclerotic patient material on which to perform genetic analyses, but will 
also assist in translation of any laboratory findings into possible treatments for patients. This in 
turn could provide future therapeutic options to halt the progression of hearing loss for 
individuals affected by otosclerosis.  
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176 RNA-seq dysregulated genes 
Downregulated genes 
 
Upregulated genes 
Gene name Z ratio 
  
Gene name Z ratio 
 
Gene name Z ratio 
  
Gene name Z ratio 
EEF1A1 -64.07 RPS15A -3.00 
 
MALAT1 84.46 SCAI 2.74 
HBB -44.36 TSPAN8 -2.98 
 
HSP90AB2P 35.68 KCNJ5 2.73 
FTL -42.74 RPS13 -2.96 
 
C1orf161 19.34 LOC219347 2.71 
B2M -20.13 RPL31 -2.94 
 
CLU 13.27 ZNF793 2.71 
SLPI -18.03 UBC -2.93 
 
APOD 12.46 PDE6A 2.70 
LUM -16.35 RPS4Y1 -2.92 
 
LOC646214 10.05 ZNF347 2.70 
RPL7 -14.42 CFH -2.90 
 
SHISA9 8.06 DCUN1D2 2.65 
RPL41 -11.95 DIO2 -2.90 
 
LOC643406 7.69 NLRP12 2.63 
RPS6 -10.20 MYL12A -2.78 
 
FAM119A 6.91 MAP1LC3C 2.63 
RPL10 -8.90 RPL27 -2.75 
 
ACTB 6.01 LOC100128288 2.60 
RPS3A -8.18 RPL17 -2.73 
 
LOC284232 5.53 FBLIM1 2.60 
RPLP0 -7.50 EIF4A2 -2.65 
 
PLUNC 5.43 CCDC142 2.59 
MYL6 -7.35 RPL24 -2.60 
 
LPP 4.59 LAIR1 2.57 
DCN -7.10 EEF1G -2.59 
 
CD74 4.56 KBTBD12 2.47 
RPL23A -7.05 PPIA -2.44 
 
IFITM1 4.26 ZNF805 2.45 
HLA-DRA -6.75 RPL23 -2.41 
 
OPHN1 4.17 ZNF493 2.41 
RPL32 -6.42 LDHB -2.35 
 
ZMAT3 4.17 PTK6 2.40 
RPS27A -5.58 SRP14 -2.28 
 
FKBP14 4.01 IL17RD 2.37 
ANXA2 -5.55 RPL35A -2.26 
 
TLCD2 3.83 CYP4V2 2.34 
PFDN5 -5.28 CD59 -2.23 
 
LOC442293 3.76 CRX 2.30 
COCH -5.26 OMD -2.23 
 
ABCC9 3.75 ENTPD4 2.29 
SPP1 -5.25 VIM -2.18 
 
IL28RA 3.63 C11orf58 2.28 
MGP -5.13 RPS25 -2.18 
 
PPP1R2P1 3.60 C10orf72 2.26 
RPS27 -4.69 RPS29 -2.14 
 
CAMK1D 3.56 RBMS2 2.24 
RPL9 -4.43 SDHD -2.13 
 
IGJ 3.53 TAF8 2.23 
RPL5 -4.32 RPS12 -2.10 
 
TMEM212 3.38 L2HGDH 2.18 
RPL15 -4.15 MYL12B -2.09 
 
KIAA1486 3.29 GEMIN8 2.16 
RPS3 -4.12 GLUL -2.09 
 
LRRC58 3.23 ZBTB8A 2.16 
RPL30 -4.10 HSP90AA1 -2.02 
 
ZNF461 3.23 GNE 2.14 
RPS11 -3.99 RPS7 -1.97 
 
PDP2 3.22 SLC9A4 2.14 
RPL14 -3.96 
    
H3F3B 3.21 LOC100272146 2.12 
SPARCL1 -3.84 
    
SLC31A1 3.19 S100A11 2.11 
SKP1 -3.82 
    
PHACTR4 3.13 PCDH11Y 2.10 
ARL6IP5 -3.79 
    
PIGX 3.13 SKA1 2.09 
RPS18 -3.78 
    
TATDN3 3.08 SIX4 2.06 
MT1X -3.73 
    
VPS53 3.06 C8orf79 2.05 
ANXA1 -3.69 
    
IFITM3 3.01 RBM34 2.05 
UBB -3.67 
    
ZNF264 3.01 ZNF490 2.05 
RPL34 -3.65 
    
PTMA 2.97 SMG1 2.03 
RPS14 -3.47 
    
FOXK1 2.96 NOL9 2.03 
SAT1 -3.43 
    
UGGT1 2.96 CHP 2.02 
RPL19 -3.40 
    
TMEM41B 2.92 SPRED1 2.02 
CALM2 -3.38 
    
C21orf62 2.89 FMN1 2.01 
CTSK -3.36 
    
HBA2 2.89 LOC90834 1.99 
HIST1H4C -3.27 
    
GOSR1 2.87 PNPT1 1.99 
RPL4 -3.19 
    
LOC283267 2.85 LOC100190938 1.98 
RPS23 -3.05 
    
GREB1 2.83 GTF2E1 1.97 
RPL11 -3.05 
    
XIAP 2.83 SIRPB2 1.97 
ASPN -3.02 
    
CTSB 2.76 
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Table showing restriction endonuclease digests 
Gene Variant 
PCR 
amplicon 
length 
Restriction 
Endonuclease 
Fragment 
sizes  
wt 
Fragment  
sizes  
het 
Fragment  
sizes 
mutant 
CYP2D6 c.345delC 505bp DrdI 505bps 505+278+226bps 278+226bp 
 
DNAH5 c.7883T>G 469bp OliI 469bp 469+319+150bp 319+150bp 
 
EGLN3 c.496C>T 446bp AciI 308+138bp 446+308+138bp 446bp 
 
mir-183 c.81G>T 473bp AvaII 473bp 473+303+170bp 303+170bp 
 
PTK6 c.652A>T 320bp MlsI 207+113bp 320+207+113bp 320bp 
 
SERPINF1 c.441G>C 440bp TseI 314+126bp 440+314+126bp 440bp 
 
TRIM17 c.915C>G 419bp RsaI 334+85bp 419+334+85bp 419bp 
 
VPS53 c.107C>G 299bp PpuMI 182+117bp 299+182+117bp 299bp 
 
Table shows the predicted fragment size and an agarose gel electrophoresis image showing 1kb DNA ladder in lane 
1, digest fragments for 23 cohort members in lanes 2-24, a known heterozygote in lane 25 (indicated by arrows) 
which acted as a positive control, and a known wild type in lane 26. 
 
 
235 
 
RNA-seq dysregulated genes–z score and RPKM overlap 
Downregulated genes 
 
Upregulated genes 
gene name Z ratio p-value Fold diff 
 
gene name Z ratio p-value Fold diff 
ASPN -3.02 0.00 5.28 
 
ZMAT3 4.17 0.01 1.50 
HIST1H4C -3.27 0.01 4.73 
 
CAMK1D 3.56 0.01 2.12 
PFDN5 -5.28 0.01 4.19 
 
KIAA1486 3.29 0.00 2.12 
RPS15A -3.00 0.00 3.98 
 
LOC219347 2.71 0.01 2.07 
RPL32 -6.42 0.00 3.89 
 
PTK6 2.40 0.00 2.06 
RPL30 -4.10 0.00 3.83 
 
LOC100128288 2.60 0.01 2.06 
RPL23 -2.41 0.00 3.74 
 
PPP1R2P1 3.60 0.00 2.03 
RPL24 -2.60 0.00 3.72 
 
LOC90834 1.99 0.00 2.00 
RPL27 -2.75 0.02 3.72 
 
PCDH11Y 2.10 0.01 1.98 
RPL23A -7.05 0.01 3.71 
 
FBLIM1 2.60 0.00 1.97 
MYL6 -7.35 0.03 3.69 
 
KCNJ5 2.73 0.01 1.96 
RPS29 -2.14 0.04 3.68 
 
IL17RD 2.37 0.00 1.95 
RPL17 -2.73 0.00 3.64 
 
PIGX 3.13 0.01 1.93 
RPL11 -3.05 0.00 3.64 
 
SIRPB2 1.97 0.01 1.93 
RPS7 -1.97 0.00 3.57 
 
GREB1 2.83 0.00 1.87 
RPS13 -2.96 0.01 3.55 
 
LOC100190938 1.98 0.02 1.86 
RPS3A -8.18 0.03 3.55 
 
NLRP12 2.63 0.02 1.85 
SDHD -2.13 0.01 3.51 
 
TLCD2 3.83 0.01 1.85 
SLPI -18.03 0.01 3.50 
 
SKA1 2.09 0.00 1.85 
RPS23 -3.05 0.00 3.49 
 
C21orf62 2.89 0.01 1.84 
RPL34 -3.65 0.01 3.41 
 
FOXK1 2.96 0.00 1.83 
SPARCL1 -3.84 0.00 3.41 
 
LOC100272146 2.12 0.01 1.82 
RPS6 -10.20 0.01 3.40 
 
ENTPD4 2.29 0.00 1.82 
RPL7 -14.42 0.00 3.40 
 
PDP2 3.22 0.01 1.81 
RPL9 -4.43 0.01 3.39 
 
PDE6A 2.70 0.03 1.81 
RPL14 -3.96 0.02 3.36 
 
KBTBD12 2.47 0.03 1.78 
RPL5 -4.32 0.01 3.31 
 
C8orf79 2.05 0.02 1.75 
RPL35A -2.26 0.01 3.31 
 
FMN1 2.01 0.01 1.75 
PPIA -2.44 0.01 3.29 
 
LOC283267 2.85 0.01 1.72 
ARL6IP5 -3.79 0.02 3.28 
 
C10orf72 2.26 0.00 1.70 
RPS27 -4.69 0.01 3.26 
 
CRX 2.30 0.02 1.69 
RPS27A -5.58 0.00 3.15 
 
DCUN1D2 2.65 0.02 1.68 
RPL41 -11.95 0.00 3.14 
 
LAIR1 2.57 0.01 1.67 
SRP14 -2.28 0.03 3.11 
 
ZNF264 3.01 0.01 1.67 
RPS25 -2.18 0.00 3.07 
 
ZNF490 2.05 0.01 1.66 
RPL31 -2.94 0.01 3.06 
 
IL28RA 3.63 0.01 1.65 
TSPAN8 -2.98 0.01 3.04 
 
PNPT1 1.99 0.03 1.64 
LDHB -2.35 0.01 3.01 
 
CCDC142 2.59 0.01 1.62 
MYL12A -2.78 0.04 2.97 
 
SCAI 2.74 0.02 1.62 
RPL4 -3.19 0.03 2.95 
 
GNE 2.14 0.00 1.61 
ANXA2 -5.55 0.03 2.89 
 
ZNF793 2.71 0.02 1.60 
VIM -2.18 0.01 2.80 
 
VPS53 3.06 0.02 1.60 
SKP1 -3.82 0.02 2.78 
 
GEMIN8 2.16 0.01 1.59 
LUM -16.35 0.01 2.77 
 
MAP1LC3C 2.63 0.03 1.58 
RPS14 -3.47 0.01 2.73 
 
ZBTB8A 2.16 0.01 1.57 
ANXA1 -3.69 0.01 2.65 
 
ZNF805 2.45 0.01 1.54 
RPS18 -3.78 0.01 2.58 
 
TAF8 2.23 0.02 1.53 
CALM2 -3.38 0.01 2.54 
 
NOL9 2.03 0.02 1.53 
HSP90AA1 -2.02 0.03 2.33 
 
SIX4 2.06 0.00 1.51 
RPL15 -4.15 0.03 2.30 
     MYL12B -2.09 0.03 2.26 
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